A biochemical assessment of Ochratoxin A stress responses in vitro, with resveratrol as a possible therapeutic intervention. by Raghubeer, Shanel.
 
 
 
 
A biochemical assessment of Ochratoxin A stress 
responses in vitro, with resveratrol as a possible 
therapeutic intervention. 
 
By 
Shanel Raghubeer 
BSc Biomedical Science 
 BMedSci (Hons) Medical Biochemistry 
Master of Medical Science 
 
Submitted in the fulfilment of the degree Doctor of Philosophy (Medical 
Biochemistry), School of Laboratory Medicine and Medical Sciences, 
College of Health Science, University of KwaZulu-Natal 
 
2017 
 
ii 
 
DECLARATION 
 
 
I, Shanel Raghubeer, declare that:  
 
i) The research reported in this thesis (unless otherwise indicated) is my original work, has not been 
submitted for any degree or examination at any other university, does not contain other persons’ data, 
diagrams, graphs, or other information, unless specifically being acknowledged as sourced from other 
persons, does not contain other persons’ writings unless being acknowledged as being sourced from 
other researchers. Where other written sources have been quoted then:  
 
a) Their work has been re-written, but the information sourced has been referenced to the 
authors  
 
b) Where their exact words have been used, their writing has been placed within quotation 
marks and referenced  
 
ii) Where I have reproduced a publication of which I am author, co-author, or editor, I have indicated 
in detail which part of the publication was written by myself alone and have properly referenced such 
publication  
 
iii) This thesis does not contain text, graphics or tables copied and pasted from the internet, unless 
specifically acknowledged and the source being detailed in the thesis and reference section  
 
 
Signed:  
 
  
       14 March 2018 
Ms Shanel Raghubeer        Date 
 
 
 
 
 
iii 
 
DEDICATION 
 
 
To my parents. Thank you for giving me opportunities you did not have; it is only through your hard 
work and sacrifice that I stand where I am today. Thank you for instilling in me the importance of 
education and fortitude. Thank you most of all for your love and support.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iv 
 
ACKNOWLEDGEMENTS 
 
 
Prof Anil Chuturgoon 
Thank you for being the most influential teacher in my life. Your passion for science, and the pursuit 
of truth has always inspired me. Thank you for believing in me when I did not believe in myself. You 
have taught me how to be a better scientist, and a better human being. Thank you for your guidance, 
wisdom, and kindness when I needed it most.  
 
The Department of Medical Biochemistry 
I will be forever grateful to the staff and students at this amazing department. Dr Savania Nagiah – 
thank you for your guidance and friendship during the past few years, seeing your face made every day 
easier. Thank you to the junior PhD students for always being eager to help, both in the lab and out. It 
was a pleasure working amongst such innovative, kind people. I cannot wait to see the great things you 
accomplish. Ms Narisha Needhi – thank you for the technical assistance and life lessons.  
 
My family 
Your love and support throughout my academic journey will always be appreciated. Thank you for 
teaching me to persevere, while allowing me to grow and discover my potential. 
 
My Friends 
Ms Yashodani Pillay – I could not have asked for a more selfless person to have by my side throughout 
this journey. Thank you for being my sounding board, my food provider, and my friend. You are 
sunshine personified. Thank you to the family I could choose – Mr Shiraz Bhoola, Ms Veyashka 
Govender, and Mr Nishal Jagjivan. Thank you for your support during the trying times and for the 
welcome distractions when I needed a break. Ms Megan Govender – thank you for teaching me to be 
tough, and for standing up for me when I couldn’t. Your faith in me kept me going. Mr Garreth Jasmin 
– thank you for the laughs, and advice, but most of all, thank you for your unwavering belief in me. 
You have all taught me that “there are more important things – friendship and bravery” (Rowling, 1997).  
  
 
 
 
 
v 
 
PUBLICATIONS 
 
1. Raghubeer, S., Nagiah, S., Phulukdaree, A., and Chuturgoon, A. (2015). The Phytoalexin Resveratrol 
Ameliorates Ochratoxin A Toxicity in Human Embryonic Kidney (HEK293) Cells.  
Journal of Cellular Biochemistry 116(12), 2947-1955 
DOI: 10.1002/jcb.25242 
 
 
2. Raghubeer, S., Nagiah, S., and Chuturgoon, A.A. (2017). Acute Ochratoxin A exposure induces 
inflammation and apoptosis in human embryonic kidney (HEK293) cells.  
Toxicon 137, 48-53. 
DOI: 10.1016/j.toxicon.2017.07.013 
 
 
3. Raghubeer, S., Nagiah, S., and Chuturgoon, A.A (2017). Varying Concentrations of Ochratoxin A 
promote Endoplasmic Reticulum stress-induced survival in human kidney and liver cells. 
Submitted to Toxicology Letters (in review) 
Manuscript number: TOXLET-D-17-00950 
 
 
4. Raghubeer, S., Nagiah, S., and Chuturgoon, A.A (2017). Ochratoxin A upregulates acute hypoxia-
induced protein response, with increased VEGF and TGFβ expression during prolonged exposure in 
human kidney and liver cells. 
Submitted to Food and Chemical Toxicology (in review) 
Manuscript number: FCT-D-17-02000 
 
  
 
 
 
 
 
 
vi 
 
PRESENTATIONS 
 
1. Raghubeer, S., Nagiah, S., Phulukdaree, A., and Chuturgoon, A. (2015). The Phytoalexin 
Resveratrol Ameliorates Ochratoxin A Toxicity in Human Embryonic Kidney (HEK293) Cells.  
College of Health Science Research Symposium 2015, University of KwaZulu-Natal, K-RITH 
Towers, Durban. Oral presentation. 
 
 
2. Raghubeer, S., Nagiah, S., Phulukdaree, A., and Chuturgoon, A. (2015). The Phytoalexin 
Resveratrol Ameliorates Ochratoxin A Toxicity in Human Embryonic Kidney (HEK293) Cells. 
12th World Cancer Conference 2016, Hilton Heathrow, London. Poster presentation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vii 
 
CONTENTS 
 
Declaration………………………………………………………………………………………..ii 
Dedication………………………………………………………………………………………...iii  
Acknowledgements……………………………………………………………………………….iv  
Publications……………………………………………………………………………………….v 
Presentations……………………………………………………………………….......................vi 
List of Figures…………………………………………………………………………………….ix 
List of Tables……………………………………………………………………………………..xvi 
Abbreviations……………………………………………………………………………………..xvii  
Abstract (English)………………………………………………………………………………...xxiii  
Abstract (isiZulu).………………………………………………………………………………...xxv  
Chapter 1: Introduction…………………………………………………………………………....1  
Chapter 2: Literature Review……………………………………………………………………...4  
2.1 Mycotoxins…………………………………………………………………………....4 
2.1.1 Ochratoxin A……………………………………………………………….4 
2.1.2 Absorption, Metabolism and Excretion………………………………….....6 
2.1.3 Related Nephropathies……………………………………………………...7 
2.2 Ochratoxin A Toxicity and Biochemical Responses………………………………….8 
2.2.1 Mitochondrial Toxicity and Oxidative Stress Induction…………………...9 
 2.2.1.1 Mitochondrial ROS Production…………………………….9 
2.2.1.2 Nuclear factor-erythroid 2-related factor 2 (Nrf2): The  
Master Regulator…………………………………………………....9 
2.2.2 Protein Synthesis and Apoptosis…………………………………………...11 
2.2.2.1 Calcium Homeostasis during Endoplasmic Reticulum  
(ER) Stress………………………………………………………….11 
2.2.2.2 Lon Protease1 (LonP1)-mediated quality control…………..12 
2.2.2.3 ER Stress and Protein Repair……………………………….12 
2.2.2.4 OTA and Apoptosis Induction……………………………...14 
2.2.3 Genotoxicity………………………………………………………………..16 
2.2.3.1 OTA-induced DNA damage………………………………..16 
2.2.3.2 DNA Damage repair………………………………………..16 
2.2.4 Inflammation, Hypoxia and the Cancer Microenvironment……………….17 
2.2.4.1 Classical Inflammatory Pathway…………………………...17 
2.2.4.2 Hypoxia Inducing Factor-1 mediation of Hypoxia and  
Cancer………………………………………………………………19   
viii 
 
2.3 Resveratrol, a Possible Therapeutic…………………………………………………...21 
2.3.1 Absorption and Metabolism…………………………………………………22 
2.3.2 Therapeutic Potential………………………………………………………...23 
2.3.2.1 Antioxidant Defence and Anti-inflammatory Action………..23 
2.3.2.2 Cardiovascular Protection…………………………………....23 
2.3.2.3 Resveratrol and Sirtuins……………………………………...24 
2.3.2.4 Chemotherapeutic Potential………………………………….24 
Chapter 3: The Phytoalexin Resveratrol Ameliorates Ochratoxin A Toxicity in Human 
     Embryonic Kidney (HEK293) Cells…………………………………………………….44 
Chapter 4: Acute Ochratoxin A exposure induces inflammation and apoptosis in  
                  human embryonic kidney (HEK293) cells………………………………………………63 
Chapter 5: Varying Concentrations of Ochratoxin A promote Endoplasmic Reticulum 
                  stress-induced survival in human kidney and liver cells…………………………….......78 
Chapter 6: Ochratoxin A upregulates acute hypoxia-induced protein response, with  
                  increased VEGF and TGFβ expression during prolonged exposure in  
                  human kidney and liver cells…………………………………………………………….96 
Chapter 7: Conclusion……………………………………………………………………………….116 
  
Appendix A…………………………………………………………………………………………..123 
Appendix B……………………………………………………………………………………..........125 
Appendix C…………………………………………………………………………………………..126 
Appendix D…………………………………………………………………………………………..127 
 
 
 
 
 
 
 
 
 
 
ix 
 
LIST OF FIGURES 
 
Figure 2.1         Chemical structure of Ochratoxin A (Hundhausen et al., 2008)…………………5 
 
Figure 2.2 Biotransformation of OTA into various metabolites by hydroxylation and  
 hydrolysis. (Adapted from Ringot et al. (2006), prepared by author  
 (Ringot et al., 2006))………………………………………………………….…..7 
 
Figure 2.3 Maps showing Balkan Peninsula (Google, 2009) and North African regions  
 (Google, 2017) where incidences of Balkan endemic nephropathy (BEN) and  
 chronic interstitial nephritis (CIN) have been reported….………………...............8 
 
Figure 2.4 Hydroxyl radical production by iron chelation during Fenton reaction  
 (Halliwell and Chirico, 1993)……………………………………………..….…....9 
 
Figure 2.5 Representation of Nrf2-Keap1 interaction and activation of antioxidant  
 response (Adapted from Kim et al. (2010), prepared by author  
 (Kim and Vaziri, 2010)).………………………………………………………….10 
 
Figure 2.6 Protein synthesis disruptions resulting from phenylalanine moiety toxicity  
 (prepared by author)……………………………………………………………….11 
 
Figure 2.7 Representation of molecular mechanisms involved in ER stress induction of the  
 UPR leading to protein repair and cell survival (Kadowaki and Nishitoh, 2013)…14 
 
Figure 2.8 The extrinsic and intrinsic mechanisms of apoptosis (Ichim and Tait, 2016)……..15 
 
Figure 2.9 The classical pathway of NFκB activation by IKK-induced phosphorylation of  
 IκBα to activate NFκB (Luo et al., 2005)…………………………………………18 
 
Figure 2.10 Representation of HIF1α-pVHL interaction during normoxia (degradation  
 by ubiquitin-proteasome system) and hypoxia (nucleus translocation). (Adapted  
 from Pires et al. (2014), prepared by author (Pires, 2014)).……..……………..….20 
 
Figure 2.11 HIF1α activators and downstream targets, resulting in cellular adaptation of  
 cancer cells to a hypoxic environment (Vaupel, 2004)……………….…………...21 
 
x 
 
Figure 2.12       Chemical structure of resveratrol (Davinelli et al., 2012)……………………….…22 
 
Figure 2.13       Beneficial effects of resveratrol as a SIRT1 activator (prepared by author)……….25 
 
Figure 2.14 Potential resveratrol targets and the compound’s involvement in  inflammation, 
oxidative and mitochondrial stress, hypoxia, and cardiovascular protection  
 (Haskó and Pacher, 2010)……………………………………………………….…..26 
 
Figure 3.1 Percentage viability of cells exposed to OTA over (A) 24h and (B) 48h. An  
IC50 of 1.5µM (24h) and 9.4 (48h) was calculated from the dose-response curve.....52 
 
Figure 3.2 Assessment of the percentage of intracellular ROS in cells exposed to OTA  
and resveratrol over 24h and 48h. Resveratrol significantly decreased the  
percentage of intracellular ROS (***p < 0.0001), whereas OTA and  
OTA+resveratrol treatments decreased the values of ROS when compared to  
control cells during 24h exposure (*p = 0.0048). Upon 48h exposure,  
OTA+resveratrol significantly increased the ROS values (***p = 0.0002),  
whereas the OTA and resveratrol treatments also increased  
intracellular ROS…………………………………………………………..………...52 
 
Figure 3.3 Assessment of DNA damage showing images of (A) comet tails during 24h  
exposure, (B) the measurement of comet tail lengths during 24h exposure, (C)  
comet tails during 48h exposure, and (D) the measurement of comet tail lengths  
during 48h exposure. OTA increased comet tail lengths during both exposure  
time periods (***p < 0.0001). Comet tail lengths doubled during the 48h exposure.  
The OTA+Resveratrol co-treatment significantly decreased lengths compared to  
cells only treated with OTA (***p < 0.0001)………………………………….…….53 
 
Figure 3.4 Concentrations of GSH in HEK293 cells after exposure to OTA and resveratrol.  
The OTA+resveratrol co-treatment increased the concentrations of GSH during the  
24h exposure compared to GSH present in OTA-treated cells (*p < 0.05).  
The co-treatment also increased GSH during the 48h exposure (***p < 0.001)…….54 
 
 
 
 
 
xi 
 
Figure 3.5 Analysis of the mRNA expression of genes associated with cellular protection.  
Nrf2 expression was seen to decrease upon exposure to OTA, resveratrol  
(*p < 0.05), and OTA+Resveratrol (**p = 0.001) for 24h. (B) The expression  
of Nrf2 was seen to decrease further when exposed to OTA (*p < 0.05) and  
resveratrol (**p = 0.0021) for 48h. The DNA glycosylase enzyme, OGG1,  
was observed to increase during 24h resveratrol exposure and significantly  
decrease during exposure to OTA+resveratrol (**p < 0.05) for 24h.  
(C) OGG1 expression was significantly decreased during OTA+resveratrol  
exposure compared to resveratrol-treated cells (p = 0.0002). (D) Recovery of  
OGG1 expression was observed during 48h exposure to OTA+resveratrol  
(**p < 0.05).………………………………………………………………………...55 
 
Figure 3.6 Western blot images and relative fold change in protein expression of Nrf2, 
pSIRT1, SIRT3, and LonP1 over 24h and 48h, in response to OTA and  
resveratrol exposure. Resveratrol decreases Nrf2 expression during 24h exposure,  
but increases Nrf2 during 48h exposure (***p < 0.0008). OTA significantly  
increased Nrf2 expression during 48h exposure (*p < 0.05). The OTA+resveratrol  
co-treatment significantly decreased Nrf2 expression during 24h exposure  
(*p < 0.05). Resveratrol significantly increased the expression of pSIRT1 during  
24h exposure (***p = 0.0002) and 48h exposure (**p = 0.0054). SIRT3  
expression decreased in all treatments during 24h exposure with a significant  
decrease during OTA exposure (***p = 0.0003). The opposite was observed  
during 48h exposure, all treatments increased SIRT3 expression with significance  
in the resveratrol treatment (*p < 0.05). LonP1 expression exhibits the inverse of  
SIRT3 expression, with an increase in LonP1 expression during 24h exposure to  
OTA (*p < 0.05) and OTA+Resveratrol (**p = 0.0011). LonP1 expression  
increased significantly upon 48h exposure to resveratrol (***p = 0.0005)…………56 
 
Figure 4.1 Densitometric analysis and western blot images showing relative fold change  
in inflammatory protein expression at 24hr exposure to OTA with a significant  
increase in p-NFκB in O1 treated HEK293 cells. ***p < 0.001 relative to un- 
treated control……………………………………………………………………….69 
 
 
 
 
 
xii 
 
Figure 4.2 Densitometric analysis and western blot images showing relative fold change  
in inflammatory protein expression over 24hr exposure to OTA. Significant  
increases were observed in IκBα in O2 and O3 treated HEK293 cells.  
Significant decreases were observed in p-IKK and total IKK in O3. *p < 0.05;  
**p < 0.005; ***p < 0.001 relative to untreated control…………………………….69 
 
Figure 4.3 Densitometric analysis and western blot images showing relative fold change in  
protein expression of tumour suppressor p53. Significant increases were observed  
in p-p53 (Ser392) in O1 and O2, as well as total p53 in O1 and O2. *p < 0.05;  
**p < 0.005 relative to untreated control. …………………………………………..70 
 
Figure 4.4 Luminometric quantification of caspase 1 and ELISA results for IL-1β  
measurement (pg/ml). IL-1β and caspase 1 was significantly decreased in O2.  
#p < 0.005 relative to treatment O1; **p < 0.05 relative to untreated control cells….70  
 
Figure 4.5 Luminometric assessment of caspase 3/7, 8 and 9 activity in HEK293  
cells. Significantly increased caspase 3/7, 8, and 9 activity was observed in O3.  
**p < 0.05, ***p < 0.001 relative to untreated control……………………………...71 
 
Figure 4.6 Intracellular ATP levels of HEK293 cells following acute exposure to OTA. 
Intracellular levels were significantly increased in O1 and O2 (p < 0.05 and p = 
0.0001 respectively). *p < 0.05 and ***p < 0.001 relative to untreated control…….71 
 
Figure 5.1 Cellular viability (%) post-exposure to a range of OTA concentrations over  
24hr and 48hr. An IC50 of 47µM (24hr) and 9µM (48hr) was calculated from  
the dose-response curves…………………………………….………………………84 
 
Figure 5.2 Densitometric analysis and western blot images showing relative fold change in  
LonP1 and HSP70 in HEK293 cells over 24hr and 48hr exposure to OTA –  
OTA0.125 (0.125µM), OTA0.25 (0.25µM) and OTA0.5 (0.5µM). *p < 0.05,  
**p < 0.005 and ***p < 0.0005 relative to untreated control.………………………85 
 
Figure 5.3 Densitometric analysis and western blot images showing relative fold change in 
LonP1 and HSP70 in HepG2 cells over 24hr and 48hr exposure to OTA –  
OTA0.125 (0.125µM), OTA0.25 (0.25µM) and OTA0.5 (0.5µM). *p < 0.05 and  
***p < 0.0005 relative to controls…………………………………………………...86 
 
xiii 
 
Figure 5.4 Analysis of protein carbonyl concentrations during exposure to a range of  
OTA in HEK293 and HepG2 cells over 24hr and 48hr. *p < 0.05 and  
***p < 0.0005 relative to respective controls…………….…………………...…….86 
 
Figure 5.5 Densitometric analysis and western blot images showing relative fold change in  
PERK and p-eIF2α following 24hr and 48hr exposure of HEK293 cells to a  
range of OTA concentrations. *p < 0.05, **p < 0.005 and ***p < 0.0005  
relative to respective controls. ………………………………….…………………...87 
 
Figure 5.6 Densitometric analysis and western blot images showing relative fold change in  
PERK and p-eIF2α following HepG2 cell exposure to a range of OTA  
concentrations over 24hr and 48hr. *p < 0.05, **p < 0.005 and ***p < 0.0005  
relative to controls………………………………………..……………………...…...88 
 
Figure 5.7 mRNA analysis of ATF4 and CHOP in HEK293 cells after treatment with a  
range of OTA concentrations over 24hr and 48hr. **p < 0.005 and  
***p < 0.0005 relative to control……………………………………………….……88 
 
Figure 5.8 Analysis of ATF4 and CHOP mRNA levels in HepG2 cells following treatment  
with a range of OTA concentration over 24hr and 48hr. *p < 0.05 and **p < 0.005  
and ***p < 0.0005 relative to untreated controls. …………………………………….90 
 
Figure 6.1 Densitometric analysis and western blot images showing relative fold change in 
pNFκB and pNrf2 in HEK293 cells over 24hr and 48hr exposure to OTA – O0.5 
(0.5µM), O0.25 (0.25µM) and O0.125 (0.125µM). *p < 0.05, **p < 0.005 and  
***p <  0.0005 relative to untreated control………………………………..………103 
 
Figure 6.2 Densitometric analysis and western blot images showing relative fold change in 
pNFκB and pNrf2 in HepG2 cells over 24hr and 48hr exposure to OTA.  
*p < 0.05 and **p < 0.005 relative to untreated control……………………………104 
 
Figure 6.3 Densitometric analysis and western blot images showing relative fold change in 
proteins related to hypoxic response. Expression of HIF1α, HSP90 and PDK1 in 
HEK293 cells over 24hr and 48hr exposure to OTA. *p < 0.05, **p < 0.005 and  
***p < 0.0005 relative to untreated control………………………………………..105 
 
xiv 
 
Figure 6.4 Densitometric analysis and western blot images showing proteins related to  
hypoxic response. Relative fold change of HIF1α, HSP90 and PDK1 in HepG2  
cells over 24hr and 48hr exposure to OTA. *p < 0.05 and **p < 0.005 relative 
to controls…………………………………………………………………………..106 
 
Figure 6.5 mRNA analysis of HIF1α, VEGF and TGFβ in HEK293 cells after treatment  
with a range of OTA concentrations over 24hr and 48hr. *p < 0.05, **p < 0.005  
and ***p < 0.0005 relative to control………………………………………………107 
 
Figure 6.6 Analysis of HIF1α, VEGF and TGFβ mRNA levels in HepG2 cells following  
treatment with a range of OTA concentrations over 24hr and 48hr. *p < 0.05 and  
**p < 0.005 and ***p < 0.0005 relative to untreated controls………………………107  
 
Figure 6.7 Luminometric quantification of ATP in HEK293 and HepG2 cells over 24hr and  
48hr post-exposure to a range of OTA concentrations. *p < 0.05 and  
**p < 0.005 compared to control measurements……………………………………108 
 
 
Appendix A Figure 1 Fluorescence peaks for DCFDA intracellular ROS assay –  
determined using BD Accuri flow cytometer…………………...…124 
   
Appendix B Figure 1 mRNA expression of genes associated with cellular protection  
and the antioxidant response determined post-exposure to OTA  
and resveratrol at 24hr in HEK293 cells. *p < 0.05, **p < 0.005…125 
 
Appendix B Figure 2 mtDNA damage induced in kidney cells exposed to OTA  
and resveratrol at 24hr. *p < 0.05 and **p < 0.005………...………125 
 
Appendix C Figure 1 Extracellular LDH levels used as a biomarker for necrosis  
and membrane damage to HEK293 cells over 24hr and 48hr  
post-exposure to varying concentrations of OTA (*p < 0.05)……...126 
 
Appendix C Figure 2 Extracellular LDH levels used as a biomarker for necrosis  
and membrane damage to HepG2 cells over 24hr and 48hr in  
response to OTA exposure………………………………………..126 
 
 
xv 
 
Appendix D Figure 1 Quantification of caspase 8 activity in OTA treated HEK293  
cells at 24hr and 48hr. *p < 0.05, **p < 0.005 and  
***p < 0.0005 relative to untreated controls………………………127 
 
Appendix D Figure 2 Quantification of caspase 9 activity in OTA treated HEK293  
cells at 24hr and 48hr. *p < 0.05, **p < 0.005 and  
***p < 0.0005 relative to untreated controls……………………….127 
 
Appendix D Figure 3 Quantification of caspase 8 activity in HepG2 cells exposed to  
varying concentrations of OTA over 24hr and 48hr. **p < 0.005  
and ***p < 0.0005 relative to untreated controls…………………128 
 
Appendix D Figure 4 Quantification of caspase 9 activity in HepG2 cells exposed to  
varying concentrations of OTA over 24hr and 48hr. *p < 0.05,  
**p < 0.005 and ***p < 0.0005 relative to untreated controls……128 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xvi 
 
LIST OF TABLES 
 
 
Chapter 5 Table 1 Caspase 3/7 and 6 activities assessed by luminometry in  
HEK293 cells over 24hr and 48hr post OTA exposure………..89 
 
Chapter 5 Table 2 Quantification of caspase 3/7 and 6 activity in OTA treated  
HepG2 cells at 24hr and 48hr………………………………….90 
 
Appendix A Table 1 Measurements of intracellular ROS in cells exposed to OTA  
and resveratrol over 24hr…………………..…………………..123 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xvii 
 
ABBREVIATIONS 
 
AMP Adenosine monophosphate 
ANOVA Analysis of variance 
APAF1 Apoptotic protease activating factor 1 
APS  Ammonium persulfate 
ARE Antioxidant response element 
ATF4 Activating transcription factor 4 
ATF6 Activating transcription factor 6 
ATP Adenosine triphosphate 
Bad B-cell lymphoma 2-associated death promoter 
Bax B-cell lymphoma 2-associated X-protein 
BCA Bicinchoninic acid 
Bcl-2 B-cell lymphoma 2 
BEN Balkan Endemic Nephropathy 
BER  Base excision repair 
BiP Binding immunoglobulin protein 
BSA Bovine serum albumin 
C/EBP CCAAT-enhancer binding protein 
cAMP Cyclic adenosine monophosphate 
Caspase Cysteine-aspartic residue 
CCM Complete culture media 
CHD Coronary heart disease  
CHOP CCAAT-enhancer binding protein homologous protein 
CIN Chronic interstitial nephritis 
CKD  Chronic kidney disease 
xviii 
 
CO2 Carbon dioxide 
COX Cyclooxygenase 
CR Calorie restriction 
cREB Cyclic adenosine monophosphate response element binding 
CYP450 Cytochrome P450 
DCFDA Dichlorodihydrofluorescein diacetate 
dH20  Deionised water 
DMEM  Dulbecco’s minimum essential media 
DMSO Dimethyl sulphoxide 
DNA Deoxyribose nucleic acid 
DNPH Dinitrophenylhydrazine 
EGFR Epidermal growth factor receptor 
eIF1α Eukaryotic initiation factor 2 alpha 
ELISA Enzyme-linked immunosorbent assay 
EMEM  Eagle’s minimum essential media 
EMT Epithelial-mesenchymal transition 
EPO Erythropoietin 
ER Endoplasmic reticulum 
ERAD Endoplasmic reticulum associated degradation 
ETC Electron transport chain  
FCS Foetal calf serum 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase  
GIT  Gastrointestinal tract 
GPx Glutathione peroxidase 
GRP78 78kDa glucose-related protein 
GSH Glutathione 
xix 
 
GSSG Glutathione disulfide 
H+ Hydrogen 
H20 Water 
H2O2 Hydrogen peroxide 
HCl Hydrochloric acid 
HDAC Histone deacetylase 
HEK293  Human embryonic kidney cells  
HIF1 Hypoxia inducing factor-1 
HO-1 Heme oxygenase 
Hr  Hours 
HRP Horse-radish peroxidase 
HSP Heat shock protein 
IARC   International Agency for Research on Cancer 
IC50 Half maximal inhibitory concentration 
IKK Inhibitory kappa B kinase 
IL-1β Interleukin-1 beta 
IRE1 Inositol requiring enzyme-1 
IκB Inhibitory kappa B 
IκBα Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor alpha 
JECFA Joint Food and Agriculture Organisation of the United Nations/WHO Expert 
Committee on Food Additives 
Keap1 Kelch-like ECH-associated protein 1 
LDL Low-density lipoprotein 
LLC-PK1 Porcine kidney epithelial cells 
LonP1 Lon protease 
MDCK  Madin-Darby canine kidney cells 
xx 
 
mRNA Messenger ribonucleic acid 
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
NaCl Sodium chloride 
NAD+  Nicotinamide adenine dinucleotide (oxidised) 
NADPH Nicotinamide adenine dinucleotide phosphate 
NER Nucleotide excision repair 
NFκB Nuclear factor kappa-light-chain-enhancer of activated B-cells 
NQO-1 Nicotinamide adenine dinucleotide phosphate quinone oxidoreductase 1 
Nrf2 Nuclear factor-erythroid 2-related factor 2 
O2 Oxygen 
O2- Superoxide anion 
OAT Organic anion transporters 
OGG1 8-oxoguanine-DNA-glycosylase 
OH-  Hydroxyl radical 
OP-OA Open-ring Ochratoxin A 
OTA  Ochratoxin A 
OTB Ochratoxin B 
OTC Ochratoxin C 
OTHQ Ochratoxin A hydroquinone 
OTα Ochratoxin alpha 
PAGE Polyacrylamide gel electrophoresis 
PBS Phosphate buffered saline 
PDH Pyruvate dehydrogenase 
PDK1 Pyruvate dehydrogenase kinase-1 
PERK Protein kinase RNA-like endoplasmic reticulum kinase 
PGC1α Peroxisome proliferator-activated receptor gamma coactivation 1-alpha 
xxi 
 
Phe Phenylalanine 
Phe-Tyr Phenylalanine-tyrosine 
pVHL von Hippel Lindau protein 
qPCR Quantitative polymerase chain reaction 
RBI Relative band intensity 
RER Rough endoplasmic reticulum 
RK13  Rabbit kidney cells 
RLU Relative light units  
RNA Ribonucleic acid 
ROS Reactive oxygen species 
RT  Room temperature 
SDS Sodium dodecyl sulphate 
Ser  Serine 
SER Smooth endoplasmic reticulum  
Sir2 Silent information regulator 2 
SIRT Sirtuin 
SMAC Second mitochondrial-derived activator of caspases 
SOD Superoxide dismutase 
SP1 Site-1 protease 
SP2 Site-2 protease 
TCA Trichloroacetic acid 
TEMED Tetramethylenediamine  
TGFβ Transforming growth factor beta 
TNF Tumour necrosis factor 
TRAILR Tumour necrosis factor-related apoptosis inducing ligand receptor 
TTBS Tween-20 Tris buffered saline 
xxii 
 
TWI Tolerable weekly intake 
UPP Ubiquitin proteasome pathway 
UPR Unfolded protein response  
UTT  Urinary tract tumour 
UV Ultraviolet 
VEGF Vascular endothelial growth factor 
WHO   World Health Organisation 
XBP1 X-box-binding protein 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
xxiii 
 
ABSTRACT 
 
Ochratoxin A (OTA), a fungal-derived toxin, contaminates foods consumed by humans (grains, fruit, 
coffee, spices) and animals. This toxin has been implicated as a possible aetiological agent in 
nephropathies across Europe (Balkan endemic nephropathy) and North Africa (chronic interstitial 
nephritis), often causing tumour formation and eventual organ failure. Research has also identified OTA 
as hepatotoxic and immunomodulatory. OTA disrupts redox homeostasis by affecting cellular responses 
to oxidative stress, DNA damage and reactive oxygen species (ROS)-related dysfunction. Although 
tumour formation and renal fibrosis have been reported, a molecular mechanism of action, to date, has 
not been elucidated.  
 
This study evaluates a range of concentrations of OTA (plasma level variations and IC50) over 24hr and 
48hr in human kidney (HEK293) and liver (HepG2) cell models. HEK293 IC50 concentrations of OTA 
at 24hr (1.5µM) and 48hr (9.4µM) increased oxidative stress by modulating the expression of 
endogenous antioxidants, Nrf2 and GSH; furthermore, OTA induced DNA fragmentation at both time 
periods. Resveratrol, a naturally produced phytoalexin found in berries and grapes, was introduced as 
an antioxidant compound. The co-treatment of OTA and resveratrol significantly ameliorated the 
toxicity of OTA; it reduced intracellular ROS, decreased DNA fragmentation, increased GSH 
concentrations and upregulated DNA repair enzyme, OGG1. Resveratrol further upregulated expression 
of repair and maintenance proteins, SIRT1 and LonP1.  
 
A sub-IC50 (0.5µM) and supra-IC50 (2µM) concentration of OTA was assessed to determine its acute 
(24hr) influence on inflammatory processes that promote transformation (epithelial-mesenchymal 
transition) and aberrant replication. The canonical pathway of inflammation was activated by the sub-
IC50 – protein expression of phosphorylated (p)-NFκB (Ser536) was significantly upregulated (p<0.05). 
OTA (0.5µM) induced inflammation (increased pNFκB and pIKK), 1.2µM OTA decreased 
inflammation (decreased caspase 1 and IL-1β, with increased IκBα protein) and 2µM OTA activated 
both the intrinsic and extrinsic pathways of apoptosis, and induced cell death (increased caspases 8, 9, 
3/7). This established that acute exposure to OTA induces inflammation and cell death, possibly 
resulting in renal dysfunction and fibrosis.  
 
Plasma range concentrations (0.125µM – 0.5µM) were used to observe the effects of OTA on tumour 
promoting pathways – ER stress, hypoxia and apoptosis, pathways often dysregulated in tumour 
suppression. OTA increased protein oxidation in HEK293 cells; ER stress-induced cell survival was 
observed in both kidney and liver cells. The protein expression of PERK and peIF2α was increased by 
OTA exposure in both cell lines, indicating protein misfolding and activation of the unfolded protein 
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response (UPR). ATF4 was upregulated; however, CHOP and executioner caspases (6 and 3/7) were 
significantly down-regulated, indicating cell survival. OTA’s effect on pNrf2 and pNFκB indicated 
increased oxidative stress and inflammatory induction. The lowest OTA concentration (0.125µM) 
induced acute hypoxia (increased HIF1α expression) in kidney and liver cells, accompanied by 
increased HSP90 expression. The mRNA expression of VEGF and TGFβ was upregulated over 
prolonged exposure to OTA in both cell lines. Increased HIF1α and HSP90 produces a highly mutagenic 
environment.  
 
The data shows that OTA disrupts several pathways, induces oxidative stress, protein damage, 
inflammation and hypoxia simultaneously. Lower concentrations of OTA induce more robust toxic 
effects and tumour promoting environments. Concurrent modulation of these cellular response 
pathways by OTA could promote cancer formation and organ dysfunction.  
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UKUQALA 
 
I-Ochratoxin A (OTA), i-toxin etholakala ngogwayi, ihlamba ukudla okudliwa ngabantu 
(okusanhlamvu, izithelo, ikhofi, izinongo) nezilwane. Le toxin ifakwe njenge-etiological agent e-
nephropathies kulo lonke elaseYurophu (i-Balkan nephropathy ephilayo) naseNyakatho Afrika (i-
nephritis engapheliyo ye-interstitial interstitial), ngokuvamile edala ukubunjwa kwe-tumor kanye 
nokuhluleka kwesinye isikhathi. Ucwaningo luye lwaphawula i-OTA njenge-hepatotoxic kanye ne-
immunomodulatory. I-OTA iphazamisa i-redox homeostasis ngokuthinta izimpendulo 
zamangqamuzana ekucindezelekeni kwe-oxidative, ukulimala kwe-DNA kanye nezinhlobo ze-oksijeni 
ezisebenzayo (i-ROS) -kusebenza okungasebenzi. Nakuba ukwakheka kwe-tumor kanye ne-renal 
fibrosis kuye kwabikwa, indlela yokusebenza yamangqamuzana, kuze kube yimanje, ingakacacisiwe. 
 
Lolu cwaningo luhlola ububanzi bezinombolo ze-OTA (ukuhluka kwezinga le-plasma ne-IC50) 
ngaphezu kwamahora angu-24 no-48h ezinso zomuntu (HEK293) namamodeli eseli (HepG2). I-
HEK293 I-IC50 yokugxila kwe-OTA ngamahora angu-24 (1.5μM) no-48hr (9.4μM) yandisa 
ukucindezeleka kwe-oxidative ngokumisa ukubonakaliswa kwama-antioxidant okungapheli, i-Nrf2 ne-
GSH; Ngaphezu kwalokho, ukuhlukaniswa kwe-DNA okwenziwe i-OTA kuzo zombili izikhathi 
zesikhathi. I-Resveratrol, i-phytoalexin eyakhiwe ngokwemvelo etholakala kumajikijolo 
namagilebhisi, yasungulwa njenge-antioxidant compound. Ukusebenzisana kwe-OTA kanye 
nokuvuselela kabusha kwamandla kakhulu kwalungisa uketshezi lwe-OTA; yanciphisa i-ROS ye-
intracellular, iyanciphisa ukuhlukaniswa kwe-DNA, ukukhushulwa kwe-GSH okwandisiwe kanye ne-
DNA yokulungisa i-enzyme ye-DNA, OGG1. I-Resveratrol iboniswa ngokuqhubekayo 
okusetshenziselwa ukuguqulwa kwamaprotheni, i-SIRT1 ne-LonP1. 
 
I-sub-IC50 (0.5μM) kanye ne-supra-IC50 (2μM) yokuhlushwa kwe-OTA yahlolwa ukuze inqume 
ithonya layo elibi (24hr) ngezinqubo zokuvuvukala ezikhuthaza ukuguqulwa (ukuguqulwa kwe-
epithelial-mesenchymal) nokuphindaphindiwe okungahambi kahle. Umzila we-canonical of 
inflammation wavulwa yi-IC-50 - amaprotheni ukubonakaliswa kwe-phosphorylated (p) -NFKB 
(Ser536) yayiphakanyisiwe kakhulu (p <0.05). I-OTA (0.5μM) yenza ukuvuvukala (ukukhuphuka kwe-
pNFκB ne-pIKK), i-1.2μM i-OTA yehle ukuvuvukala (ukwehla kwe-caspase 1 ne-IL-1β, nge-protein 
ye-IκBα eyandisiwe) no-2μM i-OTA yasebenzisa kokubili indlela yangaphakathi neyinkimbinkimbi 
ye-apoptosis, futhi yaholela ekufeni kweseli (amakhansela akhuphukile 8, 9, 3/7). Lokhu kwafakazela 
ukuthi ukuvezwa okunamandla ku-OTA kwenza kube nokuvuvukala nokufa kweseli, okungenzeka 
kubangele ukukhubazeka kwama-renal kanye ne-fibrosis. 
 
Ukugxila kwamaplasma (0.125μm - 0.5μM) kwasetshenziswa ukugcina imiphumela ye-OTA nge-
tumor ekhuthaza izindlela - ukucindezeleka kwe-ER, i-hypoxia ne-apoptosis, izindlela ezivame 
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ukuhlukunyezwa ekucindezelweni kwesisu. U-OTA ukwandise uketshezi lweprotheyini kuma-
HEK293 amaseli; Ukusinda kwengqamuzana yokucindezeleka kwe-ER kubonwe emavikini amabili 
nezinso zesibindi. Inkulumo yamaphrotheni ye-PERK ne-peIF2α yanyuswa ukuvezwa kwe-OTA 
kokubili emigqeni yamaseli, okubonisa amaprotheni ukuhlukumeza nokusebenza kwempendulo 
yamaphrotheni (UPR) ebonakalayo. 
 
I-ATF4 yayinganiselwe; Kodwa-ke, i-CHOP kanye ne-executioner caspases (6 no-3/7) yayinciphise 
kakhulu, ekhombisa ukuthi kusinda iseli. Umphumela we-OTA ku-pNrf2 futhi i-pNFκB ikhombise 
ukucindezeleka okwenyuka kwe-oxidative nokufakelwa okuvuthayo. I-concentration ye-OTA ephansi 
kunazo zonke (i-0.125μm) yenza i-hypoxia enobuchopho (inkulumo ekhulisiwe ye-HIF1α) emaqenjini 
ezinso nezinso, ehambisana nenkulumo ekhulisiwe ye-HSP90. Ukubonakaliswa kwe-MRNA ye-VEGF 
ne-TGFβ kwahlukunyezwa ngaphezu kokuvezwa isikhathi eside ku-OTA kumabili imigqa yeseli. 
Ukwanda kwe-HIF1α ne-HSP90 kuveza imvelo eningi kakhulu. 
 
Idatha ibonisa ukuthi i-OTA iphazamisa izindlela eziningana, inciphisa ukucindezeleka okwenziwe 
nge-oxidative, ukulimala kwamaprotheni, ukuvuvukala ne-hypoxia ngesikhathi esisodwa. Izibalo 
ezingezansi ze-OTA zenza imiphumela enobuthi enamandla kakhulu kanye nokugqugquzela izimo. 
Ukuguqulwa kwesimo samanje kwezimpendulo zamagciwane nge-OTA kungakhuthaza ukwakhiwa 
komdlavuza kanye nokusebenza komzimba. 
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CHAPTER 1 
INTRODUCTION 
 
Fungal contamination of foods poses a significant world-wide health problem. Mycotoxins, fungal 
secondary metabolites formed during normal metabolism, which contaminate foods consumed by 
humans and animals (Bhat, 2010). Species of Aspergillus and Penicillium fungi produce various 
mycotoxins, one of the most prevalent being Ochratoxin A (OTA) (Reddy and Bhoola, 2010), which 
frequently contaminates grains, meat products, fruit, coffee, and alcoholic beverages (Ostry et al., 
2013). Fungal and resultant mycotoxin contamination of food can be attributed to poor harvesting 
techniques, inadequate packaging and storage, and poorly regulated transport systems (Bhat, 2010). 
This toxin has a high affinity for protein binding (specifically albumin), resulting in a half-life of 35 
days in humans (Petzinger and Ziegler, 2000). OTA can also affect the health of nursing infants, as it 
has been detected in human breast milk (Jonsyn-Ellis, 2012). 
 
The International Agency for Research on Cancer (IARC) has classified OTA as a group 2B carcinogen, 
indicating that this toxin is possibly carcinogenic to humans ((IARC), 1993). Renal carcinogenicity in 
rodents exposed to OTA is well characterised (Cavin et al., 2007; Gautier et al., 2001). The toxin is 
resistant to high temperatures and pressures, therefore persisting in the food chain (Boudra et al., 1995; 
Trivedi et al., 1992). OTA is a known renal toxicant; it has also been shown to possess hepatotoxic, 
genotoxic, and immunotoxic characteristics (Gayathri et al., 2015; Pfohl-Leszkowicz et al., 1998; 
Thuvander et al., 1995). OTA has been linked as a possible contributing factor in Balkan endemic 
nephropathy (BEN), and chronic interstitial nephritis (CIN) in North African countries (Castegnaro et 
al., 2006; Zaied et al., 2011). These diseases present as progressive renal dysfunction, with eventual 
renal failure and possible tumour formation (Castegnaro et al., 2006; Wafa et al., 1998). Repeated 
exposure to OTA results in alterations to renal cell structure, consequently affecting renal efficiency 
(Heussner et al., 2007). The structurally altered cells become more fibroblast-like in nature, losing renal 
cell characteristics, and progressing to fibrosis (Heussner et al., 2007). Dopp et al. (1999) also showed 
that OTA disrupts cellular structure in Syrian hamster embryo (SHE) fibroblasts by binding to actin 
(Dopp et al., 1999).  
 
OTA-induced disruptions in redox homeostasis and antioxidant response have been researched 
extensively. Ferrante et al. (2006) reported that OTA increased oxidative stress in murine liver and 
kidney (Ferrante et al., 2006). The master regulator of the antioxidant response, nuclear-erythroid 2-
related factor 2 (Nrf2), has been shown to decrease in activity upon OTA exposure (Boesch-
Saadatmandi et al., 2009). Redox disruptions compromise cell functionality and can lead to cell death.  
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Free radical interaction with proteins causes altered structure and function, resulting in misfolded or 
unfolded proteins. Conformational changes result in protein aggregates, which need to be cleared by 
appropriate quality control mechanisms (Gregersen and Bross, 2010). If this aggregation is not cleared 
and protein damage is not repaired, the cell undergoes apoptosis directed by the endoplasmic reticulum 
(ER) and the unfolded protein response (UPR) (Mirzaei and Regnier, 2008). Gan et al. (2017) showed 
that OTA induced ER stress in pig kidney and spleen, while Sheu et al. (2017) reported that OTA 
increased oxidative stress, induced ER stress and eventual cell death in mouse and rat mesangial cells 
(Gan et al., 2017; Sheu et al., 2016). Oxidative damage to DNA results in mutations and possible tumour 
formation, as seen by OTA-promotion of DNA damage in rat liver cells (Kamp et al., 2005a). A hypoxic 
environment is often highly mutagenic, and can contribute to DNA damage and genetic instability 
(Yuan and Glazer, 1998). Stachurska et al. (2011) showed that acute exposure to OTA increased the 
activity of hypoxia inducible factors, transcription factors responsible for cellular response to 
fluctuations in oxygen tension, and decreased vascular endothelial growth factor (VEGF) in porcine 
kidney epithelial (LLC-PK1) cells (Stachurska et al., 2011). This indicates that OTA compromised 
kidney functionality, as VEGF is required for efficient glomerular filtration.  
 
Consumption of mycotoxins frequently occurs in underprivileged communities where food supply and 
storage conditions are inadequate. This becomes especially relevant in poorer communities, such as 
Sub-Saharan Africa, where the disease burden is high (Bankole et al., 2006; Jonsyn-Ellis, 2012). Many 
individuals are exposed to multiple illnesses, such as tuberculosis and HIV, as well as high levels of 
pollution, and mycotoxin ingestion. Furthermore, mycotoxins, such as OTA, have been detected in pet 
food and animal feed, posing a threat to the health of pets and livestock (Denli and Perez, 2010; Singh 
and Chuturgoon, 2017). It is important to determine how mycotoxins, such as OTA, affect biochemical 
outcomes in order to establish targeted therapeutic interventions. 
 
Naturally occurring antioxidants provide easily accessible therapy to circumvent OTA toxicity. 
Resveratrol is a phytoalexin and potent antioxidant that is naturally produced in berries, grapes, peanuts, 
and cocoa plants (Burns et al., 2002) in response to stress or injury. Resveratrol decreases oxidative 
damage (lipid peroxidation), scavenges free radicals, and augments antioxidant defence (Fremont, 
2000; Leonard et al., 2003; Miller and Rice-Evans, 1995). Resveratrol also possesses anti-cancer 
properties. Jang et al. (1997) showed resveratrol-induced inhibition of tumour initiation, promotion, and 
progression in rats (Jang et al., 1997). OTA and resveratrol affect the same biochemical pathways; thus, 
resveratrol could potentially reduce or inhibit OTA-induced toxicity and cellular damage.  
 
OTA has been linked to the progression of renal failure and tumour formation in individuals with 
BEN/CIN, it also contributes to hepatotoxicity and immune dysfunction. The toxin acts on multiple 
pathways, however, there is little knowledge about these biochemical outcomes in humans. This study 
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aimed to determine the biochemical mechanisms by which OTA exerts its toxicity. The effects of OTA 
on human kidney (HEK293) and human liver (HepG2) cells was determined by observing how this 
toxin interacted with several stress pathways. Resveratrol was included to determine if the compound 
could augment the antioxidant response during co-exposure with OTA.   
 
The specific objectives of this study were to determine the following: 
 
- OTA-induced oxidative stress in kidney cells over 24hr and 48hr, and the potential therapeutic 
effects of resveratrol in this model 
- Expression of inflammatory and apoptotic markers during acute exposure to OTA in kidney 
cells 
- Activation of the UPR and ER stress in human kidney and liver cells, in response to plasma 
levels of OTA over 24hr and 48hr 
- Effects of plasma level OTA concentrations on cellular hypoxia response and potential cancer 
biomarkers in kidney and liver cells over 24hr and 48hr 
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CHAPTER 2 
LITERATURE REVIEW 
 
2.1 Mycotoxins 
 
Mycotoxins are low-molecular weight compounds produced as secondary metabolites by various 
species of filamentous fungi around the world. These compounds contaminate a variety of food and 
feedstuffs, ranging from crops and fruit, to meat, beverages, and animal feed. Fungal contamination of 
grains occurs frequently, and often results in vast financial losses (Bhat, 2010). Human and animal 
ingestion of mycotoxins can result in illness and death. Ochratoxins, Fumonisins, and Aflatoxins 
represent a few of the most studied and prevalent toxins encountered in human foods. Fungal 
contamination and accompanying mycotoxin production can occur during harvesting, handling, 
packaging and storage (Bhat, 2010). 
 
Some species of fungi can produce multiple mycotoxins, while several fungal species may produce the 
same mycotoxin (Hussein and Brasel, 2001), as such it is important to determine the effects of toxin 
interaction within animal and human systems. Ingestion of these toxins can affect different communities 
of people. Financially disadvantaged communities would be exposed to higher levels of mycotoxins 
than wealthy communities, as foods of lower quality are likely to be cheaper and freely available. 
Mycotoxins frequently contaminate grains and cereals which make up a staple food group for many 
disadvantaged communities, such as maize and cassava consumption in Sub-Saharan Africa (Bankole 
et al., 2006; Jonsyn-Ellis, 2012). Children would be more susceptible to the effects of Patulin, a toxin 
produced by several fungal species, as it contaminates apple juice and fruit products, frequently 
consumed by young children (Fernández-Cruz et al., 2010).  
 
Certain mycotoxins have been linked as aetiological agents in human diseases – Aflatoxin and 
Fumonisin involvement in hepatocellular carcinoma, oesophageal cancer and immune dysfunction 
(Wild and Gong, 2010; Zain, 2011). Ochratoxins have been associated with the incidence of renal 
dysfunction and renal tumour formation, specifically in Europe and North Africa (Abid et al., 2003; 
Castegnaro et al., 2006), generating much speculation into the toxin’s DNA-damaging effects.  
 
2.1.1 Ochratoxin A 
 
Ochratoxins are a group of mycotoxins consisting of several members, the most common being 
Ochratoxin A (OTA), B (OTB) and C (OTC). OTA is the most prevalent and potent (Reddy and Bhoola, 
2010). Ochratoxin A, or (R)-N-[(5-chloro-3,4-dihydro-8-hydroxy-3-methyl-1-oxo-1H-2-benzopyran-7-
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yl)carbonyl)-ʟ-phenylalanine, is produced by various species of Aspergillus and Penicillium fungi, 
frequently contaminating food consumed by humans and animals (Marquardt and Frohlich, 1992; 
Walker, 2002). OTA has been found in grains, alcoholic beverages, coffee, and meat products, such as 
pork and poultry (Ostry et al., 2013).  
 
OTA was discovered in 1965 in South Africa; it has since been encountered in foods around the world 
(van der Merwe et al., 1965). The toxin has been classified as a group 2B (possibly carcinogenic to 
humans) compound by the International Agency for Research on Cancer (IARC) ((IARC), 1993). The 
Joint Food and Agriculture Organisation of the United Nations (FAO)/World Health Organisation 
(WHO) Expert Committee on Food Additives (JECFA) recommends a maximum tolerable weekly 
intake (TWI) of 112ng/kg body weight (WHO, 2002). OTA is primarily known for its nephrotoxicity 
(Creppy et al., 1995; Loboda et al., 2017; Schwerdt et al., 1999; Zanic-Grubisic et al., 2000) and has 
been linked to Balkan Endemic Nephropathy (BEN) and chronic interstitial nephritis (CIN) – 
progressive renal diseases resulting in kidney failure and possible tumour formation (Castegnaro et al., 
2006; Zaied et al., 2011). It also displays hepatotoxicity (Capraro and Rossi, 2012; Ferrante et al., 2006; 
Gayathri et al., 2015), immunotoxicity (Creppy et al., 1983; Dwivedi and Burns, 1985; Thuvander et 
al., 1995), and genotoxicity (Hibi et al., 2013b; Pfohl-Leszkowicz et al., 1998; Zeljezic et al., 2006).  
 
The chemical structure of OTA (Fig 2.1) enables it to participate in toxic biochemical reactions. OTA 
is a chlorinated isocoumarin compound; it consists of a dihydroisocoumarin moiety carboxyl-linked to 
ʟ-Phenylalanine (Phe). The presence of ʟ-Phe allows the toxin to participate in protein synthesis 
reactions, disrupting protein homeostasis (Pfohl-Leszkowicz et al., 2007). OTA is resistant to both high 
pressures (Trivedi et al., 1992) and temperatures (Boudra et al., 1995), making it difficult to remove or 
degrade the toxin by cooking.  
 
 
 
Figure 2.1: Chemical structure of Ochratoxin A (Hundhausen et al., 2008). 
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2.1.2 Absorption, Metabolism and Excretion 
 
Since OTA is a common food and beverage contaminant, the main route of OTA absorption is through 
oral ingestion. Once ingested, mono-anion and di-anion forms of the toxin are present in the duodenum, 
favouring passive absorption along the gastrointestinal tract (GIT) (Pfohl-Leszkowicz et al., 2007). 
Once in circulation, OTA readily binds to serum albumin and other proteins; up to 99% of the ingested 
toxin binds to plasma proteins (Hagelberg et al., 1989). This high affinity for protein increases the half-
life of the toxin – which varies across species. The half-life in humans is 35 days and OTA can still be 
detected in plasma samples 280 days post-exposure (Petzinger and Ziegler, 2000). The half-life was 
found to reach 4 hours (hr) in chickens (Galtier et al., 1981), 120hr in rats and 21 days in Rhesus 
Macaque monkeys (Hagelberg et al., 1989). Persistence in vivo allows for prolonged interaction and a 
greater potential for harmful outcomes.  
 
Differences in absorption rates, half-lives and toxic effects depend on differences in species, sex, toxin 
dose, health status and general diet of the animal (Pfohl-Leszkowicz et al., 2007). Organic anion 
transporters (OAT) transport OTA into the kidney. Literature has shown that OTA participates in 
enterohepatic circulation (Kumagai and Aibara, 1982; Roth et al., 1988) and kidney reabsorption 
(Ringot et al., 2006), resulting in toxin deposits located at the renal papilla and medulla, increasing cell-
toxin interaction time. Since OTA is protein-bound, it can be reabsorbed at the proximal and distal 
tubules, avoiding excretion, and accumulating in the kidneys. Distribution in vivo has been recorded 
extensively, with OTA found in the milk of rats and cows (Breitholtz-Emanuelsson et al., 1993a; 
Breitholtz-Emanuelsson et al., 1993b). It has also been detected in human breast milk, posing a 
significant health risk to breast-feeding infants (Jonsyn-Ellis, 2012).  
 
Biotransformation provides an alternative mechanism to combat toxicity and persistence of OTA, 
however each metabolic derivative possesses different characteristics and levels of toxicity. Protease-
mediated cleavage of the peptide bond separates the Phe moiety from the chlorinated 
dihydroisocoumarin moiety yielding Ochratoxin alpha (OTα) and Phe (Fig 2.2) (Sorrenti et al., 2013). 
OTα is unable to disturb protein homeostasis without the Phe moiety, resulting in a less toxic compound. 
This reaction is performed in the large intestine by gut microbiota. Hohler et al. (1999) proposed that 
ruminants (cows, sheep) would possess increased resistance to OTA toxicity as the rumen would 
contain greater communities of microorganisms (Hohler et al., 1999). This theory extends to the 
possibility of using ruminants to remove OTA from the environment by feeding contaminated grains to 
ruminants for biotransformation to less toxic metabolites, such as OTα (Hohler et al., 1999).  
 
OTA can be converted into several metabolites via phase I reactions with cytochrome P450 isoforms 
(CYP450 1A1/1A2/2B1/3A1/3A2). The kidney and liver express high levels of cytochromes, thus are 
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heavily involved in biotransformation, increasing susceptibility to OTA toxicity during excretion of the 
toxin (Ringot et al., 2006). Protein-OTA binding, however, prevents successful elimination, hence the 
need for chemical modification of the parent molecule into more soluble products. The cytochrome 
interaction yields hydroxylated derivatives – 4(R)-OH OTA, 4(S)-OH OTA, 10-OH OTA (Fig 2.2) – 
which are less toxic than OTA and can be easily eliminated (Pitout, 1969). The removal of OTA’s 
chlorine atom produces OTB (Fig 2.2), a less toxic derivative which is unable to participate in iron 
chelation or reactive oxygen species (ROS) generation via Fenton reactions (Fig 2.4), OTA can also be 
transformed into more toxic metabolites, such as OTA hydroquinone (OTHQ) and open-ring OTA (OP-
OA) – these compounds undergo clearance at a slower rate than OTA and research has shown increased 
OP-OA toxicity in rats (Xiao et al., 1996). OTA excretion occurs via biliary (faeces) and renal (urine) 
routes, as such the toxin is in close contact with both the liver and kidney, resulting in toxin 
accumulation. 
 
 
 
Figure 2.2: Biotransformation of OTA into various metabolites by hydroxylation and hydrolysis. 
(Adapted from Ringot et al. (2006), prepared by author (Ringot et al., 2006)). 
 
2.1.3 Related Nephropathies 
 
OTA has been identified as a possible contributing factor in nephropathies around the world, most 
prominently Balkan endemic nephropathy (BEN) – a renal disease experienced by individuals in the 
Balkan region of Europe (Fig 2.3) (Barnes et al., 1977; Castegnaro et al., 2006; Elling and Krogh, 1977). 
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The disease presents as progressive renal dysfunction and eventual failure, occasionally with the 
development of urinary tract tumours (UTT). This region experiences high levels of OTA contamination 
with inhabitants consuming OTA levels approaching and sometimes exceeding the TWI of 112ng/kg 
body weight (Abouzied et al., 2002; Vrabcheva et al., 2004). Chronic interstitial nephritis (CIN) 
presents with similar kidney dysfunction and tumour formation, and has been recorded in Northern 
Africa (Fig 2.3) (Abid et al., 2003; Wafa et al., 1998; Zaied et al., 2011). Heussner et al. (2007) reported 
alterations to renal cellular structure and function when repeatedly exposed to OTA (Heussner et al., 
2007). The research suggested conversion from renal epithelia to fibroblast-like cells in an attempt to 
adapt and resist OTA toxicity. During conversion, collagen levels increase, renal cells proliferate, 
migrate, and become more fibroblast-like, ultimately losing renal structure and function (Heussner et 
al., 2007). These changes present as progressive fibrosis seen in OTA-induced nephrotoxicity 
(BEN/CIN).  
 
 
 
Figure 2.3: Maps showing Balkan Peninsula (Google, 2009) and North African regions (Google, 
2017) where incidences of Balkan endemic nephropathy (BEN) and chronic interstitial nephritis 
(CIN) have been reported. 
 
2.2 Ochratoxin A Toxicity and Biochemical Responses 
 
OTA is known to exert toxic effects on the kidney (Creppy et al., 1995), liver (Capraro and Rossi, 2012) 
and immune system (Thuvander et al., 1995). It is also a known carcinogen in rodents and possibly 
contributes to various nephropathies and tumour formation (Castegnaro et al., 2006). However, the 
exact mechanism of action is elusive; the toxin acts on several signalling pathways and alters cellular 
functioning at a biochemical level. Many mechanisms of action have been proposed, all of which could 
act in concert to contribute to overall OTA toxicity. 
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2.2.1 Mitochondrial Toxicity and Oxidative Stress Induction 
2.2.1.1 Mitochondrial ROS Production 
 
The mitochondrion regulates cellular metabolism, apoptosis and, most importantly, produces adenosine 
triphosphate (ATP) via respiration. Electrons are transferred along the electron transport chain (ETC) 
located on the inner mitochondrial membrane, driving ATP synthesis, some electrons combine with 
oxygen (O2) prematurely and yield superoxide anions (O2-) (Semenza, 2011). Electron transport is 
optimised in a healthy cell to ensure efficient production of ATP without excessive ROS production, 
but disturbances in mitochondrial homeostasis destabilise this balance and result in overproduction of 
ROS. OTA has been reported to affect mitochondrial functioning, contributing to defective ATP 
synthesis, disruptions in the ETC, and increased production of ROS (O2-, hydroxyl radicals (OH-)) 
(Cooke et al., 2003). The toxin possesses a chlorine atom, which can chelate iron and promote Fenton 
reactions (Fig 2.4), further increasing cellular ROS production. ROS are very reactive with biological 
molecules, increased production of these radicals culminates in deoxyribonucleic acid (DNA) strand 
breakage, calcium disruption, lipid peroxidation and cellular dysfunction. OTA has been shown to 
induce oxidative damage in several in vitro (Arbillaga et al., 2007; Raghubeer et al., 2015b) and in vivo 
(Cavin et al., 2007; Ferrante et al., 2006; Kamp et al., 2005a) models. Cells respond to this toxic insult 
by mobilising defence and repair mechanisms, most importantly, nuclear factor-erythroid 2-related 
factor 2 (Nrf2) and the antioxidant response element (ARE) would be activated to upregulate 
transcription of defensive proteins (Nguyen et al., 2009) – catalase, glutathione peroxidase (GPx), 
superoxide dismutase (SOD) 1 in the cytoplasm and SOD2 in the mitochondria. Ferrante et al. (2006) 
reported increased oxidative stress and concomitant lipid peroxidation in the liver and kidneys of mice 
exposed to OTA (Ferrante et al., 2006). 
 
 
 
Figure 2.4: Hydroxyl radical production by iron chelation during Fenton reaction (Halliwell and 
Chirico, 1993). 
 
2.2.1.2 Nuclear factor-erythroid 2-related factor 2 (Nrf2): The Master Regulator 
 
Nrf2, a transcription factor closely associated with its repressor, Kelch-like ECH-associated protein 1 
(Keap1), is responsible for mounting the antioxidant defence response. Keap1 acts as an oxidative stress 
sensor (Kobayashi et al., 2004). During absences of stress stimuli, Keap1 sequesters Nrf2 in the 
cytoplasm and prevents its translocation to the nucleus (Fig 2.5). In this complex, Nrf2 is rapidly 
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degraded by the ubiquitin-proteasome pathway (UPP) (Itoh et al., 1999; McMahon et al., 2003; Stewart 
et al., 2003). Upon interaction with free radicals, Keap1 breaks the association with Nrf2 allowing the 
transcription factor to translocate to the nucleus, heterodimerize with a small Maf protein, and bind to 
the ARE in the promoter regions of antioxidant enzyme genes (Fig 2.5), such as NADPH quinone 
oxidoreductase 1 (NQO1) and heme oxygenase 1 (HO-1) (Motohashi and Yamamoto, 2004; Vomhof-
DeKrey and Picklo, 2012). The activation of this element upregulates transcription of a battery of 
antioxidant genes, such as SOD, catalase, and GPx, attempting to restore homeostasis and neutralise 
excessive ROS. SOD cleaves mitochondrial ROS produced from the ETC and transforms it into 
hydrogen peroxide (H2O2) and O2 (Pias et al., 2003). Thereafter, catalase, a cytosolic selenoprotein, 
facilitates the reduction of H2O2 to water (H2O) (Alfonso-Prieto et al., 2012). GPx and its cofactor, 
tripeptide thiol glutathione (GSH), confer protection against ROS by scavenging free radicals. GSH, 
consisting of glutamate, cysteine, and glycine, scavenges free radicals and is oxidised during this 
reaction, forming glutathione disulphide (GSSG) (Wu et al., 2004). The ratio of GSH:GSSG indicates 
the extent of cellular oxidative stress (Zitka et al., 2012). Research has shown that OTA downregulates 
Nrf2 activity affecting overall antioxidant defence responses (Boesch-Saadatmandi et al., 2009; Cavin 
et al., 2007; Stachurska et al., 2013). Disruptions in this pathway would render the cell vulnerable to 
further oxidative damage, protein synthesis impairment, and DNA strand breaks, contributing to disease 
manifestation. Manipulation of the Nrf2-Keap1 pathway could hold the key to combatting OTA 
toxicity, and research has shown that natural compounds, such as resveratrol and sulforaphane, could 
be used to modulate Nrf2 activity, enhancing the antioxidant response (Bishayee et al., 2010; Cheung 
and Kong, 2010).  
 
 
 
Figure 2.5: Representation of Nrf2-Keap1 interaction and activation of antioxidant response (Adapted 
from Kim et al. (2010), prepared by author (Kim and Vaziri, 2010)). 
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2.2.2 Protein Synthesis and Apoptosis 
2.2.2.1 Calcium Homeostasis during Endoplasmic Reticulum (ER) Stress 
 
Disruptions in calcium homeostasis indicate an early event of ROS-induced damage. Calcium plays an 
important role as a secondary messenger, mediating the transfer of biological information; if not tightly 
regulated disturbances in calcium homeostasis could be fatal to the cell. Altered homeostasis causes 
increased calcium release from cellular stores, such as the endoplasmic reticulum (ER) (Brini et al., 
2013). This response jeopardises functionality of calcium-sensitive channels, causing depolarisation of 
the mitochondrial membrane, release of cytochrome c, and activation of the caspase cascade, driving 
the cell toward apoptosis. Dopp et al. (1999) showed that OTA disrupted intracellular calcium levels in 
Syrian hamster embryo (SHE) fibroblasts by releasing intracellular stores and increasing extracellular 
influx (Dopp et al., 1999). As a result, this alteration disrupted the cytoskeleton by directly binding to 
actin, ultimately compromising cellular structure and function (Dopp et al., 1999). Structural damage 
could be the cause of OTA-induced renal cell impairment and the progression to fibrosis.  
 
Disruptions in ER homeostasis would further increase calcium release; these disruptions occur when 
OTA affects protein synthesis. OTA contains a Phe moiety, which allows the toxin to compete with Phe 
during protein interactions (Fig 2.6). OTA competitively inhibits phenylalanine-tyrosine (Phe-Tyr) 
synthase interaction with Phe, disrupting peptide elongation and amino acylation (Creppy et al., 1990; 
Zanic-Grubisic et al., 2000). Phe hydroxylase mediates Phe metabolism by converting Phe to Tyr using 
an irreversible hydroxylation reaction (Zanic-Grubisic et al., 2000). OTA could disrupt this process by 
competitive inhibition as a substrate for the enzyme, leading to decreased synthesis of Phe-requiring 
proteins and accumulation of Phe in the blood (Ringot et al., 2006). In this way, OTA would induce 
protein synthesis stress, activating several quality control pathways.  
 
 
Figure 2.6: Protein synthesis disruptions resulting from phenylalanine moiety toxicity (prepared by 
author).  
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2.2.2.2 Lon Protease1 (LonP1)-mediated quality control 
 
Proteins have unique structures dependent on their functionality; disruptions in this structure would lead 
to misfolded and dysfunctional proteins. Oxidative stress impacts protein structure, consequently 
affecting protein function (Gregersen and Bross, 2010). Proteins can be affected by ROS in several 
ways – oxidation of the protein backbone causing fragmentation, oxidation of amino acid side chains, 
and formation of protein carbonyl derivatives (Berlett and Stadtman, 1997). ROS-induced alterations 
to protein conformation lead to changes in hydrophobicity and protein aggregation – failure to remove 
these aggregates by proteolytic means would disrupt metabolism and even lead to cell death (Mirzaei 
and Regnier, 2008). Lon protease-1 (LonP1) is involved in mitochondrial quality control and the 
maintenance of mitochondrial DNA turnover (Quirós et al., 2014). This protease degrades damaged 
proteins and promotes cellular survival. LonP1 activity is increased by hypoxia, oxidative and ER stress, 
and has also been linked to tumourigenesis if overexpressed (Quiros et al., 2014). Sirtuin 3 (SIRT3), is 
a mitochondrially located deacetylase which functions in mitochondrial responses to oxidative stress 
and protein misfolding (Giralt and Villarroya, 2012). SIRT3 has been reported to regulate the 
acetylation of LonP1, affecting its stability and expression (Hebert et al., 2013). Accumulation of 
specific proteins is often linked to disease conditions, such as Alzheimer’s, and aging (Mirzaei and 
Regnier, 2008).  
 
2.2.2.3 ER Stress and Protein Repair 
 
During oxidative stress the incidence of unfolded proteins increases, initiating the unfolded protein 
response (UPR) to restore protein conformation or induce apoptosis if the damage is too significant. 
The ER is a specialised organelle responsible for the synthesis, folding and transport of proteins to 
appropriate destinations. It also manufactures phospholipids and steroids, and serves as a calcium 
reservoir (Bravo et al., 2013). The ER is divided into two types – smooth endoplasmic reticulum (SER) 
and rough endoplasmic reticulum (RER). RER contains ribosomes for protein synthesis, while SER is 
ribosome-free and specialises in lipid manufacture. The localisation of SER and RER depends on cell 
function (i.e., protein or steroid synthesis specialisation) (Bravo et al., 2013). ER stress is induced by 
circumstances that alter ER homeostasis and function, such as nutrient deprivation, toxic insult, and 
protein misfolding. This in turn, activates the UPR – a three-pronged mechanism of protein repair. The 
UPR seeks to restore protein homeostasis by simultaneously decreasing global protein synthesis, 
increasing the folding capacity by increasing chaperone proteins, and degrading excess damaged 
proteins (Rozpędek et al., 2016).  
 
Protein kinase RNA-like endoplasmic reticulum kinase (PERK), a marker for ER stress, phosphorylates 
eukaryotic initiation factor 2 alpha (eIF2α), which inhibits global protein synthesis to decrease client 
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load in the ER lumen (Fig 2.7). eIF2α also selectively translates activating transcription factor 4 (ATF4) 
to mediate expression of genes relating to amino acid metabolism, redox homeostasis, and cell survival 
(Ye et al., 2010). ATF4 can upregulate expression of CCAAT-enhancer binding protein (C/EBP) 
homologous protein (CHOP), a mediator of apoptosis (Nishitoh, 2012). The PERK-eIF2α-ATF4-CHOP 
pathway aims to decrease overall protein synthesis to alleviate accumulation of non-native proteins in 
the ER lumen (Bravo et al., 2013).  
 
The inositol requiring enzyme-1 (IRE1) pathway, the second branch of the UPR, senses the 
accumulation of unfolded proteins in the ER lumen (Shamu and Walter, 1996) and increases the 
expression of ER chaperone proteins (such as heat shock proteins (HSP)), in this manner promoting cell 
survival during ER stress (Fig 2.7) (Cox et al., 1993). IRE1α and IRE1β are two paralogs present in 
mammalian cells. During ER stress IRE1α catalyses X-box-binding protein 1 (XBP1) RNA splicing 
(Tirasophon et al., 1998), yielding a protein which regulates genes responsible for ER protein synthesis, 
protein folding, redox metabolism, and degradation of misfolded proteins via ER-associated 
degradation (ERAD – ubiquitin-proteasome pathway) and autophagy (lysosomal pathway) (Walter and 
Ron, 2011).  
 
The third branch of the UPR is the activating transcription factor 6 (ATF6) pathway. During ER stress 
activation this transcription factor is cleaved by Site-1 protease (SP1 – yielding p50ATF6α and site-2 
protease (SP2 – yielding p60ATF6β) at the Golgi apparatus. p50ATF6α (the N-terminal fragment) 
enters the nucleus and upregulates UPR gene transcription to increase protein folding capacity (Fig 2.7). 
This activity leads to increased binding immunoglobulin (BiP) or 78kDA glucose-regulated protein 
(GRP78) (Schroder and Kaufman, 2005; Yamamoto et al., 2004), CHOP (Ma et al., 2002), and XBP1 
(Yoshida et al., 2001). PERK, IRE1 and ATF6 are all rendered inactive during periods of low stress by 
BiP/GRP78, an ER chaperone (Wang et al., 2009). Upon sensing ER stress BiP/GRP78 releases the ER 
transmembrane signal transducers (PERK/IRE1/ATF6), inducing their activation and subsequent UPR 
activity. The pro-apoptotic function of CHOP is activated during periods of excessive ER stress, and if 
the UPR cannot restore homeostasis (Li et al., 2014). CHOP promotes the expression of pro-apoptotic 
genes, resulting in the progression of apoptosis. 
 
Gan et al. (2017) reported that OTA induced ER stress in pig kidney and spleen, by upregulation of 
GRP78 protein (Gan et al., 2017). Sheu et al. (2017) further reported that OTA increased expression of 
phosphorylated PERK, phosphorylated eIF2α, and CHOP in mouse and rat mesangial cells (Sheu et al., 
2016). This research showed OTA-induced ER stress, ROS production and resultant apoptosis (Sheu et 
al., 2016). OTA is known for renal and hepatic toxicity, however, research on ER stress in human kidney 
and liver cells is lacking, this leaves a gap in knowledge with regards to OTA-induced ER stress and 
UPR activity in human cells.  
14 
 
 
 
Figure 2.7: Representation of molecular mechanisms involved in ER stress induction of the UPR 
leading to protein repair and cell survival (Kadowaki and Nishitoh, 2013). 
 
2.2.2.4 OTA and Apoptosis Induction 
 
Apoptosis or programmed cell death is a carefully controlled process that is fundamental to long term 
survival in multicellular organisms. Apoptosis regulates cellular proliferation during development or 
injury (Orrenius et al., 2011). This process is carried out in a clinical manner, minimising leakage of 
cell contents, which in turn prevents mass inflammation. Apoptosis occurs during periods of cellular 
stress, where the cell becomes damaged and cannot be repaired. Apoptosis is controlled by families of 
pro- or anti-apoptotic proteins. Induction is modulated by the pro-apoptotic family of B-cell lymphoma 
2 (Bcl-2) proteins (Bcl-2-associated X protein (Bax), Bcl-2-associated death promoter (Bad)) 
(Tsujimoto, 1998). Bouaziz et al. (2011) showed that OTA can modulate the expression of these Bcl-2 
proteins in various human cancer cells to induce apoptosis (Bouaziz et al., 2011). 
 
Apoptosis can occur via two mechanisms; both require a cascade of cysteine-aspartic proteases 
(caspases). When cognate ligands bind to death receptors, such as the tumour necrosis factor (TNF)-
related apoptosis-inducing ligand receptor (TRAILR) and Fas, initiator caspases 8 and 10 are activated 
and in turn cleave and activate executioner caspases 3 and 7, resulting in apoptosis (Fig 2.8) (Ichim and 
Tait, 2016). This is termed the extrinsic pathway. During the second pathway, certain cellular stimuli 
(DNA damage, ER stress, hypoxia) trigger the activity of pro-apoptotic proteins (Bax, Bad), these 
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proteins induce permeabilisation of the outer mitochondrial membrane releasing cytochrome c and 
second mitochondrial-derived activator of caspases (SMAC) into the cytosol (Fig 2.8), inducing the 
formation of an apoptosome when cytochrome c interacts with apoptotic protease activating factor 1 
(APAF1) (Ichim and Tait, 2016). This activates caspase 9, which activates executioner caspases 3 and 
7, completing the intrinsic, or mitochondrial, mechanism of apoptosis. Literature shows that OTA is 
capable of inducing apoptosis in vitro in neuronal cells (Zhang et al., 2009), MDCK-C7 cells (Gekle et 
al., 2000) and human kidney cells (Raghubeer et al., 2017), as well as in vivo in rats (Petrik et al., 2003) 
and mice (Atroshi et al., 2000). Excessive apoptosis could cause tissue wasting and compromise organ 
functionality, whereas insufficient apoptosis would allow unchecked cellular proliferation and possible 
cancer formation.  
 
 
 
Figure 2.8: The extrinsic and intrinsic mechanisms of apoptosis (Ichim and Tait, 2016). 
 
 
 
 
 
16 
 
2.2.3 Genotoxicity 
2.2.3.1 OTA-induced DNA damage 
 
OTA-induced DNA damage is greatly debated, with some authors maintaining that OTA can directly 
induce genotoxicity, while others believe DNA damage is a secondary outcome due to OTA-induced 
oxidative stress (Sorrenti et al., 2013). DNA strand breakage is observed when OH- radicals are inserted 
into DNA double bonds (yielding adduct radicals) or when hydrogen (H+) is abstracted from thymine 
methyl groups (yielding allyl radicals) (Cooke et al., 2003). The radicals produce multiple DNA 
products, which can be removed if the cell is functioning optimally, however if the antioxidant and 
DNA repair responses are defective then the bases would persist and compromise genomic integrity. 
Genomic instability is a critical event in cancer initiation, with many studies reporting OTA-induced 
DNA fragmentation (Bouslimi et al., 2008; Golli-Bennour et al., 2010; Pfohl-Leszkowicz et al., 1991), 
although the method of this consequence is unknown. Raghubeer et al. (2015) demonstrated DNA 
fragmentation in human kidney cells exposed to OTA, and Kamp et al. (2005) showed DNA damage in 
rat liver cells (Kamp et al., 2005a; Raghubeer et al., 2015b). OTA has also been shown to upregulate 
genes related to DNA damage repair in primary rat hepatocytes (Chopra et al., 2010).  
 
2.2.3.2 DNA Damage repair 
 
Oxidative stress-induced DNA damage has been researched extensively, with a similar conclusion – 
excessive oxidative stress frequently results in DNA damage (Cerutti, 1989; Halliwell and Aruoma, 
1991; Junod et al., 1989; Kleiman et al., 1990; Storz et al., 1987). DNA strand breakage can result in 
mutations and genomic instability (Cooke et al., 2003). Secondary measures are put into effect should 
the antioxidant defence systems fail, and oxidative DNA damage occurs. The cell imposes several check 
points to repair damage and prevent replication of aberrant DNA. A central tumour suppressor, p53, 
known as the “guardian of the genome” is involved in a number of DNA damage response pathways 
(Williams and Schumacher, 2016). p53 plays an important role in cell cycle control, by acting as a 
check point before allowing replication to occur. If DNA damage is detected, p53 arrests cell cycle 
progression to allow DNA repair (Williams and Schumacher, 2016). Wang et al. (1995) and Smith et 
al. (1995) showed that p53 is active in the nucleotide excision repair (NER) pathway, involved in 
repairing damage induced by ultraviolet (UV) irradiation (Smith et al., 1995; Wang et al., 1995b). p53 
has been reported to participate in the base excision repair (BER) pathway, by augmenting the activity 
of base repair machinery via cell cycle control; should the BER pathway fail p53 could direct the cell 
towards apoptosis (Offer et al., 2001).  
 
Another member of the BER process is 8-oxoguanine-DNA-glycosylase (OGG1), an enzyme which 
removes 8-oxoguanine base lesions which are commonly produced by ROS exposure (Cooke et al., 
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2003). These highly mutagenic lesions result from adenine mispairs, inducing G:C to T:A transverse 
mutations (Abedin et al., 2013). OGG1 therefore, plays a fundamental role in preventing ROS-induced 
mutations, dysfunction of this enzyme would result in base lesion accumulation, increased mutation 
frequency and greater risk of carcinogenesis.  
 
2.2.4 Inflammation, Hypoxia and the Cancer Microenvironment 
2.2.4.1 Classical Inflammatory Pathway 
 
Inflammation is a mechanistic response to cellular stressors by the innate immune system, it functions 
to remove the source of stress, repair the cellular damage, and restore homeostasis (Lawrence and 
Gilroy, 2007). However, prolonged or chronic inflammation can be a major determining factor in the 
onset and progression of diseases such as diabetes, cardiovascular diseases (CVD) and cancer (Khansari 
et al., 2009). The transcription factor, nuclear factor kappa-light-chain-enhancer of activated B-cells 
(NFκB) consisting of two subunits (p65 and p50) (Fig 2.9), is responsible for both pro- and anti-
inflammatory induction (Lawrence, 2009). During normal cellular conditions, NFκB is held inactive by 
its inhibitor, nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor alpha (IκBα), 
in the cytosol until specific signals are received to activate NFκB. At this point, IκB kinase (IKK) is 
activated and phosphorylates IκBα, causing its degradation by ubiquitination (Fig 2.9) (Israël, 2010). 
This results in IκBα dissociating from NFκB, allowing the transcription factor to translocate to the 
nucleus and transcribe numerous genes associated with inflammation, redox response, cellular repair, 
and apoptosis (Chaves et al., 2009; Pahl, 1999). Known inducers of NFκB are ROS, interleukin-1 beta 
(IL-1β), and TNFα (Denes et al., 2012; Fitzgerald et al., 2007; Renard et al., 1997). Caspase 1 
(interleukin-1 converting enzyme (ICE)) processes inactive pro-IL-1β to the active form – IL-1β, which 
promotes NFκB activity.  
 
Persistent inflammation could result in apoptosis if homeostasis cannot be reached; it could also alter 
cellular structure and function. Epithelial-mesenchymal transition (EMT) is characterised as the trans-
differentiation of epithelial into mesenchymal cells, when uncontrolled it could lead to fibrotic 
conditions and cancer induction (Lamouille et al., 2014). Inflammation has been noted as an initiating 
factor in the progression of EMT (Li et al., 2016). Research has shown that inflammatory factors (TNFα, 
IL-1β) can exacerbate the effects of transforming growth factor beta (TGFβ) on EMT induction in 
bronchial cells (Borthwick et al., 2013; Doerner and Zuraw, 2009; Kamitani et al., 2011). Hennemeier 
et al. (2012) showed that OTA upregulates genes associated with inflammation and malignant 
transformation in human primary proximal tubular cells (Hennemeier et al., 2012). OTA induced 
oxidative stress and NFkB activation in HepG2 cells, with quercetin (a flavonoid found in fruits and 
vegetables) used as therapeutic intervention (Ramyaa and Padma, 2013). Little data exists detailing the 
inflammatory effects of OTA in human kidney cells.  
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Figure 2.9: The classical pathway of NFκB activation by IKK-induced phosphorylation of IκBα to 
activate NFκB (Luo et al., 2005). 
 
TGFβ is a cytokine which plays an important role in angiogenesis, apoptosis, proliferation and 
differentiation (Massagué et al., 2000). It can be activated by several stimuli, such as oxidative stress 
and inflammation. Cancer cells can exploit the function of TGFβ and escape proliferative control, 
resulting in malignancy and metastasis (Elliott and Blobe, 2005); overexpression of TGFβ has been 
linked with numerous human cancers (dos Reis et al., 2011; Higashi et al., 2001). Al Anati (2009) 
reported increased expression of TNFα and subsequent inflammation in rat liver post-OTA exposure 
(Al-Anati et al., 2009). Raghubeer et al. (2017) demonstrated that OTA induced inflammation in human 
kidney cells, by upregulation of active NFκB (Raghubeer et al., 2017). Furthermore, inhibition of 
inflammatory factors (TNFα) assists in reducing the occurrence of EMT (Borthwick et al., 2013), 
inhibiting NFκB reduced interstitial fibrosis (Miyajima et al., 2003), and upregulating the inhibitor of 
NFκB, IκBα, reduces fibrosis of the lung and kidney. Understanding EMT is particularly important for 
determining the mechanism underlying OTA toxicity and its ability to induce progressive fibrosis in 
the kidney (Lopez-Novoa and Nieto, 2009).  
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2.2.4.2 Hypoxia Inducing Factor-1 mediation of Hypoxia and Cancer   
 
The cancer microenvironment represents the cellular surroundings in which cancer cells survive, this 
environment can be very hostile, but can also provide the perfect combination of factors for tumour 
cells to thrive. The environment contains areas of hypoxia, with an acidic pH, and nutrient deprivation 
(Vaupel, 2004). For tumours to develop into malignancies, they must pass through the hallmarks of 
cancer and acquire certain abilities to promote survival and dissemination (Mbeunkui and Johann, 
2009). These abilities include moving within the tumour mass, as well as being able to survive transport 
in blood, the ability to degrade extracellular matrix, and re-establish growth in a new tissue environment 
(Weinberg, 2007). These characteristics all point towards malignant growth and metastasis. Hypoxia is 
often a common characteristic of the tumour microenvironment. Limited O2 availability prompts 
tumour cells to adapt in order to survive, it also promotes genetic instability as hypoxic conditions are 
often mutagenic (Yuan and Glazer, 1998). 
 
Cellular adaptive responses are mediated by hypoxia inducing factor-1 (HIF1), the master regulator of 
cellular hypoxia response, consisting of two subunits – HIF1α and HIF1β (Chun et al., 2002; Wang et 
al., 1995a). HIF1α is the O2-dependent, cytoplasmic subunit; it is continually degraded during normoxia 
by the ubiquitin-proteasome system (Fig 2.10). HIF1β is O2-independent and constitutively expressed 
in the nucleus (Semenza, 2001a). Specific prolyl residues of HIF1α are hydroxylated in well-
oxygenated cells by O2-dependent enzymes; these modified sites bind to the von Hippel-Lindau protein 
(pVHL), marking HIF1α for degradation (Cockman et al., 2000; Maxwell et al., 1999). During hypoxic 
conditions the prolyl sites are not hydroxylated, preventing pVHL binding and consequent proteasomal 
degradation; HIF1α is free to translocate to the nucleus to heterodimerize with HIF1β and activate 
hypoxia response genes (Fig 2.10), such as vascular endothelial growth factor (VEGF), erythropoietin 
(EPO), growth factors, and glycolytic enzymes (Fig 2.11) (Vaupel, 2004). VEGF is the most potent 
angiogenic promoter, it is essential for efficient glomerular filtration, and the formation of new blood 
vessels (Pepper et al., 1991; Semenza, 2001b). EPO promotes the formation of new blood cells during 
hypoxia (Haase, 2013), while glycolytic enzymes (such as hexokinase) ensure that ATP levels are 
maintained in O2-deprived cells (Marin-Hernandez et al., 2009).  
 
Pyruvate dehydrogenase kinase-1 (PDK1) functions with HIF1α for cellular adaptation to hypoxia 
(Prigione et al., 2014). PDK1 inactivates pyruvate dehydrogenase (PDH) – which converts pyruvate 
into acetyl-CoA, used in the Krebs cycle to produce ATP. In this way PDK1 decreases pyruvate 
oxidation and increases lactate formation, called the “Pasteur Effect” (Liu and Yin, 2017). For cancer 
cell survival, HIF1α and PDK1 would produce a metabolic shift (Fig 2.11) to ensure an adequate supply 
of nutrients (Prigione et al., 2014). PDK1 could promote the Warburg effect, which would allow cancer 
cells to produce energy without pyruvate oxidation (Vander Heiden et al., 2009). 
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Figure 2.10: Representation of HIF1α-pVHL interaction during normoxia (degradation by ubiquitin-
proteasome system) and hypoxia (nucleus translocation). (Adapted from Pires et al (2014), prepared by 
author (Pires, 2014)). 
 
Heat shock protein 90 (HSP90) functions to stabilise protein conformation and degrade damaged 
proteins (Buchner, 1999). It interacts closely with HIF1α and is a crucial regulator of HIF1α activity 
(Isaacs et al., 2002). HSP90 participates in steroid receptor functioning; however, this ability can prove 
detrimental as HSP90 can modulate the functioning of growth factor receptors, such as epidermal 
growth factor receptor (EGFR), and alter apoptosis signalling (Lurje and Lenz, 2009). HSP90 has been 
linked to tumourigenesis as it influences growth signals, stabilises mutant proteins and induces VEGF 
(Fontana et al., 2002). These abilities indicate that HSP90 can select for cells with DNA mutations, as 
well as promote angiogenesis and cell proliferation of compromised cells. HSPs are often overexpressed 
in tumours, as such current research has focused on targeting HSPs in search of anti-cancer therapeutics 
(Whitesell and Lindquist, 2005).  
 
The effects of OTA on hypoxia inducible factors (HIFs) in porcine kidney epithelial (LLC-PK1) cells 
has been reported by Stachurska et al. (2011), indicating that acute OTA exposure increases activity of 
HIFs and decreases VEGF production, compromising kidney functionality (Stachurska et al., 2011). 
This data poses an interesting question as to how OTA-induced modulation of hypoxia responses 
contributes to nephrotoxicity; how do these effects differ during periods of extended exposure to the 
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toxin? Presently, no data exists on the relationship between OTA and the hypoxia response in human 
kidney or liver cells.  
 
Taken together, these factors contribute to tumour cell adaptation and metastasis in hypoxic 
environments. Yasuda et al. (2004) demonstrated that HIF1α induces a metabolic switch in cancer cells 
by upregulating VEGF and hexokinase expression in hepatocellular carcinoma (Yasuda et al., 2004), 
while Kallergi et al. (2009) reported increased levels of HIF1α and VEGF in metastatic breast cancer 
(Kallergi et al., 2009). Cancer cells are able to respond and adapt to hostile conditions with HIF1α as 
the mediator of adaptation, exerting selective pressure on malignant cells by selecting adapted 
(increased proliferation and apoptosis resistance) over non-adapted cells (Graeber et al., 1996). 
  
 
 
Figure 2.11: HIF1α activators and downstream targets, resulting in cellular adaptation of cancer cells 
to a hypoxic environment (Vaupel, 2004). 
 
2.3 Resveratrol, a Possible Therapeutic 
 
Resveratrol is a naturally produced plant compound reported to possess an array of medical benefits. It 
can be found in various foods, such as berries, cocoa products, peanuts, wine and grapes (Burns et al., 
2002). Resveratrol was discovered in 1940 when it was isolated from the roots of Veratum grandiflorum 
or white hellebore (Takaoka, 1940). Large amounts of resveratrol are produced by Vitis vinifera 
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(common grape vine) in response to cellular stress or injury, UV radiation damage or fungal infection 
(specifically Botrytis cinerea) (Langcake et al., 1979). In 1976 trans-resveratrol (Fig 2.12) was 
discovered in grape skins by Langcake and Pryce (1976) (Langcake et al., 1979). This nutraceutical is 
frequently found in wines due to its presence in grape skin. The concentration of resveratrol in wine 
depends on several factors – the type of wine, the type of grape being used, the extent of fungal infection 
and the geographical region of the vineyards (Fremont, 2000). Red wine often contains greater 
concentrations of resveratrol because the skin, seed and stem (greatest sources of resveratrol production 
in grapes) are macerated during wine production (Gambini et al., 2015). Since resveratrol is poorly 
soluble in water, grape fermentation processes promote the extraction of resveratrol into the alcohol 
(Gambini et al., 2015).  
 
 
Figure 2.12: Chemical structure of resveratrol (Davinelli et al., 2012). 
 
2.3.1 Absorption and Metabolism 
 
Human ingestion of resveratrol varies as the content in food varies; grapes, berries and wine can be high 
in resveratrol; however, absorption and bioavailability pose a problem. The compound is readily 
absorbed from the GIT upon ingestion, thereafter it enters the bloodstream where several forms of 
resveratrol can be found. The liver carries out phase II metabolism on resveratrol by sulphate and 
glucuronic acid conjugation – yielding resveratrol-3-O-glucuronide and resveratrol-3-O-sulphate. Some 
resveratrol remains free in the blood and can bind to albumin, which could act as a reservoir to preserve 
bioavailability (Delmas et al., 2011). Enterohepatic cycling of resveratrol has been suggested in rats 
and humans, this process sees the majority of resveratrol being metabolised, reducing the concentration 
of free resveratrol reaching target tissues in the body (Marier et al., 2002).  
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2.3.2 Therapeutic Potential  
2.3.2.1 Antioxidant Defence and Anti-inflammatory Action 
 
Research has shown that resveratrol is able to augment the antioxidant defence response. This response 
is initiated when cells experience a redox shift, favouring free radical formation. The antioxidant 
defence attempts to restore homeostasis by reducing the damaging effects of ROS (Birben et al., 2012). 
Resveratrol has been shown to decrease lipid peroxidation, increase antioxidant activity and scavenge 
free radicals (Fremont, 2000; Leonard et al., 2003; Miller and Rice-Evans, 1995). It exerts these 
protective effects over both the liver and kidney by upregulating Nrf2 (Fig 2.14), thereby altering 
expression of antioxidant enzymes – GPx, catalase, and SOD (Bishayee et al., 2010; Kitada and Koya, 
2013; Sharma et al., 2006). Literature has shown that OTA disrupts the Nrf2 pathway, thus resveratrol 
could be used as a therapeutic intervention to augment cellular antioxidant responses.  
 
2.3.2.2 Cardiovascular Protection 
 
The use of resveratrol against heart disease has been recorded as far as 2000 years ago, when it was 
used in Ayurvedic medication (Paul et al., 1999). In 1982, Arichi et al. (1982) reported that resveratrol 
reduced lipogenesis in the liver of rats, this research indicated metabolic effects of resveratrol, 
particularly with regards to cardio-protective qualities (Arichi et al., 1982). The “French Paradox” 
explains the observation that French people consume foods high in saturated fat, however, experience 
low incidence of coronary heart disease (CHD); it was observed that the individuals in this region also 
frequently consumed red wine (Catalgol et al., 2012; Kopp, 1998). It was thought that red wine 
(containing resveratrol) could contribute to the low incidence of CHD. Frankel et al. (1993) showed 
that resveratrol protected against oxidation of low-density lipoprotein (LDL), an indication that 
resveratrol could prevent atherosclerosis (Frankel et al., 1993).  
 
Resveratrol decreases inflammation in a manner similar to non-steroidal anti-inflammatory drugs 
(NSAIDs). It increases vasodilation and inhibits the activity of cyclooxygenase (COX), preventing 
conversion of arachidonic acid to prostaglandins, which cause platelet aggregation (Fig 2.14) (Chen 
and Pace-Asciak, 1996; Guilford and Pezzuto, 2011; Jang et al., 1997). The antioxidant and anti-
inflammatory properties of resveratrol would contribute to overall cardiac protection. Scavenging of 
free radicals decreases the oxidation of LDL, preventing its accumulation in atherosclerotic lesions (Luo 
et al., 2014; Martinet and Kockx, 2001). Decreased platelet aggregation coupled with mediation of the 
COX pathway would decrease vasodilation and protect against CHD (Bradamante et al., 2004; 
Momchilova et al., 2014).   
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2.3.2.3 Resveratrol and Sirtuins 
 
Sirtuins (SIRTs) are histone deacetylases (HDACs) dependent on nicotinamide adenine dinucleotide 
(NAD+), linking their function to the cellular nutrition state (Dang, 2014). There are seven SIRT 
members (SIRT1 – SIRT7) found in humans, SIRT function is linked to cellular longevity and the 
ability to protect against diseases associated with aging (Morris, 2013). The silent information regulator 
2 (Sir2) protein, found in Saccharomyces cerevisiae (yeast), functions in transcriptional silencing, 
mediating cellular health and controlling lifespan (Brachmann et al., 1995; Gottlieb and Esposito, 1989; 
Tennen et al., 2012). SIRT1 is a mammalian homologue to Sir2, it is the most studied and functions in 
cellular stress response and metabolic alterations (Saunders and Verdin, 2007). SIRT1 has been reported 
to modulate peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1α) and p53 
in the nucleus, and NFκB and HIF1α in the cytosol (Morris, 2013), influencing cell survival and 
proliferation.  
 
SIRT3 (mitochondrially located) is also activated by resveratrol, and participates in oxidative stress 
response, mitochondrial stress and cardio-protection (Fig 2.13) (Chen et al., 2015; Mathieu et al., 2016; 
Zhou et al., 2014). Conversely, OTA is reported to influence oxidative and mitochondrial stress, as well 
as inflammatory pathways; it would prove valuable to determine the effects of SIRT1 and resveratrol 
on these pathways in combination with OTA, since the two compounds are often found together (e.g. 
grapes/wine).  
 
Aging is outlined as the progressive loss of cellular responsiveness, cellular homeostasis disruptions 
and increased dysfunction (López-Otín et al., 2013). Calorie restriction (CR) has been found to decrease 
the effects of aging and extend lifespan by activating SIRT1, this in turn modifies cellular stress 
response and DNA repair processes, reducing genomic instability and promoting cell survival (Fig 2.14) 
(Baur, 2010; Tennen et al., 2012). Resveratrol has been identified as a CR mimetic, activating SIRT1 
and subsequently delaying cellular aging (Barger JL, 2008).  
 
2.3.2.4 Chemotherapeutic Potential 
 
The hallmarks of cancer are defined as acquired biochemical capabilities for the progression of 
tumourigenesis. There are six hallmarks: continuous proliferation, bypassing apoptosis, non-
responsiveness to growth suppressive signals, immune system evasion, inducing angiogenesis and 
fostering metastatic characteristics (Hanahan and Weinberg, 2011). To attain these qualities, the cell 
requires a level of genomic instability and an inflammatory environment, which OTA toxicity provides. 
Research has shown that resveratrol is able to disrupt a number of these requirements. Together, the 
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antioxidant and anti-inflammatory capabilities of resveratrol could remedy genomic instability, chronic 
inflammation and angiogenesis (Delmas et al., 2006; She et al., 2003). Cyclooxygenase action can 
metabolically activate carcinogens, inducing DNA damage, while prostaglandins stimulate tumour 
growth and disrupt immune system functioning. By downregulating inflammatory responses resveratrol 
prevents COX and prostaglandin contribution to carcinogenesis (Jang et al., 1997).  
 
 
 
  
Figure 2.13: Beneficial effects of resveratrol as a SIRT1 activator (prepared by author). 
 
Jang et al. (1997) proved the chemopreventive potential of resveratrol in rats, where resveratrol was 
shown to inhibit biochemical incidences of tumour initiation, promotion and progression (Jang et al., 
1997). Carbo et al. (1999) noted that resveratrol induced apoptosis in a rat tumour model (Carbo et al., 
1999), while Bishayee et al. (2010) showed reduced oxidative stress and inflammation in chemically 
induced hepatic tumours in rats exposed to resveratrol (Bishayee et al., 2010). Resveratrol has been 
shown to modulate inflammatory proteins to prevent 7,12-Dimethylben(a)anthracene (a tumour 
initiator) induced mammary carcinogenesis in rats (Banerjee et al., 2002). This evidence makes a 
compelling case for resveratrol’s potential use in chemotherapy.  
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Figure 2.14: Potential resveratrol targets and the compound’s involvement in inflammation, oxidative 
and mitochondrial stress, hypoxia, and cardiovascular protection (Haskó and Pacher, 2010).  
 
It is important to note that inflammation, UPR activation, oxidative stress, and hypoxia all function in 
concert and influence cell survival. Pereira et al. (2014) demonstrated that ER stress was able to 
potentiate HIF1 activity and increase VEGF expression to higher levels than if hypoxia or ER stress had 
been induced alone (Pereira et al., 2014). The PERK-eIF2α branch has the ability to induce NFκB 
activation by inhibiting IκBα synthesis, thereby allowing transcription of NFκB targets in the nucleus 
(Deng et al., 2004). Lim et al. (2010) and Joo et al. (2015) proved that SIRT1 (activated by resveratrol) 
interacts with HIF1α and influences its activity during both normoxic and hypoxic conditions (Joo et 
al., 2015; Lim et al., 2010).  
 
The effect of OTA on oxidative stress pathways is well documented, however, investigations into how 
hypoxia, ER stress and inflammation are affected together will be valuable in determining the 
carcinogenicity of OTA in humans. Integration of these pathways is fundamental in elucidating the 
mechanism of OTA toxicity and in establishing possible therapeutic interventions, such as resveratrol. 
 
 
 
 
27 
 
2.4 References 
(IARC), I.A.f.R.o.C. (1993). Some naturally occurring substances: food items and constituents, 
heterocyclic aromatic amines and mycotoxins. IARC Monographs on the Evaluation of Carcinogenic 
Risks to Humans 56, 489-521. 
Abedin, Z., Louis-Juste, M., Stangl, M., and Field, J. (2013). The role of base excision repair genes 
OGG1, APN1 and APN2 in benzo[a]pyrene-7,8-dione induced p53 mutagenesis. Mutation Research 
750, 121-128. 
Abid, S., Hassen, W., Achour, A., Skhiri, H., Maaroufi, K., Ellouz, F., Creppy, E., and Bacha, H. (2003). 
Ochratoxin A and human chronic nephropathy in Tunisia: is the situation endemic? Human & 
Experimental Toxicology 22, 77-84. 
Abouzied, M.M., Horvath, A.D., Podlesny, P.M., Regina, N.P., Metodiev, V.D., Kamenova-Tozeva, 
R.M., Niagolova, N.D., Stein, A.D., Petropoulos, E.A., and Ganev, V.S. (2002). Ochratoxin A 
concentrations in food and feed from a region with Balkan Endemic Nephropathy. Food Additives and 
Contaminants 19, 755-764. 
Al-Anati, L., Essid, E., Reinehr, R., and Petzinger, E. (2009). Silibinin protects OTA-mediated TNF-
alpha release from perfused rat livers and isolated rat Kupffer cells. Molecular Nutrition & Food 
Research 53, 460-466. 
Alfonso-Prieto, M., Vidossich, P., and Rovira, C. (2012). The reaction mechanisms of heme catalases: 
An atomistic view by ab initio molecular dynamics. Archives of Biochemistry and Biophysics 525, 
121-130. 
Arbillaga, L., Azqueta, A., Ezpeleta, O., and Lopez de Cerain, A. (2007). Oxidative DNA damage 
induced by Ochratoxin A in the HK-2 human kidney cell line: evidence of the relationship with 
cytotoxicity. Mutagenesis 22, 35-42. 
Arichi, H., Kimura, Y., Okuda, H., Baba, K., Kozawa, M., and Arichi, S. (1982). Effects of stilbene 
components of the roots of Polygonum cuspidatum Sieb. et Zucc. on lipid metabolism. Chemical & 
Pharmaceutical Bulletin 30, 1766-1770. 
Atroshi, F., Biese, I., Saloniemi, H., Ali-Vehmas, T., Saari, S., Rizzo, A., and Veijalainen, P. (2000). 
Significance of apoptosis and its relationship to antioxidants after Ochratoxin A administration in mice. 
Journal of Pharmacy & Pharmaceutical Sciences 3, 281-291. 
Banerjee, S., Bueso-Ramos, C., and Aggarwal, B.B. (2002). Suppression of 7,12-
dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: role of nuclear 
factor-kappaB, cyclooxygenase 2, and matrix metalloprotease 9. Cancer Research 62, 4945-4954. 
Bankole, S., Schollenberger, M., and Drochner, W. (2006). Mycotoxins in food systems in Sub Saharan 
Africa: A review. Mycotoxin Research 22, 163-169. 
Barger JL, K.T., Vann JM, Arias EB, Wang J, et al. (2008). A Low Dose of Dietary Resveratrol Partially 
Mimics Caloric Restriction and Retards Aging Parameters in Mice. PLoS ONE 3(6). 
28 
 
Barnes, J.M., Austwick, P.K., Carter, R.L., Flynn, F.V., Peristianis, G.C., and Aldridge, W.N. (1977). 
Balkan (endemic) nephropathy and a toxin-producing strain of Penicillium verrucosum var cyclopium: 
An experimental model in rats. Lancet 1, 671-675. 
Baur, J.A. (2010). Resveratrol, sirtuins, and the promise of a DR mimetic. Mechanisms of Ageing and 
Development 131, 261-269. 
Berlett, B.S., and Stadtman, E.R. (1997). Protein Oxidation in Aging, Disease, and Oxidative Stress. 
Journal of Biological Chemistry 272, 20313-20316. 
Bhat, R., Rai, R.V., Karim, A.A. (2010). Mycotoxins in Food and Feed: Present Status and Future 
Concerns. Comprehensive Reviews in Food Science and Food Safety 9. 
Birben, E., Sahiner, U.M., Sackesen, C., Erzurum, S., and Kalayci, O. (2012). Oxidative Stress and 
Antioxidant Defense. The World Allergy Organization Journal 5, 9-19. 
Bishayee, A., Barnes, K.F., Bhatia, D., Darvesh, A.S., and Carroll, R.T. (2010). Resveratrol suppresses 
oxidative stress and inflammatory response in diethylnitrosamine-initiated rat hepatocarcinogenesis. 
Cancer Prevention Research (Philadelphia, Pa) 3, 753-763. 
Boesch-Saadatmandi, C., Wagner, A.E., Graeser, A.C., Hundhausen, C., Wolffram, S., and Rimbach, 
G. (2009). Ochratoxin A impairs Nrf2-dependent gene expression in porcine kidney tubulus cells. 
Journal Of Animal Physiology And Animal Nutrition 93, 547-554. 
Borthwick, L.A., Corris, P.A., Mahida, R., Walker, A., Gardner, A., Suwara, M., Johnson, G.E., 
Moisey, E.J., Brodlie, M., Ward, C., et al. (2013). TNFalpha from classically activated macrophages 
accentuates epithelial to mesenchymal transition in obliterative bronchiolitis. American Journal Of 
Transplantation 13, 621-633. 
Bouaziz, C., Sharaf el dein, O., Martel, C., El Golli, E., Abid-Essefi, S., Brenner, C., Lemaire, C., and 
Bacha, H. (2011). Molecular events involved in Ochratoxin A induced mitochondrial pathway of 
apoptosis, modulation by Bcl-2 family members. Environmental Toxicology 26, 579-590. 
Boudra, H., Le Bars, P., and Le Bars, J. (1995). Thermostability of Ochratoxin A in wheat under two 
moisture conditions. Applied And Environmental Microbiology 61, 1156-1158. 
Bouslimi, A., Bouaziz, C., Ayed-Boussema, I., Hassen, W., and Bacha, H. (2008). Individual and 
combined effects of Ochratoxin A and citrinin on viability and DNA fragmentation in cultured Vero 
cells and on chromosome aberrations in mice bone marrow cells. Toxicology 251, 1-7. 
Brachmann, C.B., Sherman, J.M., Devine, S.E., Cameron, E.E., Pillus, L., and Boeke, J.D. (1995). The 
SIR2 gene family, conserved from bacteria to humans, functions in silencing, cell cycle progression, 
and chromosome stability. Genes & Development 9, 2888-2902. 
Bradamante, S., Barenghi, L., and Villa, A. (2004). Cardiovascular Protective Effects of Resveratrol. 
Cardiovascular Drug Reviews 22, 169-188. 
Bravo, R., Parra, V., Gatica, D., Rodriguez, A.E., Torrealba, N., Paredes, F., Wang, Z.V., Zorzano, A., 
Hill, J.A., Jaimovich, E., et al. (2013). Endoplasmic Reticulum and the Unfolded Protein Response: 
29 
 
Dynamics and Metabolic Integration. International Review Of Cell And Molecular Biology 301, 215-
290. 
Breitholtz-Emanuelsson, A., Olsen, M., Oskarsson, A., Palminger, I., and Hult, K. (1993a). Ochratoxin 
A in cow's milk and in human milk with corresponding human blood samples. Journal of AOAC 
International 76, 842-846. 
Breitholtz-Emanuelsson, A., Palminger-Hallen, I., Wohlin, P.O., Oskarsson, A., Hult, K., and Olsen, 
M. (1993b). Transfer of Ochratoxin A from lactating rats to their offspring: a short-term study. Natural 
Toxins 1, 347-352. 
Brini, M., Cali, T., Ottolini, D., and Carafoli, E. (2013). Intracellular calcium homeostasis and signaling. 
Metal Ions in Life Sciences 12, 119-168. 
Buchner, J. (1999). Hsp90 & Co. - a holding for folding. Trends in biochemical sciences 24, 136-141. 
Burns, J., Yokota, T., Ashihara, H., Lean, M.E., and Crozier, A. (2002). Plant foods and herbal sources 
of resveratrol. Journal of Agricultural and Food Chemistry 50, 3337-3340. 
Capraro, J., and Rossi, F. (2012). The effects of Ochratoxin A on liver metabolism. Mediterranean 
Journal of Nutrition and Metabolism 5, 177-185. 
Carbo, N., Costelli, P., Baccino, F.M., Lopez-Soriano, F.J., and Argiles, J.M. (1999). Resveratrol, a 
natural product present in wine, decreases tumour growth in a rat tumour model. Biochemical and 
Biophysical Research Communications 254, 739-743. 
Castegnaro, M., Canadas, D., Vrabcheva, T., Petkova-Bocharova, T., Chernozemsky, I.N., and Pfohl-
Leszkowicz, A. (2006). Balkan endemic nephropathy: role of ochratoxins A through biomarkers. 
Molecular Nutrition & Food Research 50, 519-529. 
Catalgol, B., Batirel, S., Taga, Y., and Ozer, N.K. (2012). Resveratrol: French Paradox Revisited. 
Frontiers in Pharmacology 3. 
Cavin, C., Delatour, T., Marin-Kuan, M., Holzhauser, D., Higgins, L., Bezencon, C., Guignard, G., 
Junod, S., Richoz-Payot, J., Gremaud, E., et al. (2007). Reduction in antioxidant defenses may 
contribute to Ochratoxin A toxicity and carcinogenicity. Toxicological Sciences 96, 30-39. 
Cerutti, P.A. (1989). Mechanisms of action of oxidant carcinogens. Cancer Detection And Prevention 
14, 281-284. 
Chaves, M., Eissing, T., and Allgöwer, F. (2009). Regulation of Apoptosis via the NFκB Pathway: 
Modeling and Analysis. In Dynamics On and Of Complex Networks: Applications to Biology, 
Computer Science, and the Social Sciences, N. Ganguly, A. Deutsch, and A. Mukherjee, eds. (Boston, 
MA: Birkhäuser Boston), pp. 19-33. 
Chen, C.K., and Pace-Asciak, C.R. (1996). Vasorelaxing activity of resveratrol and quercetin in isolated 
rat aorta. General Pharmacology 27, 363-366. 
Chen, T., Li, J., Liu, J., Li, N., Wang, S., Liu, H., Zeng, M., Zhang, Y., and Bu, P. (2015). Activation 
of SIRT3 by resveratrol ameliorates cardiac fibrosis and improves cardiac function via the TGF-
30 
 
beta/Smad3 pathway. American Journal of Physiology Heart and Circulatory Physiology 308, H424-
434. 
Cheung, K.L., and Kong, A.N. (2010). Molecular targets of dietary phenethyl isothiocyanate and 
sulforaphane for cancer chemoprevention. The AAPS journal 12, 87-97. 
Chopra, M., Link, P., Michels, C., and Schrenk, D. (2010). Characterization of Ochratoxin A -induced 
apoptosis in primary rat hepatocytes. Cell Biology And Toxicology 26, 239-254. 
Chun, Y.S., Kim, M.S., and Park, J.W. (2002). Oxygen-dependent and -independent regulation of HIF-
1alpha. Journal of Korean Medical Science 17, 581-588. 
Cockman, M.E., Masson, N., Mole, D.R., Jaakkola, P., Chang, G.W., Clifford, S.C., Maher, E.R., Pugh, 
C.W., Ratcliffe, P.J., and Maxwell, P.H. (2000). Hypoxia inducible factor-alpha binding and 
ubiquitylation by the von Hippel-Lindau tumor suppressor protein. The Journal Of Biological 
Chemistry 275, 25733-25741. 
Cooke, M.S., Evans, M.D., Dizdaroglu, M., and Lunec, J. (2003). Oxidative DNA damage: 
mechanisms, mutation, and disease. The FASEB Journal 17, 1195-1214. 
Cox, J.S., Shamu, C.E., and Walter, P. (1993). Transcriptional induction of genes encoding endoplasmic 
reticulum resident proteins requires a transmembrane protein kinase. Cell 73, 1197-1206. 
Creppy, E.E., Baudrimont, I., and Betbeder, A.M. (1995). Prevention of nephrotoxicity of Ochratoxin 
A, a food contaminant. Toxicology Letters 82-83, 869-877. 
Creppy, E.E., Chakor, K., Fisher, M.J., and Dirheimer, G. (1990). The myocotoxin Ochratoxin A is a 
substrate for phenylalanine hydroxylase in isolated rat hepatocytes and in vivo. Archives Of Toxicology 
 64, 279-284. 
Creppy, E.E., Stormer, F.C., Roschenthaler, R., and Dirheimer, G. (1983). Effects of two metabolites 
of Ochratoxin A, (4R)-4-hydroxyochratoxin A and Ochratoxin alpha, on immune response in mice. 
Infection And Immunity 39, 1015-1018. 
Dang, W. (2014). The controversial world of sirtuins. Drug Discovery Today: Technologies 12, e9-e17. 
Davinelli, S., Sapere, N., Zella, D., Bracale, R., Intrieri, M., and Scapagnini, G. (2012). Pleiotropic 
protective effects of phytochemicals in Alzheimer's disease. Oxidative Medicine And Cellular 
Longevity 2012, 386527. 
Delmas, D., Aires, V., Limagne, E., Dutartre, P., Mazue, F., Ghiringhelli, F., and Latruffe, N. (2011). 
Transport, stability, and biological activity of resveratrol. Annals of the New York Academy of 
Sciences 1215, 48-59. 
Delmas, D., Lancon, A., Colin, D., Jannin, B., and Latruffe, N. (2006). Resveratrol as a 
Chemopreventive Agent: A Promising Molecule for Fighting Cancer. Current Drug Targets 7, 423-442. 
Denes, A., Lopez-Castejon, G., and Brough, D. (2012). Caspase-1: is IL-1 just the tip of the ICEberg? 
Cell Death and Disease 3, e338. 
31 
 
Deng, J., Lu, P.D., Zhang, Y., Scheuner, D., Kaufman, R.J., Sonenberg, N., Harding, H.P., and Ron, D. 
(2004). Translational repression mediates activation of nuclear factor kappa B by phosphorylated 
translation initiation factor 2. Molecular and Cellular Biology 24, 10161-10168. 
Denli, M., and Perez, J.F. (2010). Ochratoxins in Feed, a Risk for Animal and Human Health: Control 
Strategies. Toxins 2, 1065-1077. 
Doerner, A.M., and Zuraw, B.L. (2009). TGF-β(1) induced epithelial to mesenchymal transition (EMT) 
in human bronchial epithelial cells is enhanced by IL-1β but not abrogated by corticosteroids. 
Respiratory Research 10, 100. 
Dopp, E., Muller, J., Hahnel, C., and Schiffmann, D. (1999). Induction of genotoxic effects and 
modulation of the intracellular calcium level in syrian hamster embryo (SHE) fibroblasts caused by 
Ochratoxin A. Food And Chemical Toxicology 37, 713-721. 
dos Reis, S.T., Pontes-Júnior, J., Antunes, A.A., de Sousa-Canavez, J.M., Abe, D.K., da Cruz, J.A.S., 
Dall'Oglio, M.F., Crippa, A., Passerotti, C.C., Ribeiro-Filho, L.A., et al. (2011). Tgf-β1 expression as a 
biomarker of poor prognosis in prostate cancer. Clinics 66, 1143-1147. 
Dwivedi, P., and Burns, R.B. (1985). Immunosuppressive effects of ochratoxin A in young turkeys. 
Avian Pathology 14, 213-225. 
Elling, F., and Krogh, P. (1977). Fungal toxins and Balkan (endemic) nephropathy. Lancet 1, 1213. 
Elliott, R.L., and Blobe, G.C. (2005). Role of Transforming Growth Factor Beta in Human Cancer. 
Journal of Clinical Oncology 23, 2078-2093. 
Fernández-Cruz, M.L., Mansilla, M.L., and Tadeo, J.L. (2010). Mycotoxins in fruits and their processed 
products: Analysis, occurrence and health implications. Journal of Advanced Research 1, 113-122. 
Ferrante, M.C., Bilancione, M., Raso, G.M., Esposito, E., Iacono, A., Zaccaroni, A., and Meli, R. 
(2006). Expression of COX-2 and hsp72 in peritoneal macrophages after an acute ochratoxin A 
treatment in mice. Life Sciences 79, 1242-1247. 
Fitzgerald, D.C., Meade, K.G., McEvoy, A.N., Lillis, L., Murphy, E.P., MacHugh, D.E., and Baird, 
A.W. (2007). Tumour necrosis factor-alpha (TNF-alpha) increases nuclear factor kappaB (NFkappaB) 
activity in and interleukin-8 (IL-8) release from bovine mammary epithelial cells. Veterinary 
Immunology And Immunopathology 116, 59-68. 
Fontana, J., Fulton, D., Chen, Y., Fairchild, T.A., McCabe, T.J., Fujita, N., Tsuruo, T., and Sessa, W.C. 
(2002). Domain mapping studies reveal that the M domain of hsp90 serves as a molecular scaffold to 
regulate Akt-dependent phosphorylation of endothelial nitric oxide synthase and NO release. 
Circulation Research 90, 866-873. 
Frankel, E.N., Waterhouse, A.L., and Kinsella, J.E. (1993). Inhibition of human LDL oxidation by 
resveratrol. Lancet 341, 1103-1104. 
Fremont, L. (2000). Biological effects of resveratrol. Life Sciences 66, 663-673. 
Galtier, P., Alvinerie, M., and Charpenteau, J.L. (1981). The pharmacokinetic profiles of ochratoxin A 
in pigs, rabbits and chickens. Food And Cosmetics Toxicology 19, 735-738. 
32 
 
Gambini, J., Ingl, #xe9, s, M., Olaso, G., Lopez-Grueso, R., Bonet-Costa, V., Gimeno-Mallench, L., 
Mas-Bargues, C., Abdelaziz, K.M., et al. (2015). Properties of Resveratrol: In Vitro and In Vivo Studies 
about Metabolism, Bioavailability, and Biological Effects in Animal Models and Humans. Oxidative 
Medicine And Cellular Longevity 2015, 13. 
Gan, F., Hou, L., Zhou, Y., Liu, Y., Huang, D., Chen, X., and Huang, K. (2017). Effects of Ochratoxin 
A on ER stress, MAPK signaling pathway and autophagy of kidney and spleen in pigs. Environmental 
Toxicology 32, 2277-2286. 
Gautier, J.C., Holzhaeuser, D., Markovic, J., Gremaud, E., Schilter, B., and Turesky, R.J. (2001). 
Oxidative damage and stress response from Ochratoxin A exposure in rats. Free Radical Biology & 
Medicine 30, 1089-1098. 
Gayathri, L., Dhivya, R., Dhanasekaran, D., Periasamy, V.S., Alshatwi, A.A., and Akbarsha, M.A. 
(2015). Hepatotoxic effect of Ochratoxin A and citrinin, alone and in combination, and protective effect 
of vitamin E: In vitro study in HepG2 cell. Food And Chemical Toxicology 83, 151-163. 
Gekle, M., Schwerdt, G., Freudinger, R., Mildenberger, S., Wilflingseder, D., Pollack, V., Dander, M., 
and Schramek, H. (2000). Ochratoxin A induces JNK activation and apoptosis in MDCK-C7 cells at 
nanomolar concentrations. The Journal of pharmacology and experimental therapeutics 293, 837-844. 
Giralt, A., and Villarroya, F. (2012). SIRT3, a pivotal actor in mitochondrial functions: metabolism, 
cell death and aging. Biochemical Journal 444, 1-10. 
Golli-Bennour, E.E., Kouidhi, B., Bouslimi, A., Abid-Essefi, S., Hassen, W., and Bacha, H. (2010). 
Cytotoxicity and genotoxicity induced by aflatoxin B1, Ochratoxin A, and their combination in cultured 
Vero cells. Journal Of Biochemical And Molecular Toxicology 24, 42-50. 
Google (2009). Balkans: Map data ©2017 GeoBasis-DE/BKG (©2009), Google, Inst. Geogr. 
Nacional, Mapa GIsrael, ORION-ME. Retrieved from: 
https://www.google.co.za/maps/vt/data=VJdSzefNggFq9YETlrjHyKFQFEPOlG_lHpz-
Lw7MbLe8_91d52nRZSeA4v2SBXDXPFnPzKl9mDagElRRzXmAOLjwGQaTcrwgDTT3qZn_lMB
GMnH1HMUeKZMVEQNh6MJvXkTtZu2MWwePYdybjsUmzBoYCeNmSobXW7HnKH0uhH8P_
PF8cwMLf-nztXXSTY3jLFedlJedfbDKh4bxywstAQ,  
Google (2017). Northern Africa: Map data ©2017 Google, INEGI. Retrieved from: 
https://www.google.co.za/maps/vt/data=cYq8ZZ0TLXJYa4uHzmCQaq9yjOhixazcs-
9MXydwONmtADawrNKUw-
OVN3RlTRWUzhqdQD82kDaBENgfbmVw3xLY9NhBXO1i5FMiX9nyHnvxwUAZ7z1fV8-
sXQlidVuw3kwg1IYCY9KLl9yLYJ8XNdv4ClTnC6cgVcg2g8GTMWdq_Z4HOr5Mk71rVKcuk-
e0mI9K9xz16uR8Beh0XuiIYg 
Gottlieb, S., and Esposito, R.E. (1989). A new role for a yeast transcriptional silencer gene, SIR2, in 
regulation of recombination in ribosomal DNA. Cell 56, 771-776. 
33 
 
Graeber, T.G., Osmanian, C., Jacks, T., Housman, D.E., Koch, C.J., Lowe, S.W., and Giaccia, A.J. 
(1996). Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. 
Nature 379, 88-91. 
Gregersen, N., and Bross, P. (2010). Protein misfolding and cellular stress: an overview. Methods In 
Molecular Biology (Clifton, NJ) 648, 3-23. 
Guilford, J.M., and Pezzuto, J.M. (2011). Wine and Health: A Review. American Journal of Enology 
and Viticulture 62, 471-486. 
Haase, V.H. (2013). Regulation of erythropoiesis by hypoxia-inducible factors. Blood Reviews 27, 41-
53. 
Hagelberg, S., Hult, K., and Fuchs, R. (1989). Toxicokinetics of Ochratoxin A in several species and 
its plasma-binding properties. Journal Of Applied Toxicology : JAT 9, 91-96. 
Halliwell, B., and Aruoma, O.I. (1991). DNA damage by oxygen-derived species. Its mechanism and 
measurement in mammalian systems. FEBS Letters 281, 9-19. 
Halliwell, B., and Chirico, S. (1993). Lipid peroxidation: its mechanism, measurement, and 
significance. The American journal of clinical nutrition 57, 715S-724S  
Hanahan, D., and Weinberg, Robert A. (2011). Hallmarks of Cancer: The Next Generation. Cell 144, 
646-674. 
Haskó, G., and Pacher, P. (2010). Endothelial Nrf2 activation: a new target for resveratrol? American 
Journal of Physiology - Heart and Circulatory Physiology 299, H10-H12. 
Hebert, A.S., Dittenhafer-Reed, K.E., Yu, W., Bailey, D.J., Selen, E.S., Boersma, M.D., Carson, J.J., 
Tonelli, M., Balloon, A., Higbee, A.J., et al. (2013). Calorie restriction and SIRT3 trigger global 
reprogramming of the mitochondrial protein acetylome. Molecular Cell 49, 186-199. 
Hennemeier, I., Humpf, H.U., Gekle, M., and Schwerdt, G. (2012). The food contaminant and 
nephrotoxin Ochratoxin A enhances Wnt1 inducible signaling protein 1 and tumor necrosis factor-alpha 
expression in human primary proximal tubule cells. Molecular nutrition & food research 56, 1375-1384. 
Heussner, A.H., O'Brien, E., and Dietrich, D.R. (2007). Effects of repeated ochratoxin exposure on 
renal cells in vitro. Toxicology in Vitro 21, 72-80. 
Hibi, D., Kijima, A., Suzuki, Y., Ishii, Y., Jin, M., Sugita-Konishi, Y., Yanai, T., Nishikawa, A., and 
Umemura, T. (2013). Effects of p53 knockout on Ochratoxin A -induced genotoxicity in p53-deficient 
gpt delta mice. Toxicology 304, 92-99. 
Higashi, T., Sasagawa, T., Inoue, M., Oka, R., Shuangying, L., and Saijoh, K. (2001). Overexpression 
of latent transforming growth factor-beta 1 (TGF-beta 1) binding protein 1 (LTBP-1) in association 
with TGF-beta 1 in ovarian carcinoma. Japanese Journal Of Cancer Research 92, 506-515. 
Hohler, D., Sudekum, K.H., Wolffram, S., Frohlich, A.A., and Marquardt, R.R. (1999). Metabolism 
and excretion of Ochratoxin A fed to sheep. Journal Of Animal Science 77, 1217-1223. 
34 
 
Hundhausen, C., Boesch-Saadatmandi, C., Matzner, N., Lang, F., Blank, R., Wolffram, S., Blaschek, 
W., and Rimbach, G. (2008). Ochratoxin A lowers mRNA levels of genes encoding for key proteins of 
liver cell metabolism. Cancer Genomics & Proteomics 5, 319-332. 
Hussein, H.S., and Brasel, J.M. (2001). Toxicity, metabolism, and impact of mycotoxins on humans 
and animals. Toxicology 167, 101-134. 
Ichim, G., and Tait, S.W.G. (2016). A fate worse than death: apoptosis as an oncogenic process. Nature 
Reviews Cancer 16, 539-548. 
Isaacs, J.S., Jung, Y.-J., Mimnaugh, E.G., Martinez, A., Cuttitta, F., and Neckers, L.M. (2002). Hsp90 
Regulates a von Hippel Lindau-independent Hypoxia-inducible Factor-1α-degradative Pathway. 
Journal of Biological Chemistry 277, 29936-29944. 
Israël, A. (2010). The IKK Complex, a Central Regulator of NF-κB Activation. Cold Spring Harbor 
Perspectives in Biology 2, a000158. 
Itoh, K., Ishii, T., Wakabayashi, N., and Yamamoto, M. (1999). Regulatory mechanisms of cellular 
response to oxidative stress. Free Radical Research 31, 319-324. 
Jang, M., Cai, L., Udeani, G.O., Slowing, K.V., Thomas, C.F., Beecher, C.W., Fong, H.H., Farnsworth, 
N.R., Kinghorn, A.D., Mehta, R.G., et al. (1997). Cancer chemopreventive activity of resveratrol, a 
natural product derived from grapes. Science (New York, NY) 275, 218-220. 
Jonsyn-Ellis, F. (2012). Ochratoxin A: Any Cause for Concern in Sub Saharan Africa? Science Journal 
of Environmental Engineering Research Volume 2012, 5. 
Joo, H.Y., Yun, M., Jeong, J., Park, E.R., Shin, H.J., Woo, S.R., Jung, J.K., Kim, Y.M., Park, J.J., Kim, 
J., et al. (2015). SIRT1 deacetylates and stabilizes hypoxia-inducible factor-1alpha (HIF-1alpha) via 
direct interactions during hypoxia. Biochemical and Biophysical Research Communications 462, 294-
300. 
Junod, A.F., Jornot, L., and Petersen, H. (1989). Differential effects of hyperoxia and hydrogen peroxide 
on DNA damage, polyadenosine diphosphate-ribose polymerase activity, and nicotinamide adenine 
dinucleotide and adenosine triphosphate contents in cultured endothelial cells and fibroblasts. Journal 
Of Cellular Physiology 140, 177-185. 
Kadowaki, H., and Nishitoh, H. (2013). Signaling Pathways from the Endoplasmic Reticulum and Their 
Roles in Disease. Genes 4, 306. 
Kallergi, G., Markomanolaki, H., Giannoukaraki, V., Papadaki, M.A., Strati, A., Lianidou, E.S., 
Georgoulias, V., Mavroudis, D., and Agelaki, S. (2009). Hypoxia-inducible factor-1α and vascular 
endothelial growth factor expression in circulating tumor cells of breast cancer patients. Breast Cancer 
Research : BCR 11, R84-R84. 
Kamitani, S., Yamauchi, Y., Kawasaki, S., Takami, K., Takizawa, H., Nagase, T., and Kohyama, T. 
(2011). Simultaneous stimulation with TGF-beta1 and TNF-alpha induces epithelial mesenchymal 
transition in bronchial epithelial cells. International Archives Of Allergy And Immunology 155, 119-
128. 
35 
 
Kamp, H.G., Eisenbrand, G., Janzowski, C., Kiossev, J., Latendresse, J.R., Schlatter, J., and Turesky, 
R.J. (2005). Ochratoxin A induces oxidative DNA damage in liver and kidney after oral dosing to rats. 
Molecular Nutrition & Food Research 49, 1160-1167. 
Khansari, N., Shakiba, Y., and Mahmoudi, M. (2009). Chronic inflammation and oxidative stress as a 
major cause of age-related diseases and cancer. Recent Patents On Inflammation & Allergy Drug 
Discovery 3, 73-80. 
Kim, H.J., and Vaziri, N.D. (2010). Contribution of impaired Nrf2-Keap1 pathway to oxidative stress 
and inflammation in chronic renal failure. American Journal of Physiology - Renal Physiology 298, 
F662-F671. 
Kitada, M., and Koya, D. (2013). Renal protective effects of resveratrol. Oxidative Medicine And 
Cellular Longevity 2013, 568093. 
Kleiman, N.J., Wang, R.R., and Spector, A. (1990). Hydrogen peroxide-induced DNA damage in 
bovine lens epithelial cells. Mutation Research 240, 35-45. 
Kobayashi, A., Kang, M.-I., Okawa, H., Ohtsuji, M., Zenke, Y., Chiba, T., Igarashi, K., and Yamamoto, 
M. (2004). Oxidative Stress Sensor Keap1 Functions as an Adaptor for Cul3-Based E3 Ligase To 
Regulate Proteasomal Degradation of Nrf2. Molecular and Cellular Biology 24, 7130-7139. 
Kopp, P. (1998). Resveratrol, a phytoestrogen found in red wine. A possible explanation for the 
conundrum of the 'French paradox'? European Journal Of Endocrinology 138, 619-620. 
Kumagai, S., and Aibara, K. (1982). Intestinal absorption and secretion of Ochratoxin A in the rat. 
Toxicology And Applied Pharmacology 64, 94-102. 
Lamouille, S., Xu, J., and Derynck, R. (2014). Molecular mechanisms of epithelial–mesenchymal 
transition. Nature Reviews Molecular Cell Biology 15, 178-196. 
Langcake, P., Cornford, C.A., and Pryce, R.J. (1979). Identification of pterostilbene as a phytoalexin 
from Vitis vinifera leaves. Phytochemistry 18, 1025-1027. 
Lawrence, T. (2009). The Nuclear Factor NF-κB Pathway in Inflammation. Cold Spring Harbor 
Perspectives in Biology 1, a001651. 
Lawrence, T., and Gilroy, D.W. (2007). Chronic inflammation: a failure of resolution? International 
Journal of Experimental Pathology 88, 85-94. 
Leonard, S.S., Xia, C., Jiang, B.H., Stinefelt, B., Klandorf, H., Harris, G.K., and Shi, X. (2003). 
Resveratrol scavenges reactive oxygen species and effects radical-induced cellular responses. 
Biochemical and Biophysical Research Communications 309, 1017-1026. 
Li, M., Luan, F., Zhao, Y., Hao, H., Zhou, Y., Han, W., and Fu, X. (2016). Epithelial-mesenchymal 
transition: An emerging target in tissue fibrosis. Experimental Biology and Medicine 241, 1-13. 
Li, Y., Guo, Y., Tang, J., Jiang, J., and Chen, Z. (2014). New insights into the roles of CHOP-induced 
apoptosis in ER stress. Acta Biochim Biophys Sin (Shanghai) 46, 629-640. 
Lim, J.H., Lee, Y.M., Chun, Y.S., Chen, J., Kim, J.E., and Park, J.W. (2010). Sirtuin 1 modulates 
cellular responses to hypoxia by deacetylating hypoxia-inducible factor 1alpha. Mol Cell 38, 864-878. 
36 
 
Liu, T., and Yin, H. (2017). PDK1 promotes tumor cell proliferation and migration by enhancing the 
Warburg effect in non-small cell lung cancer. Oncology Reports 37, 193-200. 
Loboda, A., Stachurska, A., Podkalicka, P., Sobczak, M., Mucha, O., Witalisz-Siepracka, A., 
Jozkowicz, A., and Dulak, J. (2017). Effect of heme oxygenase-1 on Ochratoxin A -induced 
nephrotoxicity in mice. The International Journal Of Biochemistry & Cell Biology 84, 46-57. 
Lopez-Novoa, J.M., and Nieto, M.A. (2009). Inflammation and EMT: an alliance towards organ fibrosis 
and cancer progression. Embo Molecular Medicine 1, 303-314. 
López-Otín, C., Blasco, M.A., Partridge, L., Serrano, M., and Kroemer, G. (2013). The Hallmarks of 
Aging. Cell 153, 1194-1217. 
Luo, J.-L., Kamata, H., and Karin, M. (2005). IKK/NF-κB signaling: balancing life and death – a new 
approach to cancer therapy. The Journal of Clinical Investigation 115, 2625-2632. 
Luo, X.-Y., Qu, S.-L., Tang, Z.-H., Zhang, Y., Liu, M.-H., Peng, J., Tang, H., Yu, K.-L., Zhang, C., 
Ren, Z., et al. (2014). SIRT1 in cardiovascular aging. Clinica Chimica Acta 437, 106-114. 
Lurje, G., and Lenz, H.J. (2009). EGFR signaling and drug discovery. Oncology 77, 400-410. 
Ma, Y., Brewer, J.W., Diehl, J.A., and Hendershot, L.M. (2002). Two distinct stress signaling pathways 
converge upon the CHOP promoter during the mammalian unfolded protein response. Journal Of 
Molecular Biology 318, 1351-1365. 
Marier, J.F., Vachon, P., Gritsas, A., Zhang, J., Moreau, J.P., and Ducharme, M.P. (2002). Metabolism 
and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic 
recirculation evidenced by a linked-rat model. The Journal Of Pharmacology And Experimental 
Therapeutics 302, 369-373. 
Marin-Hernandez, A., Gallardo-Perez, J.C., Ralph, S.J., Rodriguez-Enriquez, S., and Moreno-Sanchez, 
R. (2009). HIF-1alpha modulates energy metabolism in cancer cells by inducing over-expression of 
specific glycolytic isoforms. Mini Reviews In Medicinal Chemistry 9, 1084-1101. 
Marquardt, R.R., and Frohlich, A.A. (1992). A review of recent advances in understanding 
ochratoxicosis. Journal Of Animal Science 70, 3968-3988. 
Martinet, W., and Kockx, M.M. (2001). Apoptosis in atherosclerosis: focus on oxidized lipids and 
inflammation. Current Opinion In Lipidology 12, 535-541. 
Massagué, J., Blain, S.W., and Lo, R.S. (2000). TGFb Signaling in Growth Control, Cancer, and 
Heritable Disorders. Cell 103, 295-309. 
Mathieu, L., Costa, A.L., Le Bachelier, C., Slama, A., Lebre, A.S., Taylor, R.W., Bastin, J., and 
Djouadi, F. (2016). Resveratrol attenuates oxidative stress in mitochondrial Complex I deficiency: 
Involvement of SIRT3. Free Radical Biology & Medicine 96, 190-198. 
Maxwell, P.H., Wiesener, M.S., Chang, G.-W., Clifford, S.C., Vaux, E.C., Cockman, M.E., Wykoff, 
C.C., Pugh, C.W., Maher, E.R., and Ratcliffe, P.J. (1999). The tumour suppressor protein VHL targets 
hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399, 271-275. 
37 
 
Mbeunkui, F., and Johann, D.J. (2009). Cancer and the tumor microenvironment: a review of an 
essential relationship. Cancer Chemotherapy And Pharmacology 63, 571-582. 
McMahon, M., Itoh, K., Yamamoto, M., and Hayes, J.D. (2003). Keap1-dependent proteasomal 
degradation of transcription factor Nrf2 contributes to the negative regulation of antioxidant response 
element-driven gene expression. The Journal Of Biological Chemistry 278, 21592-21600. 
Miller, N.J., and Rice-Evans, C.A. (1995). Antioxidant activity of resveratrol in red wine. Clinical 
Chemistry 41, 1789. 
Mirzaei, H., and Regnier, F. (2008). Protein:protein aggregation induced by protein oxidation. Journal 
of chromatography B, Analytical Technologies In The Biomedical And Life Sciences 873, 8-14. 
Miyajima, A., Kosaka, T., Seta, K., Asano, T., Umezawa, K., and Hayakawa, M. (2003). Novel nuclear 
factor kappa B activation inhibitor prevents inflammatory injury in unilateral ureteral obstruction. The 
Journal Of Urology 169, 1559-1563. 
Momchilova, A., Petkova, D., Staneva, G., Markovska, T., Pankov, R., Skrobanska, R., Nikolova-
Karakashian, M., and Koumanov, K. (2014). Resveratrol alters the lipid composition, metabolism and 
peroxide level in senescent rat hepatocytes. Chemico-Biological Interactions 207, 74-80. 
Morris, B.J. (2013). Seven sirtuins for seven deadly diseases of aging. Free Radical Biology & Medicine 
56, 133-171. 
Motohashi, H., and Yamamoto, M. (2004). Nrf2–Keap1 defines a physiologically important stress 
response mechanism. Trends in Molecular Medicine 10, 549-557. 
Nguyen, T., Nioi, P., and Pickett, C.B. (2009). The Nrf2-antioxidant response element signaling 
pathway and its activation by oxidative stress. Journal of Biological Chemistry 284, 13291-13295. 
Nishitoh, H. (2012). CHOP is a multifunctional transcription factor in the ER stress response. The 
Journal of Biochemistry 151, 217-219. 
Offer, H., Zurer, I., Banfalvi, G., Reha'k, M., Falcovitz, A., Milyavsky, M., Goldfinger, N., and Rotter, 
V. (2001). p53 modulates base excision repair activity in a cell cycle-specific manner after genotoxic 
stress. Cancer Research 61, 88-96. 
Orrenius, S., Nicotera, P., and Zhivotovsky, B. (2011). Cell death mechanisms and their implications 
in toxicology. Toxicological sciences : an official journal of the Society of Toxicology 119, 3-19. 
Ostry, V., Malir, F., and Ruprich, J. (2013). Producers and important dietary sources of Ochratoxin A 
and citrinin. Toxins 5, 1574-1586. 
Pahl, H.L. (1999). Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18, 
6853-6866. 
Paul, B., Masih, I., Deopujari, J., and Charpentier, C. (1999). Occurrence of resveratrol and 
pterostilbene in age-old darakchasava, an ayurvedic medicine from India. Journal of 
Ethnopharmacology 68, 71-76. 
38 
 
Pepper, M.S., Ferrara, N., Orci, L., and Montesano, R. (1991). Vascular endothelial growth factor 
(VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular 
endothelial cells. Biochemical And Biophysical Research Communications 181, 902-906. 
Pereira, E.R., Frudd, K., Awad, W., and Hendershot, L.M. (2014). Endoplasmic reticulum (ER) stress 
and hypoxia response pathways interact to potentiate hypoxia-inducible factor 1 (HIF-1) transcriptional 
activity on targets like vascular endothelial growth factor (VEGF). The Journal Of Biological Chemistry 
289, 3352-3364. 
Petrik, J., Zanic-Grubisic, T., Barisic, K., Pepeljnjak, S., Radic, B., Ferencic, Z., and Cepelak, I. (2003). 
Apoptosis and oxidative stress induced by Ochratoxin A in rat kidney. Archives Of Toxicology 77, 685-
693. 
Petzinger, E., and Ziegler, K. (2000). Ochratoxin A from a toxicological perspective. Journal Of 
Veterinary Pharmacology And Therapeutics 23, 91-98. 
Pfohl-Leszkowicz, A., Chakor, K., Creppy, E.E., and Dirheimer, G. (1991). DNA adduct formation in 
mice treated with Ochratoxin A. Iarc Scientific Publications, 245-253. 
Pfohl-Leszkowicz, A., Pinelli, E., Bartsch, H., Mohr, U., and Castegnaro, M. (1998). Sex- and strain-
specific expression of cytochrome P450s in Ochratoxin A -induced genotoxicity and carcinogenicity in 
rats. Molecular Carcinogenesis 23, 76-85. 
Pfohl-Leszkowicz, A., Tozlovanu, M., Manderville, R., Peraica, M., Castegnaro, M., and Stefanovic, 
V. (2007). New molecular and field evidences for the implication of mycotoxins but not aristolochic 
acid in human nephropathy and urinary tract tumor. Molecular Nutrition & Food Research 51, 1131-
1146. 
Pias, E.K., Ekshyyan, O.Y., Rhoads, C.A., Fuseler, J., Harrison, L., and Aw, T.Y. (2003). Differential 
Effects of Superoxide Dismutase Isoform Expression on Hydroperoxide-induced Apoptosis in PC-12 
Cells. Journal of Biological Chemistry 278, 13294-13301. 
Pires, B.R.B., Mencalha, A.L., Ferreira, G.M., Panis, C., Silva, R.C.M.C., Abdelhay, E. (2014). The 
Hypoxia-Inducible Factor-1α Signaling Pathway and its Relation to Cancer and Immunology. American 
Journal of Immunology 10, 215-224. 
Pitout, M.J. (1969). The hydrolysis of Ochratoxin A by some proteolytic enzymes. Biochemical 
Pharmacology 18, 485-491. 
Prigione, A., Rohwer, N., Hoffmann, S., Mlody, B., Drews, K., Bukowiecki, R., Blumlein, K., Wanker, 
E.E., Ralser, M., Cramer, T., et al. (2014). HIF1alpha modulates cell fate reprogramming through early 
glycolytic shift and upregulation of PDK1-3 and PKM2. Stem Cells 32, 364-376. 
Quirós, P.M., Bárcena, C., and López-Otín, C. (2014). Lon protease: A key enzyme controlling 
mitochondrial bioenergetics in cancer. Molecular & Cellular Oncology 1, e968505. 
Quiros, P.M., Espanol, Y., Acin-Perez, R., Rodriguez, F., Barcena, C., Watanabe, K., Calvo, E., 
Loureiro, M., Fernandez-Garcia, M.S., Fueyo, A., et al. (2014). ATP-dependent Lon protease controls 
tumor bioenergetics by reprogramming mitochondrial activity. Cell Reports 8, 542-556. 
39 
 
Raghubeer, S., Nagiah, S., and Chuturgoon, A.A. (2017). Acute Ochratoxin A exposure induces 
inflammation and apoptosis in human embryonic kidney (HEK293) cells. Toxicon 137, 48-53. 
Raghubeer, S., Nagiah, S., Phulukdaree, A., and Chuturgoon, A. (2015). The Phytoalexin Resveratrol 
Ameliorates Ochratoxin A Toxicity in Human Embryonic Kidney (HEK293) Cells. Journal Of Cellular 
Biochemistry 116, 2947-2955. 
Ramyaa, P., and Padma, V.V. (2013). Ochratoxin-induced toxicity, oxidative stress and apoptosis 
ameliorated by quercetin--modulation by Nrf2. Food and Chemical Toxicology 62, 205-216. 
Reddy, L., and Bhoola, K. (2010). Ochratoxins—Food Contaminants: Impact on Human Health. Toxins 
2, 771-779. 
Renard, P., Zachary, M.-D., Bougelet, C., Mirault, M.-E., Haegeman, G., Remacle, J., and Raes, M. 
(1997). Effects of antioxidant enzyme modulations on interleukin-1-induced nuclear factor kappa B 
Activation. Biochemical Pharmacology 53, 149-160. 
Ringot, D., Chango, A., Schneider, Y.J., and Larondelle, Y. (2006). Toxicokinetics and toxicodynamics 
of Ochratoxin A, an update. Chemico-Biological Interactions 159, 18-46. 
Roth, A., Chakor, K., Creppy, E.E., Kane, A., Roschenthaler, R., and Dirheimer, G. (1988). Evidence 
for an enterohepatic circulation of Ochratoxin A in mice. Toxicology 48, 293-308. 
Rozpędek, W., Pytel, D., Mucha, B., Leszczyńska, H., Diehl, J.A., and Majsterek, I. (2016). The Role 
of the PERK/eIF2α/ATF4/CHOP Signaling Pathway in Tumor Progression During Endoplasmic 
Reticulum Stress. Current Molecular Medicine 16, 533-544. 
Saunders, L.R., and Verdin, E. (2007). Sirtuins: critical regulators at the crossroads between cancer and 
aging. Oncogene 26, 5489-5504. 
Schroder, M., and Kaufman, R.J. (2005). ER stress and the unfolded protein response. Mutation 
Research 569, 29-63. 
Schwerdt, G., Freudinger, R., Mildenberger, S., Silbernagl, S., and Gekle, M. (1999). The nephrotoxin 
Ochratoxin A induces apoptosis in cultured human proximal tubule cells. Cell Biology And Toxicology 
15, 405-415. 
Semenza, G.L. (2001a). Hypoxia-inducible factor 1: control of oxygen homeostasis in health and 
disease. Pediatric Research 49, 614-617. 
Semenza, G.L. (2001b). Regulation of hypoxia-induced angiogenesis: a chaperone escorts VEGF to the 
dance. Journal of Clinical Investigation 108, 39-40. 
Semenza, G.L. (2011). Hypoxia-inducible factor 1: Regulator of mitochondrial metabolism and 
mediator of ischemic preconditioning. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 
1813, 1263-1268. 
Shamu, C.E., and Walter, P. (1996). Oligomerization and phosphorylation of the Ire1p kinase during 
intracellular signaling from the endoplasmic reticulum to the nucleus. The EMBO Journal 15, 3028-
3039. 
40 
 
Sharma, S., Anjaneyulu, M., Kulkarni, S.K., and Chopra, K. (2006). Resveratrol, a polyphenolic 
phytoalexin, attenuates diabetic nephropathy in rats. Pharmacology 76, 69-75. 
She, Q.B., Ma, W.Y., Wang, M., Kaji, A., Ho, C.T., and Dong, Z. (2003). Inhibition of cell 
transformation by resveratrol and its derivatives: differential effects and mechanisms involved. 
Oncogene 22, 2143-2150. 
Sheu, M.L., Shen, C.C., Chen, Y.S., and Chiang, C.K. (2016). Ochratoxin A induces ER stress and 
apoptosis in mesangial cells via a NADPH oxidase-derived reactive oxygen species-mediated calpain 
activation pathway. Oncotarget 8., 19376-19388. 
Singh, S.D., and Chuturgoon, A.A. (2017). A comparative analysis of mycotoxin contamination of 
supermarket and premium brand pelleted dog food in Durban, South Africa. Journal of the South 
African Veterinary Association 88, e1-e6. 
Smith, M.L., Chen, I.T., Zhan, Q., O'Connor, P.M., and Fornace, A.J., Jr. (1995). Involvement of the 
p53 tumor suppressor in repair of u.v.-type DNA damage. Oncogene 10, 1053-1059. 
Sorrenti, V., Di Giacomo, C., Acquaviva, R., Barbagallo, I., Bognanno, M., and Galvano, F. (2013). 
Toxicity of Ochratoxin A and Its Modulation by Antioxidants: A Review. Toxins 5, 1742-1766. 
Stachurska, A., Ciesla, M., Kozakowska, M., Wolffram, S., Boesch-Saadatmandi, C., Rimbach, G., 
Jozkowicz, A., Dulak, J., and Loboda, A. (2013). Cross-talk between microRNAs, nuclear factor E2-
related factor 2, and heme oxygenase-1 in Ochratoxin A -induced toxic effects in renal proximal tubular 
epithelial cells. Molecular Nutrition & Food Research 57, 504-515. 
Stachurska, A., Kozakowska, M., Jozkowicz, A., Dulak, J., and Loboda, A. (2011). Aristolochic acid I 
and Ochratoxin A differentially regulate VEGF expression in porcine kidney epithelial cells--the 
involvement of SP-1 and HIFs transcription factors. Toxicology Letters 204, 118-126. 
Stewart, D., Killeen, E., Naquin, R., Alam, S., and Alam, J. (2003). Degradation of transcription factor 
Nrf2 via the ubiquitin-proteasome pathway and stabilization by cadmium. The Journal Of Biological 
Chemistry 278, 2396-2402. 
Storz, G., Christman, M.F., Sies, H., and Ames, B.N. (1987). Spontaneous mutagenesis and oxidative 
damage to DNA in Salmonella typhimurium. Proceedings of the National Academy of Sciences of the 
United States of America 84, 8917-8921. 
Takaoka, M. (1940). The Phenolic Substances of White Hellebore (Veratrum Grandiflorum Loes. Fill). 
V Synthesis of Resveratrol (3, 5, 4-Trioxystilbene) and its Derivatives. NIPPON KAGAKU KAISHI 
61, 1067-1069. 
Tennen, Ruth I., Michishita-Kioi, E., and Chua, Katrin F. (2012). Finding a Target for Resveratrol. Cell 
148, 387-389. 
Thuvander, A., Breitholtz-Emanuelsson, A., and Olsen, M. (1995). Effects of Ochratoxin A on the 
mouse immune system after subchronic exposure. Food And Chemical Toxicology 33, 1005-1011. 
41 
 
Tirasophon, W., Welihinda, A.A., and Kaufman, R.J. (1998). A stress response pathway from the 
endoplasmic reticulum to the nucleus requires a novel bifunctional protein kinase/endoribonuclease 
(Ire1p) in mammalian cells. Genes & Development 12, 1812-1824. 
Trivedi, A.B., Doi, E., and Kitabatake, N. (1992). Detoxification of Ochratoxin A on Heating under 
Acidic and Alkaline Conditions. Bioscience, Biotechnology, and Biochemistry 56, 741-745. 
Tsujimoto, Y. (1998). Role of Bcl-2 family proteins in apoptosis: apoptosomes or mitochondria? Genes 
to cells : devoted to molecular & cellular mechanisms 3, 697-707. 
van der Merwe, K.J., Steyn, P.S., Fourie, L., Scott, D.B., and Theron, J.J. (1965). Ochratoxin A, a toxic 
metabolite produced by Aspergillus ochraceus Wilh. Nature 205, 1112-1113. 
Vander Heiden, M.G., Cantley, L.C., and Thompson, C.B. (2009). Understanding the Warburg Effect: 
The Metabolic Requirements of Cell Proliferation. Science (New York, NY) 324, 1029-1033. 
Vaupel, P. (2004). The Role of Hypoxia-Induced Factors in Tumor Progression. The Oncologist 9, 10-
17. 
Vomhof-DeKrey, E.E., and Picklo, M.J. (2012). The Nrf2-antioxidant response element pathway: a 
target for regulating energy metabolism. The Journal of Nutritional Biochemistry 23, 1201-1206. 
Vrabcheva, T., Petkova-Bocharova, T., Grosso, F., Nikolov, I., Chernozemsky, I.N., Castegnaro, M., 
and Dragacci, S. (2004). Analysis of Ochratoxin A in foods consumed by inhabitants from an area with 
balkan endemic nephropathy: a 1 month follow-up study. Journal of Agricultural And Food Chemistry 
52, 2404-2410. 
Wafa, E.W., Yahya, R.S., Sobh, M.A., Eraky, I., el-Baz, M., el-Gayar, H.A., Betbeder, A.M., and 
Creppy, E.E. (1998). Human ochratoxicosis and nephropathy in Egypt: a preliminary study. Human & 
Experimental Toxicology 17, 124-129. 
Walker, R. (2002). Risk assessment of ochratoxin: current views of the European Scientific Committee 
on Food, the JECFA and the Codex Committee on Food Additives and Contaminants. Advances In 
Experimental Medicine And Biology 504, 249-255. 
Walter, P., and Ron, D. (2011). The unfolded protein response: from stress pathway to homeostatic 
regulation. Science (New York, NY) 334, 1081-1086. 
Wang, G.L., Jiang, B.H., Rue, E.A., and Semenza, G.L. (1995a). Hypoxia-inducible factor 1 is a basic-
helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proceedings of the National 
Academy of Sciences 92, 5510-5514. 
Wang, M., Wey, S., Zhang, Y., Ye, R., and Lee, A.S. (2009). Role of the Unfolded Protein Response 
Regulator GRP78/BiP in Development, Cancer, and Neurological Disorders. Antioxidants & Redox 
Signaling 11, 2307-2316. 
Wang, X.W., Yeh, H., Schaeffer, L., Roy, R., Moncollin, V., Egly, J.M., Wang, Z., Freidberg, E.C., 
Evans, M.K., Taffe, B.G., et al. (1995b). p53 modulation of TFIIH-associated nucleotide excision repair 
activity. Nature Genetics 10, 188-195. 
Weinberg, R.A. (2007). The Biology of Cancer. Garland Science,  Taylor & Francis Group, LLC. 
42 
 
Whitesell, L., and Lindquist, S.L. (2005). HSP90 and the chaperoning of cancer. Nature Reviews 
Cancer 5, 761-772. 
WHO (2002). Evaluation of Certain Mycotoxins in Food: Ochratoxin A. WHO; Geneva, Switzerland 
WHO Technical Report Series 906. 
Wild, C.P., and Gong, Y.Y. (2010). Mycotoxins and human disease: a largely ignored global health 
issue. Carcinogenesis 31, 71-82. 
Williams, A.B., and Schumacher, B. (2016). p53 in the DNA-Damage-Repair Process. Cold Spring 
Harbor Perspectives in Medicine 6. 
Wu, G., Fang, Y.Z., Yang, S., Lupton, J.R., and Turner, N.D. (2004). Glutathione metabolism and its 
implications for health. Journal of Nutrition 134, 489-492. 
Xiao, H., Madhyastha, S., Marquardt, R.R., Li, S., Vodela, J.K., Frohlich, A.A., and Kemppainen, B.W. 
(1996). Toxicity of ochratoxin A, its opened lactone form and several of its analogs: structure-activity 
relationships. Toxicology and Applied Pharmacology 137, 182-192. 
Yamamoto, K., Yoshida, H., Kokame, K., Kaufman, R.J., and Mori, K. (2004). Differential 
contributions of ATF6 and XBP1 to the activation of endoplasmic reticulum stress-responsive cis-acting 
elements ERSE, UPRE and ERSE-II. Journal of Biochemistry 136, 343-350. 
Yasuda, S., Arii, S., Mori, A., Isobe, N., Yang, W., Oe, H., Fujimoto, A., Yonenaga, Y., Sakashita, H., 
and Imamura, M. (2004). Hexokinase II and VEGF expression in liver tumors: correlation with 
hypoxia-inducible factor 1 alpha and its significance. Journal of Hepatology 40, 117-123. 
Ye, J., Kumanova, M., Hart, L.S., Sloane, K., Zhang, H., De Panis, D.N., Bobrovnikova-Marjon, E., 
Diehl, J.A., Ron, D., and Koumenis, C. (2010). The GCN2-ATF4 pathway is critical for tumour cell 
survival and proliferation in response to nutrient deprivation. The EMBO Journal 29, 2082-2096. 
Yoshida, H., Matsui, T., Yamamoto, A., Okada, T., and Mori, K. (2001). XBP1 mRNA is induced by 
ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. Cell 
107, 881-891. 
Yuan, J., and Glazer, P.M. (1998). Mutagenesis induced by the tumor microenvironment. Mutation 
Research 400, 439-446. 
Zaied, C., Bouaziz, C., Azizi, I., Bensassi, F., Chour, A., Bacha, H., and Abid, S. (2011). Presence of 
Ochratoxin A in Tunisian blood nephropathy patients. Exposure level to OTA. Experimental and 
toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie 63, 613-618. 
Zain, M.E. (2011). Impact of mycotoxins on humans and animals. Journal of Saudi Chemical Society 
15, 129-144. 
Zanic-Grubisic, T., Zrinski, R., Cepelak, I., Petrik, J., Radic, B., and Pepeljnjak, S. (2000). Studies of 
Ochratoxin A -induced inhibition of phenylalanine hydroxylase and its reversal by phenylalanine. 
Toxicology And Applied Pharmacology 167, 132-139. 
43 
 
Zeljezic, D., Domijan, A.M., and Peraica, M. (2006). DNA damage by Ochratoxin A in rat kidney 
assessed by the alkaline comet assay. Brazilian Journal Of Medical And Biological Research 39, 1563-
1568. 
Zhang, X., Boesch-Saadatmandi, C., Lou, Y., Wolffram, S., Huebbe, P., and Rimbach, G. (2009). 
Ochratoxin A induces apoptosis in neuronal cells. Genes & Nutrition 4, 41-48. 
Zhou, X., Chen, M., Zeng, X., Yang, J., Deng, H., Yi, L., and Mi, M.t. (2014). Resveratrol regulates 
mitochondrial reactive oxygen species homeostasis through Sirt3 signaling pathway in human vascular 
endothelial cells. Cell Death and Disease 5, e1576. 
Zitka, O., Skalickova, S., Gumulec, J., Masarik, M., Adam, V., Hubalek, J., Trnkova, L., Kruseova, J., 
Eckschlager, T., and Kizek, R. (2012). Redox status expressed as GSH:GSSG ratio as a marker for 
oxidative stress in paediatric tumour patients. Oncology Letters 4, 1247-1253. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
44 
 
CHAPTER 3 
 
The Phytoalexin Resveratrol Ameliorates Ochratoxin A Toxicity in Human Embryonic Kidney 
(HEK293) Cells. 
Shanel Raghubeer1, Savania Nagiah1, Alisa Phulukdaree2, and Anil Chuturgoon1* 
1Discipline of Medical Biochemistry, School of Laboratory Medicine and Medical Sciences, College of Health Sciences, 
University of KwaZulu-Natal, Durban 4041, South Africa 
2Department of Physiology, School of Medicine, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa 
 
*Correspondence to: Prof. Anil A. Chuturgoon; Discipline of Medical Biochemistry and Chemical 
Pathology, Faculty of Health Sciences, George Campbell Building, Howard College, University of 
KwaZulu-Natal, Durban 4041, South Africa  
e-mail: chutur@ukzn.ac.za 
 
 
Grant sponsor: NRF-DAAD Master’s Scholarship 2014; University of KwaZulu-Natal College of 
Health Sciences Scholarship 2014 (Laboratory Expenses). 
 
 
Figures: 6    
Tables: 0 
 
 
Conflict of Interest: None 
 
 
Journal of Cellular Biochemistry 116:2947–2955 (2015) 
DOI: 10.1002/jcb.25242 
 
 
 
 
 
 
 
 
 
45 
 
Abstract 
Ochratoxin A (OTA) is a nephrotoxic mycotoxin produced by Aspergillus and Penicillium fungi. It 
contaminates human and animal food products, and chronic exposure is associated with renal fibrosis 
in humans (Balkan endemic nephropathy). Resveratrol, a phytoalexin, possesses anti-cancer and 
antioxidant properties. We investigated the mechanism of cellular oxidative stress induced by OTA, 
and the effect of resveratrol in human embryonic kidney (HEK293) cells over 24h and 48h. Cells were 
exposed to OTA [IC50 = 1.5 µM (24h) and 9.4µM (48h) determined using MTT assay] and 25µM 
resveratrol. Glutathione was quantified by luminometry and gene expression of Nrf2 and OGG1 was 
determined by qPCR. Protein expression of Nrf2, LonP1, SIRT3, and pSIRT1 was assessed by Western 
blot, DNA damage (comet assay), and intracellular reactive oxygen species (flow cytometry). At 24h, 
resveratrol increased mRNA expression of the DNA repair enzyme, OGG1 (p<0.05), whereas OTA and 
OTA+resveratrol significantly decreased OGG1 expression (p<0.05). OGG1 expression increased 
during 48h exposure to resveratrol and OTA+resveratrol (p<0.05). Comet tail lengths doubled in 48h 
OTA-treated cells, whereas at both time periods, OTA+resveratrol yielded shorter comet tails 
(p<0.0001). During 24h and 48h exposure, OTA, resveratrol, and OTA+resveratrol significantly 
decreased mRNA expression of Nrf2 (p<0.05). Luminometry analysis of GSH revealed an increase by 
OTA+resveratrol for 24h and 48h (p<0.05 and p<0.001, respectively). Western blot analysis showed 
decreased Nrf2 protein expression during 24h exposure, but increased Nrf2 expression during 48h. 
LonP1 protein expression increased during 24h exposure to OTA (p<0.05) and OTA+resveratrol 
(p<0.0011) and during 48h exposure to resveratrol (p<0.0005).  
 
Keywords: Resveratrol, Ochratoxin A, Oxidative stress, LonP1, HEK293 cells 
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Introduction 
Ochratoxin A (OTA) is a common contaminant of foods, such as grains, fruit, and animal feed [Marin-
Kuan et al., 2008]. It is ubiquitously produced by fungal species of Aspergillus and Penicillium, 
specifically Aspergillus ochraceus (Schilter et al., 2005). Rural populations in developing countries rely 
heavily on grains as a staple source of sustenance; many of these communities lack proper storage 
facilities for harvested grains; this leads to increased fungal contamination and potentially increased 
production of OTA (Bankole et al., 2006). OTA was first discovered in South Africa (SA) in 1965 (van 
der Merwe et al., 1965) and has since been found in food sources around the world (Jonsyn-Ellis, 2012). 
Although first discovered in SA, there is still little documented information on OTA mycotoxicosis in 
SA. Understanding the mechanism of OTA toxicity is particularly important for African countries as 
grains, such as cassava and maize, contribute to a large part of the daily sustenance for a high percentage 
of the population (Jonsyn-Ellis, 2012).  
 
Microorganisms in the gastrointestinal tract (GIT) hydrolyse OTA to the less toxic by-product, 
Ochratoxin α (OTα) (Hohler et al., 1999), which is then excreted via the liver and kidney (Cheng et al., 
2013). Exposure to high levels of OTA has been linked to renal dysfunction and tumourigenesis in 
humans (Özçelik et al., 2004). OTA is nephrotoxic and results in destruction of the renal tubular 
epithelium, causing progressive renal failure (Pfohl-Leszkowicz and Manderville, 2007). This disease 
is particularly prominent in the Balkan regions, such as Bulgaria and Romania, and is known as Balkan 
endemic nephropathy (BEN) (Pfohl-Leszkowicz and Manderville, 2007).  
 
OTA exerts its toxic effects via a number of mechanisms, the most prominent method is by alteration 
of the antioxidant potential of the cell (Meyer et al., 2013), resulting in oxidative stress induction, and 
increased reactive oxygen species (ROS) (Schaaf et al., 2002). During oxidative stress, nuclear factor-
erythroid 2-related factor 2 (Nrf2) dissociates from its inhibitor, Kelch-like ECH-associated protein 1 
(Keap-1), translocates into the nucleus, and binds to the antioxidant response element (ARE), resulting 
in the transcription of proteins associated with the antioxidant defence system (Nguyen et al., 2009). 
Therefore, we aimed to investigate the interactions of both OTA and resveratrol with the Nrf2 
antioxidant defence system in cultured human kidney cells.  
 
Resveratrol (3, 5, 4’-trihydroxy-trans-stilbene) is a polyphenol found in the skin of injured grapes and 
some fruit, and is, therefore, commonly present in wine and grape juice (Athar et al., 2007).  Resveratrol, 
synthesized by plants as a defensive mechanism, is proposed to have antimicrobial, antioxidant, anti-
carcinogenic, and anti-inflammatory properties (Athar et al., 2007). This compound is widely studied 
and holds great potential in disease treatment. Resveratrol possesses free radical scavenging potential, 
contributing to its antioxidant capacity [Borra et al., 2005]. The phytoalexin is also known to activate 
sirtuin 1 (SIRT1), a NAD+-dependent deacetylase known for its ability to modulate transcription of 
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proteins that augment the oxidative stress response, as well as proteins that promote cell survival in 
times of stress (Borra et al., 2005; Timmers et al., 2012). These attributes could contribute to the 
compound’s chemo-preventive ability, as well as the ability to diminish cellular damage due to 
oxidative stress (Baur and Sinclair, 2006). Both resveratrol and OTA have been found in grapes; 
therefore, it is important to have an understanding of the dynamic between these two compounds.  
 
OTA exposure is widespread throughout Europe, through the ingestion of grape products, such as wine 
and juice. This is especially prominent in the grape producing regions of Italy (Visconti et al., 2008). 
The mechanisms of OTA toxicity and the cellular antioxidant response are relatively unknown. This 
study investigated the cytotoxic effects of OTA on HEK293 cells after 24h and 48h exposure. Further, 
the therapeutic effects of resveratrol in both untreated and OTA-treated HEK293 cells were 
investigated. We believe these results will provide valuable insight into OTA toxicity in human kidney 
cells, and whether resveratrol can be used as a potential treatment to combat this toxicity. 
 
Materials 
Tissue culture consumables were purchased from Whitehead Scientific (Johannesburg, South Africa). 
The HEK293 cells were obtained from Highveld Biological (Johannesburg, South Africa). Ochratoxin 
A and resveratrol were purchased from Sigma–Aldrich (St Louis, MO). Methylthiazoltetrazolium 
(MTT) salt, phosphate buffered saline (PBS) tablets, and agarose were purchased from Capital 
Laboratory Supplies (Johannesburg, South Africa). The bicinchoninic acid (BCA) assay kit and tris-
chloride were purchased from Sigma–Aldrich. Kits and reagents used for luminometry (GSH-Glo™ 
Glutathione Assay kit) were purchased from Promega (Madison, USA). Reagents for qPCR were 
purchased from Bio-Rad (Hercules, CA) and the primer sequences were purchased from Inqaba 
Biotechnologies (Pretoria, South Africa). Western blotting reagents (Laemmli sample buffer and 
chemiluminescent reagents) were obtained from Bio-Rad. Primary antibodies (rabbit anti-Nrf2 (8882), 
rabbit anti-SIRT3 (C73E7), and rabbit antipSIRT1 (2314L) were purchased from Cell Signaling 
Technology (Danvers, MO). Rabbit anti-LonP1 (HPA002192-100UL) was purchased from Sigma-
Aldrich (St. Louis, MO) and horse-radish peroxidase (HRP)-conjugated secondary antibodies (anti-
rabbit IgG) were purchased from Cell Signaling Technology. Proteins were normalized to anti-β-actin 
(A3854) from Sigma–Aldrich. All other solvents and salts were purchased from Merck Chemicals 
(Johannesburg, South Africa). Protein isolation was conducted using Cytobuster™ (Novagen), 
supplemented with protease inhibitors (Roche 05892791001) and phosphatase inhibitors 
(04906837001).  
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Methods 
Cell Culture 
HEK293 cells were cultured in monolayer (106 cells per 25 cm3 culture flask). The cells were 
maintained in complete culture medium [CCM: Dulbecco’s minimum essential media (DMEM), 10% 
fetal calf serum, 1% Penstrepfungizone, and 1% L-glutamine] and incubated overnight at 37°C in a 
humidified incubator supplied with 5% CO2. Cells were washed with 0.1M PBS. Once flasks were 
confluent, cells were treated, removed by trypsinisation and agitation, and counted using the trypan blue 
exclusion assay.  
 
Ochratoxin A Treatments 
A stock solution of 200µM OTA was prepared in 60% dimethyl sulphoxide (DMSO). Cells were treated 
with a range (0.25–50µM) of concentrations to obtain a half maximal inhibitory concentration (IC50) 
for 24h and 48h incubation times.  
 
Methylthiazol Tetrazolium (MTT) Assay 
Cells were seeded into a 96-well microtiter plate (15,000 cells/well) and allowed to attach overnight. 
Attached cells were treated with a range of OTA concentrations (0.25–50µM) for 24h and 48h. 
Treatment media was removed and replaced with CCM (100µl) and 20µl MTT salt solution (5mg/ml 
in PBS). Cells were incubated with the MTT salt solution for 4h, thereafter the MTT solution was 
discarded and DMSO (100µl) was added; the cells were incubated with DMSO for 1h. Absorbance was 
read using a Bio-Tek MQx200 spectrophotometer at 595 nm (reference wavelength 655 nm). An 
inhibitory concentration at which 50% of cell growth was inhibited (IC50) was calculated using 
GraphPad Prism statistical software (version 5).  
 
Resveratrol Treatments 
Stock solutions of 10mM resveratrol were prepared in 100% DMSO. Preliminary assays were carried 
out to determine the optimal resveratrol concentrations for all subsequent treatments. Cells were treated 
with 25µM, 50µM, and 100µM resveratrol during pre-, post- and co-OTA treatments for 24h, 
respectively. Flow cytometry was used to observe which resveratrol concentration greatly decreased 
the percentage of intracellular ROS, whereas luminometry was used to detect the levels of intracellular 
glutathione (GSH), thus indicating which concentration provided a more robust defence against 
oxidative damage. Based on these results, 25µM resveratrol was used for all subsequent assays. 
 
Cell Preparation for Assays 
Cells were incubated with the treatments for 24h and 48h. Treatments included a control (CCM 
containing the solvent vehicle, DMSO), the IC50 values of OTA, a resveratrol control (CCM containing 
25mM resveratrol), and a co-treatment (IC50 values of OTA and 25µM resveratrol in CCM). Cells were 
49 
 
removed by trypsinisation and agitation, the trypan blue method of cell counting was employed to 
determine cell viability and number as required per assay performed. 
The control was used for statistical comparison to all other treatments.  
 
Glutathione Assay 
The GSH assay [per GSH-Glo™ glutathione assay protocol (Promega)] was used to determine the 
concentration of GSH in HEK293 cells. Cells (104cells/well) were seeded in a luminometry plate in 
triplicate. Standards (0-50µM) were added in triplicate to generate a standard curve of known GSH 
concentrations. The GSH- Glo™ reagent (50µl) was added to each well; the plate was agitated for 30s, 
and incubated in the dark (RT, 30min). The luciferin detection reagent (100µl) was added to each 
sample and incubated as previously described (RT, 15min). The plates were read on a Modulus™ 
microplate luminometer (Turner Biosystems, Sunnyvale, CA). The GSH concentrations were 
determined by extrapolation from the standard curve.  
 
Single Cell Gel Electrophoresis (SCGE) Assay 
Cells were incubated with the treatments for 24h and 48h, thereafter cells were removed by 
trypsinisation and agitation, then counted; 15,000 cells were removed and resuspended in 25µl PBS. 
Low melting point agarose (LMPA) was used to prepare the gels. The first gel layer (700µl 2% LMPA) 
was formed on a frosted microscope slide, covered with a coverslip, and incubated at 4°C (10min). 
Thereafter, the coverslip was removed, a second gel layer (including 1.5µl GR red dye, 25µl cell 
suspension (104 cells) in 175µl 1% LMPA) was added, coverslips were placed over slides, and 
incubated as above. Coverslips were removed, and a third layer was added (1% LMPA, 200µl) onto the 
second. Once the third layer solidified, coverslips were removed, slides were submerged in an ice-cold 
cell lysing solution [10mM Tris (pH 10), 1% Triton X-100, 2.5M NaCl, 100mMEDTA, and 10% 
DMSO), and incubated in the dark (4°C, 1h). The lysing solution was removed, slides were placed in 
an electrophoresis tank filled with electrophoresis buffer (300mM NaOH and 1mM Na2EDTA), and 
allowed to equilibrate for 20min. The electrophoresis tank was sealed, and a constant voltage was 
applied (25 V, 35min). After electrophoresis, slides were washed thrice (5min each) with neutralization 
buffer (0.4M Tris, pH 7.4). Slides were viewed using an Olympus IX5I inverted fluorescent microscope 
(510–560nm excitation, 590nm emission filters) using analySIS Image Processing Software (Novell). 
Approximately 50 comets per treatment (three replicates) were counted and analysed by measuring tail 
length (µm). 
 
RNA Extraction  
RNA was isolated following an in-house protocol using Trizol. Trizol reagent (500µl) was added to 
each flask and incubated (4°C, 10min). Cells were removed from flasks, transferred to 1.5ml 
eppendorfs, and stored in Trizol at -80 °C overnight. Chloroform (100µl) was added to thawed samples 
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and incubated (RT, 3min). Thereafter, cell suspensions were centrifuged (12,000g, 4°C, 15min), the 
aqueous phase removed, 250µl isopropanol was added, and samples were left overnight at -80 °C. 
Samples were thawed and centrifuged (12,000g, 4°C, 20min). The supernatant was discarded, the pellet 
was retained and washed with 75% cold ethanol (500µl), and centrifuged (7,400g, 4°C, 15min). Ethanol 
was removed, and samples were allowed to air dry. The pellet was resuspended in nuclease-free water 
(15µl) and incubated (RT, 3min). The RNA was quantified using the Nanodrop2000 spectrophotometer 
(Thermo-Scientific) and the A260/A280 ratio was used to assess the RNA integrity. The concentration 
of RNA was standardized to 2,500 ng/µl and used to prepare cDNA using the iScript cDNA synthesis 
Kit (Bio-Rad) as per manufacturer’s instructions (4µL 5X iScript reaction mix, 1µL iScript reverse 
transcriptase, 11µL nuclease-free water, and 4µL of each RNA sample). 
 
Quantitative Polymerase Chain Reaction (qPCR) 
Gene expression was analysed using the iScript SYBR Green PCR kit (Bio-Rad), according to the 
manufacturer’s instructions. The final reaction volume totalled 25µl (12.5µl SYBR Green, 1µl 
forward primer, 1µl reverse primer, 9µl nuclease-free water, and 1.5µl cDNA sample). All primers 
were obtained from Inqaba Biotec. The mRNA expressions of oxoguanine glycosylase 1 (OGG1) 
(forward 5’-GCATCGTACTCTAGCCTCCAC-3’; reverse 5’-GGACTTTGCTCCCTCCAC-3’) and 
Nrf2 (forward 5’-AGTGGATCTGCCAACTACTC-3’; reverse 5’-
CATCTACAAACGGGAATGTCTG-3’) were investigated. This assay was carried out using three 
replicates per treatment and b-actin (forward 5’-TGACGGGTCACCCACACTGTGCCCAT-3’; 
reverse 5’-CTAGAAGCATTTGCGGTGGACGATGGAGGG-3’) as a house-keeping gene. The 
initial denaturation occurred at 95 °C (4min). This was followed by 37 cycles of denaturation (95 °C; 
15s), annealing (40s; OGG1-60 °C; Nrf2-58 °C), and extension (72°C; 30s). The method described by 
Livak and Schmittgen was employed to determine the changes in relative mRNA expression, where 2-
∆∆Ct represents the fold change observed in mRNA expression (Livak and Schmittgen, 2001). 
 
SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) And Western Blotting 
Crude protein was isolated from cells using Cytobuster™ (Novagen) supplemented with protease 
inhibitors (Roche 05892791001) and phosphatase inhibitors (04906837001). Cytobuster reagent 
(250µl) was added to flasks following treatments; the cells were scraped and transferred to a 1.5 ml 
tube and incubated on ice (10min). The cell solution was centrifuged (10,000g, 4°C, 5min). The 
supernatant was used for protein quantification using the bicinchoninic acid (BCA) assay. Bovine serum 
albumin (BSA) standards (0–1mg/ml) were prepared. Samples and standards (25µl) were pipetted into 
a 96-well microtiter plate in duplicate. The BCA reagent was prepared (198µL BCA: 4µL CuSO4 per 
reaction) and 200µL of this working solution was added to each well. After incubation (37°C, 30min), 
the absorbance was read on a Bio-Tek MQx200 spectrophotometer at 562nm. A standard curve was 
constructed, and proteins were standardized to 1mg/ml. Laemmli buffer [dH2O, 0.5M Tris-HCl (pH 
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6.8), glycerol, 10% SDS, β-mercaptoethanol, 1% bromophenol blue] was added to each sample (1:1, 
total volume 200 µl), and heated to 100°C (5min).  
 
Samples were separated on SDS polyacrylamide gel (7.5% resolving gel and 4% stacking gel) for 1h at 
150V, and transferred onto nitrocellulose membranes using the Transblot® Turbo™ Transfer system 
(Bio-Rad). Membranes were blocked with 3% BSA in Tris-buffered saline [TTBS, 25mM Tris (pH 7.6) 
150mM NaCl, 0.05% Tween 20] for 30 min, and incubated with a primary antibody (1:1000, 3% BSA 
In TTBS at 4°C overnight). Antibodies used were anti-Nrf2 (8882), anti-phospo SIRT1 (2314L), anti-
SIRT3 (C73E7), and anti-LonP1 (HPA002192-100UL). Protein concentrations were standardized to 
anti-β-actin (Sigma–Aldrich A3854). After incubation, the primary antibody was removed, membranes 
were washed thrice with TTBS (10min), and incubated with a horseradish peroxidase (HRP)-conjugated 
secondary antibody (Santa Cruz Biotechnology, Inc.) in 3% BSA (1:10 000) for 1h. Following 
incubation, membranes were washed with TTBS. Clarity Western ECL Substrate (Bio-Rad) (400µl) 
was added to the membranes and images were captured using a gel documentation system (UviTech 
Alliance 2.7). The membranes were then quenched with hydrogen peroxide, incubated in a blocking 
solution (3% BSA, 1h, RT), rinsed twice in TTBS, and probed with HRP-conjugated anti-β actin 
(house-keeping protein) (Sigma). Densitometry analysis was performed using the UviTech Analysis 
software and protein expression was read as relative band intensity (Arbillaga et al., 2007). Protein 
expression was reported as RBI of the protein of interest divided by the RBI of the loading control.  
 
Flow Cytometry – Intracellular Reactive Oxygen Species (ROS) 
Treated cells were removed and counted, 500,000 cells were required per treatment. Cells were 
incubated in phenol red-free media, supplemented with 10% FCS and 10µM 
dichlorodihydrofluorescein diacetate (DCFDA), in the dark (45min, 37°C). Thereafter, cells were rinsed 
thrice with 0.1M PBS and centrifuged (400g, RT, 5min), then suspended in 150µl 0.1M PBS and 
analysed using a BD Accuri™ flow cytometer. Live cells were gated and analysed using CFlow Plus 
Software (BD Biosciences). 
 
Statistical Analysis 
Statistical analyses were performed using a one-way analysis of variance (ANOVA) test and the 
Students’ t-test, using GraphPad Prism version 5.0 (GraphPad Software, San Diego, CA). All data are 
expressed as mean ± standard error. All assays were run in triplicate and differences were considered 
statistically significant at values of p < 0.05.  
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Results  
MTT Assay 
The MTT assay was used to determine the IC50 value of OTA during 24h incubation (1.5µM) and 48h 
incubation (9.4µM) in HEK293 cells (Fig. 3.1). The IC50 values were used for all subsequent assays.  
 
Figure 3.1: Percentage viability of cells exposed to OTA over (A) 24h and (B) 48h. An IC50 of 1.5µM 
(24h) and 9.4 (48h) was calculated from the dose-response curve. 
 
Resveratrol Decreases Intracellular Ros Production During 24h Exposure. 
Flow cytometry was used to measure intracellular ROS production in HEK293 cells. Resveratrol 
significantly reduced intracellular ROS in the kidney cells from 47.7% to 20.2% (Fig. 3.2; p < 0.0001). 
Both the OTA (25.3%) and OTA+resveratrol (28.9%) treatments significantly reduced ROS when 
compared to control cells (47.7%) (Fig. 3.2; p = 0.0048). The opposite was observed during the 48h 
exposure, where all treatments increased the intracellular ROS when compared to control cells. A 
significant increase was observed when cells were exposed to OTA+resveratrol over 48h (Fig. 3.2; p = 
0.0002). 
 
Figure 3.2: Assessment of the percentage of intracellular ROS in cells exposed to OTA and resveratrol 
over 24h and 48h. Resveratrol significantly decreased the percentage of intracellular ROS (***p < 
0.0001), whereas OTA and OTA+resveratrol treatments decreased the values of ROS when compared 
to control cells during 24h exposure (*p = 0.0048). Upon 48h exposure, OTA+resveratrol significantly 
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increased the ROS values (***p = 0.0002), whereas the OTA and resveratrol treatments also increased 
intracellular ROS. 
 
Assessment of DNA Damage and Repair 
OTA-treated cells (24h) had significantly longer comet tails (44.82 ± 1.516µm; p < 0.0001) as compared 
to the control cells (Fig. 3.3B). In contrast, resveratrol significantly decreased comet tail lengths 
compared to all other treatments (11.69 ± 0.695µm; p < 0.0001). Interestingly, cells co-treated with 
OTA+resveratrol also showed significantly decreased comet tail lengths as compared to cells only 
exposed to OTA (Fig. 3.3B; 29.03 ± 1.110µm vs. 44.82 ± 1.516µm; p < 0.0001). These observations 
were similar for the 48h exposure period; however, the comet tails almost doubled in length. OTA-
treated cells (48h) had significantly longer comet tails (86.67µm) as compared to the 24h treatment 
(44.82µm) (Fig. 3.3D). In addition, the comet tails were brighter and longer in OTA-treated cells, 
indicating that more DNA activity and increased DNA strand breaks occurred with increased exposure. 
The co-treatment (OTA+resveratrol) significantly decreased comet tail lengths compared to OTA-
treated cells (Fig. 3.3D; 70.72 ± 1.030µm vs. 86.67 ± 1.694µm; p < 0.0001). 
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Figure 3.3: Assessment of DNA damage showing images of (A) comet tails during 24h exposure, (B) 
the measurement of comet tail lengths during 24h exposure, (C) comet tails during 48h exposure, and 
(D) the measurement of comet tail lengths during 48h exposure. OTA increased comet tail lengths 
during both exposure time periods (***p < 0.0001). Comet tail lengths doubled during the 48h exposure. 
The OTA+Resveratrol co-treatment significantly decreased lengths compared to cells only treated with 
OTA (***p < 0.0001). 
 
Measurement of GSH Concentrations 
Intracellular concentration of GSH was determined using luminometry. GSH concentrations in HEK293 
cells were significantly increased by OTA+resveratrol treatment as compared to OTA-treated cells (p 
< 0.05); however, this concentration doubled after 48h exposure (p < 0.001) (Fig. 3.4). The co-treatment 
of cells with OTA+resveratrol yields increased concentrations of GSH than in cells exposed to OTA 
alone. Generally, the GSH concentrations are far higher over 48h exposure times than 24h exposures 
(Fig. 3.4). The concentration of GSH was seen to decrease in OTA-treated cells compared to controls, 
thus indicating that longer exposure to OTA could deplete the antioxidant defence of the cells, allowing 
ROS to overrun the cell. 
 
Figure 3.4: Concentrations of GSH in HEK293 cells after exposure to OTA and resveratrol. The 
OTA+resveratrol co-treatment increased the concentrations of GSH during the 24h exposure compared 
to GSH present in OTA-treated cells (*p < 0.05). The co-treatment also increased GSH during the 48h 
exposure (***p < 0.001). 
 
qPCR Analysis of Antioxidant Response  
The mRNA expression of Nrf2 and OGG1 was assessed by qPCR. The expression of Nrf2, an 
antioxidant defence regulator, was significantly decreased by OTA, resveratrol, and OTA+resveratrol 
after 24h exposure (Fig. 3.5A; p < 0.05); Nrf2 expression decreased further after 48h (Fig. 3.5B). 
Resveratrol increased the expression of OGG1 (p < 0.05), whereas the co-treatment significantly 
decreased its expression after 24h (Fig. 3.5C; p < 0.05). The co-treatment, however, significantly 
increased OGG1 expression when measured after 48h (Fig. 3.5D; p < 0.05).  
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Figure 3.5: Analysis of the mRNA expression of genes associated with cellular protection. Nrf2 
expression was seen to decrease upon exposure to OTA, resveratrol (*p < 0.05), and OTA+Resveratrol 
(**p = 0.001) for 24h. (B) The expression of Nrf2 was seen to decrease further when exposed to OTA 
(*p < 0.05) and resveratrol (**p = 0.0021) for 48h. The DNA glycosylase enzyme, OGG1, was observed 
to increase during 24h resveratrol exposure and significantly decrease during exposure to 
OTA+resveratrol (**p < 0.05) for 24h. (C) OGG1 expression was significantly decreased during 
OTA+resveratrol exposure compared to resveratrol-treated cells (p = 0.0002). (D) Recovery of OGG1 
expression was observed during 48h exposure to OTA+resveratrol (**p < 0.05). 
 
Western Blotting 
The protein expression of Nrf2, LonP1, SIRT3, and pSIRT1 was determined using Western blot. Nrf2 
protein expression was decreased by all treatments after 24h exposure, significantly by 
OTA+resveratrol (p < 0.05), but increased by OTA (p < 0.05) and resveratrol (p < 0.0008) after 48h. 
An inverse relationship was found to exist between SIRT3 and LonP1 after 24h, SIRT3 decreased and 
LonP1 increased. Resveratrol increased SIRT3 (p < 0.05) and LonP1 (p = 0.0005) expression (48h), 
and pSIRT1 at both time periods (p = 0.0002 and p = 0.0054, respectively) (Fig. 3.6).  
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Figure 3.6: Western blot images and relative fold change in protein expression of Nrf2, pSIRT1, SIRT3, 
and LonP1 over 24h and 48h, in response to OTA and resveratrol exposure. Resveratrol decreases Nrf2 
expression during 24h exposure, but increases Nrf2 during 48h exposure (***p < 0.0008). OTA 
significantly increased Nrf2 expression during 48h exposure (*p < 0.05). The OTA+resveratrol co-
treatment significantly decreased Nrf2 expression during 24h exposure (*p < 0.05). Resveratrol 
significantly increased the expression of pSIRT1 during 24h exposure (***p = 0.0002) and 48h 
exposure (**p = 0.0054). SIRT3 expression decreased in all treatments during 24h exposure with a 
significant decrease during OTA exposure (***p = 0.0003). The opposite was observed during 48h 
exposure, all treatments increased SIRT3 expression with significance in the resveratrol treatment (*p 
< 0.05). LonP1 expression exhibits the inverse of SIRT3 expression, with an increase in LonP1 
expression during 24h exposure to OTA (*p < 0.05) and OTA+Resveratrol (**p = 0.0011). LonP1 
expression increased significantly upon 48h exposure to resveratrol (***p = 0.0005). 
 
Discussion 
OTA is a mycotoxin that frequently contaminates a wide range of foods. Once ingested, OTA exerts its 
toxic effects via several pathways. One such pathway in the kidney is increased oxidative stress, 
resulting in DNA damage and progressive renal failure in individuals who chronically ingest foods 
contaminated with high concentrations of OTA (Pfohl-Leszkowicz and Manderville, 2007). OTA poses 
a health risk to populations in developing countries, as they depend largely on agricultural crops often 
heavily contaminated with fungi, such as Aspergillus and Penicillium (Castegnaro et al., 2006). OTA 
has been identified as an etiological agent in BEN (Castegnaro et al., 2006). The exact mechanism of 
OTA toxicity is still relatively unknown, although many mechanisms have been proposed. The general 
trend of reduced antioxidant defence capacity has been documented in different cell lines, such as the 
normal rat kidney (NRK) epithelial cells (Cavin et al., 2007; Schilter et al., 2005). In this study, we 
provide insight into the biochemical changes induced by OTA in human embryonic kidney (HEK293) 
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cells. Resveratrol, a phytoalexin, possesses antioxidant characteristics, chemopreventive potential, and 
has been proposed as a treatment for illnesses, such as diabetes, cancer, and cardiovascular disease 
(Rossi et al., 2012). Our study determined whether resveratrol could reduce/prevent OTA-induced 
cytotoxicity in kidney cells. Our aim was to determine whether resveratrol could prevent cytotoxicity 
induced by OTA in kidney cells.  
 
Under normal conditions, ROS regulates intracellular signalling; however, under conditions of 
excessive ROS production, intracellular signalling is compromised and will result in cellular damage 
(Wang et al., 2013). Excessive oxidative stress induces cytotoxicity and alters cellular functioning 
(Weydert and Cullen, 2010). Lipids, proteins, and DNA are susceptible to ROS attack and subsequent 
damage (Marin-Kuan et al., 2011). OTA decreased intracellular ROS (as determined by FACS), but 
still induced single strand DNA breaks (comet assay). Exposure to OTA (24h, 1.5µM) resulted in 
significant DNA strand breaks in HEK293 cells, suggesting that OTA is genotoxic. In comparison to 
control cells, OTA significantly increased the lengths of comet tails by 16.8%, whereas resveratrol 
significantly decreased comet tail lengths by 69.5% (Fig. 3.3). Resveratrol also significantly reduced 
OTA genotoxicity as the co-treatment decreased DNA tail lengths (35.2%). In addition, the intracellular 
ROS was the lowest in resveratrol-treated cells (20.2%).  
 
When DNA damage occurs, the cell activates DNA repair enzymes, such as OGG1 – a DNA 
glycosylase enzyme, which removes 8-oxoguanine base lesions, that could result in mutations and 
carcinogenesis if left to accumulate (Cheng et al., 2013). OTA decreased expression of OGG1 and 
increased DNA tail lengths. This suggests that OGGI enzyme activity is compromised and as a 
consequence, base lesions persist. However, resveratrol increased OGG1 expression in kidney cells, 
resulting in significantly shorter DNA tail lengths, whereas the co-treatment, although inducing low 
expression of OGG1, significantly decreased DNA tail lengths. In the co-treatment, resveratrol afforded 
a protective function, due to its antioxidant properties, by decreasing intracellular ROS and increasing 
OGG1 expression. This may explain its cyto-protective and potential anti-cancer property. The 48h 
ROS results differ, in that all treatments show increased intracellular ROS (Fig. 3.2) and a concomitant 
significant increase in OGG1 expression and shorter comet tails. This suggests that resveratrol aided 
the cells to survive in response to OTA toxicity.  
 
Palma et al. (2007) showed that OTA induced DNA damage by increasing the production of free 
radicals. Our data are in agreement with this study as demonstrated by the comet and flow cytometry 
ROS assays (Palma et al., 2007). GSH, a low molecular weight thiol found abundantly in cells, is a 
potent endogenous antioxidant (Wu et al., 2004). GSH depletion indicates an increase in ROS and 
oxidative stress. OTA severely depleted GSH concentrations (5.06µM) in kidney cells, whereas 
resveratrol increased GSH (2.65µM at 24h; 7.14µM at 48h). Further in the co-treated cells, resveratrol 
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significantly increased GSH from 5.68µM (24h) to 11.39µM (48h). These results indicate that 
resveratrol increases the antioxidant capacity of the cell over longer periods of time by increasing GSH 
synthesis. In addition, resveratrol clearly shows its potent antioxidant capacity by dampening the effects 
of OTA induced toxicity in kidney cells. At both 24h and 48h treatment periods, Nrf2 mRNA expression 
was significantly decreased. Nrf2 expression was lowest at 24h but higher at 48h in the co-treated cells. 
Although resveratrol induced low expression of Nrf2 compared to other treatments, the concentrations 
of GSH were significantly increased and DNA tail lengths were shorter.  
 
Taken together, our data show that resveratrol is a potent antioxidant that can function independently 
in the cell without influence from Nrf2. OTA induced a non-significant increase in Nrf2 expression 
with increased DNA damage, high ROS levels, and lower GSH concentrations. Western blot protein 
analysis revealed changes in Nrf2 expression over the two treatment periods; at 24h, all treatments 
decreased Nrf2 expression, whereas at 48h, Nrf2 expression was increased. The decreased Nrf2 
expression strongly suggests that resveratrol itself mediates the antioxidant defence response, in 
keeping with its antioxidant properties (Momchilova et al., 2014). The protein and mRNA expression 
of Nrf2 at 24h is in agreement; however, these results are different at 48h. The mRNA expression of 
Nrf2 is significantly decreased, but the protein expression is significantly increased. This result could 
be due to alterations in post-translational modifications or the increased expression of LonP1.  
 
LonP1, a protease, is known for its regulatory function and could assist in degrading potentially 
compromised proteins (Bota et al., 2005). SIRT3 has been identified as a regulator of LonP1 expression; 
increased SIRT3 decreases LonP1 (Gibellini et al., 2014). This inverse relationship is clearly evident at 
24h decreased SIRT3 and increased LonP1 expression. A significant increase in LonP1 and decreased 
SIRT3 expression was observed in OTA and cotreated kidney cells. The increased expression of LonP1 
is triggered by increased oxidative stress to combat accumulation of defective proteins. This 
mitochondrial protease could have acted in a compensatory manner by degrading proteins damaged by 
oxidative stress (Zhang et al., 2014).  
 
SIRT1, a NAD+-dependent deacetylase, is activated by resveratrol. In our study, resveratrol increased 
SIRT1 expression in cells at both 24h and 48h. Activated SIRT1 by phosphorylation influences many 
processes, such as DNA repair and cellular metabolism, thereby impacting the cellular stress response. 
Phosphorylated SIRT1 increases nuclear localization of the protein, as well as increased enzymatic 
activity (Sasaki et al., 2008). The stress protection pathway is mediated by SIRT1, increased 
phosphorylation would influence this function, and induce possible deacetylation of stress proteins, 
such as p53 and PGC-1α, causing cellular protection and survival (Nasrin et al., 2009).  
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These data provide insight into the behaviour of OTA, as well as the therapeutic potential of resveratrol. 
We are proposing that short-term effects of OTA contribute to its toxicity. The cells experience an 
increase in the antioxidant response due to the recognition of a cytotoxic environment; however, it is 
not possible to sustain an increased protective response while DNA damage occurs. This is evidenced 
by the 48h data, as time progresses, so too does the extent of damage inflicted on the cell by the toxin. 
Our data suggest that OTA exhausts the cell’s antioxidant reservoir during acute exposure, and thus the 
cell is left vulnerable as the exposure period continues. Taken together, these data suggest that 
resveratrol could be a potential treatment for OTA toxicity, as well as a possible therapy for other 
oxidative stress-inducing toxins. Regarding the information on DNA damage prevention, this research 
also attests to the chemopreventive potential of resveratrol. 
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Abstract 
Ochratoxin A (OTA), a common contaminant of grain and fruit and known carcinogen, has been linked 
to impaired antioxidant response and cellular repair. The effect of OTA on inflammation in cells has 
not been explored. This study investigated OTA's influence on inflammatory mediators using a range 
of OTA concentrations (0.5µM (sub-IC50), 1.2µm (IC50) and 2µm (supra-IC50)) on human embryonic 
kidney (HEK293) cells over 24hr. The markers of inflammation in HEK293 cells were evaluated using 
the following techniques: western blotting (phosphorylated (p-)NFκB (Ser536), p-IKK (Ser176/180) 
and p-p53 (Ser392), total NFκB, IKK, IκBα and p53), luminometry (caspases 1, 3/7, 8, 9, ATP) and 
ELISA to determine IL-1β levels. The results indicate increased activation of the inflammatory pathway 
in the sub-IC50 concentration, evidenced by significant increases in p-NFκB (p = 0.0006). The IC50 
concentration indicates decreased inflammatory induction supported by decreased levels of IL-1β and 
caspase 1 (p = 0.0186 and p = 0.0068 respectively) with decreased IKK and increased IκBα (p = 0.0046 
and p = 0.0006 respectively). Furthermore, a decrease in inflammatory pathway activation was seen in 
O3 (increased IκBα, p < 0.05) coupled with increased apoptosis via elevated caspase 3/7 (p = 0.0002), 
8 (p = 0.0011) and 9 activity (p = 0.0002); as well as decreased ATP levels. This data suggests a new 
mechanism of OTA toxicity and its involvement in inflammation, kidney disease and fibrosis. 
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Introduction 
Toxic insult on the kidney promotes inflammatory processes as a means of cytoprotection, however, 
persistent inflammation in the kidney causes tubulointerstitial damage, diminished functionality and 
eventual fibrosis (Rodríguez-Iturbe et al., 2005). Ochratoxin A (OTA), a mycotoxin, is a known renal 
toxicant (Marin-Kuan et al., 2011), however the role of nuclear factor kappa-light-chain-enhancer of 
activated B cells (NFκB), a key transcription factor in the inflammatory response, has been overlooked 
as a mechanism of OTA toxicity in the kidney.  
 
OTA is present in Penicillium and Aspergillus fungi contaminated foods, such as grains and cereals, 
fruit, coffee, and wine (Boesch-Saadatmandi et al., 2008; Pfohl-Leszkowicz and Manderville, 2007). 
Known mechanisms of OTA toxicity include increased production of reactive oxygen species (ROS) 
leading to oxidative stress (Liu et al., 2012), mitochondrial dysfunction, and genotoxicity promoting 
cellular mutations (Marin-Kuan et al., 2011). This mycotoxin has been linked to several disease 
conditions, such as renal dysfunction, immunotoxicity and tumorigenesis (Darif et al., 2016). It has 
been identified as a causal factor in Balkan Endemic Nephropathy (BEN), a disease observed in the 
Balkan regions of Europe, which presents as damage to renal tubular epithelium and progressive renal 
failure with the potential development of urinary tract tumours (UTT) (Castegnaro et al., 2006). The 
kidney is highly susceptible to OTA-induced damage, as it plays a role in the removal of the toxin by 
excreting OTA into the urine; however OTA forms protein adducts, specifically with albumin, thus 
extending its half-life in humans and prevents excretion (Koszegi and Poor, 2016). This results in an 
accumulation of OTA and allows the toxin to exert its toxic effects on the kidney tubules, impairing 
kidney functioning (Koszegi and Poor, 2016).  
 
A previous study demonstrated OTA-induced oxidative damage via stress pathways in human kidney 
cells and based on these observations it seemed likely that inflammatory pathways may be activated 
(Raghubeer et al., 2015a). This study proposes a mechanism of action for OTA induction of 
inflammation that can eventually lead to apoptosis in human embryonic kidney (HEK293) cells. The 
acute effects of a range of OTA concentrations on HEK293 cells was investigated over 24 hours (hr). 
It is well documented that persistent inflammation influences cellular proliferation and fibrosis (Kalluri 
and Weinberg, 2009), therefore our research question was whether OTA increased inflammatory 
activation in human cells.  OTA’s inflammatory properties (and chronic exposure) may have 
contributed to the aetiology of BEN and the formation of UTT. The NFκB pathway, its inhibitor 
(nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor alpha - IκBα), and its 
downstream effects, as well as apoptosis induction was examined. These results provide a novel insight 
into OTA-induced human renal toxicity. 
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Materials 
Human embryonic kidney (HEK293) cells were obtained from Highveld Biological (Johannesburg, 
South Africa). Tissue culture consumables and cell culture medium (Dulbecco’s Minimum Essential 
Media (DMEM)) were purchased from Corning (New York, USA) and Lonza (Basel, Switzerland) 
respectively. Phosphate buffered saline (PBS) tablets, Ochratoxin A (OTA), Bicinchoninic acid (BCA) 
assay kit, Tris (hydroxymethyl) aminomethane, bis acrylamide and ammonium persulfate (APS) were 
obtained from Sigma-Aldrich (Missouri, USA). Tetramethylethylenediamine (TEMED), salts and 
solvents were purchased from Merck (Darmstadt, Germany). Luminometry assay kits were purchased 
from Promega (Madison, USA) for the determination of intracellular ATP (CellTiter-Glo® 
Luminescent Cell Viability Assay), caspase 1 (Caspase-Glo® 1 Inflammasome Assay) and caspases, 8, 
9, 3/7 (Caspase-Glo® 8, 9, 3/7 Assay). Cytobuster was obtained from Novagen (San Diego, CA, USA), 
with phosphatase (04906837001) and protease (05892791001) inhibitors from Roche (Basel, 
Switzerland) and nitrocellulose membrane from AEC Amersham (Johannesburg, South Africa). The 
IL-1β enzyme-linked immunosorbent assay (ELISA) was purchased from BD Biosciences (San Jose, 
CA, USA). All antibodies were purchased from Cell Signaling Technology (Massachusetts, USA).  
 
Methods 
Cell Culture 
Human embryonic kidney (HEK293) cells were cultured in 25cm3 flasks, in a monolayer (106 cells per 
flask), using DMEM supplemented with 10% foetal calf serum (FCS), 1% Penstrepfungizone and 1% 
L-glutamine. The cells were cultured in a 37°C humidified incubator (5% CO2). Once 80% confluent, 
cells were treated with concentrations of OTA, incubated for 24hr, thereafter removed using trypsin, 
counted, and adjusted for each subsequent assay using the trypan blue exclusion method of cell 
counting. 
 
OTA Treatments 
A 200µM stock solution of OTA was prepared in 60% dimethyl sulphoxide (DMSO). Concentrations 
of OTA treatments were based on an inhibitory concentration of 50% (IC50) - 1.2µM; at 24hr in a 
previous study (Raghubeer et al, 2015). The range of OTA concentrations were conducted as O1: sub-
IC50 (0.5M), O2: IC50 (1.2µM) and O3: supra-IC50 (2M). 
 
Luminometry Assays 
Luminometry assay kits were used for the determination of intracellular ATP, caspases- 1, 3/7, 8 and 9 
as per the manufacturer’s protocol. Briefly, post-treatment 20,000 cells in 0.1M PBS were seeded per 
well in triplicate in an opaque microtitre plate. The respective detection reagents were added to each 
well (20µL), plates were incubated at room temperature (RT) in the dark for 1hr and read on a 
Modulus™ microplate luminometer (Turner Biosystems, Sunnyvale, CA).  
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IL-1β ELISA 
Detection of IL-1β was carried out as per the manufacturer’s instructions. Briefly, 96-well microtitre 
plates were coated with capture antibody diluted in coating buffer and incubated at 4°C overnight. The 
wells were then washed thrice (300µL/well) and residual buffer was removed. Plates were blocked with 
assay diluent (200µL/well) and incubated at RT for 1hr, thereafter assay diluent was removed and plates 
were washed thrice. Standards and samples were added to each well (100µL) and incubated at RT for 
2hr, thereafter plates were washed five times. Detection antibody was added (100µL) and incubated at 
RT for 1hr; the plates were then washed five times. Diluted enzyme reagent (horse-radish peroxidase 
(HRP)-conjugated Streptavidin (Sav-HRP)) was added (100µL), incubated at RT for 30min, then 
removed and washed seven times. Substrate solution was then added (100µL) and incubated at RT for 
30min in the dark. Following this incubation, stop solution was added to each well (50µL) and the plate 
was read using a Bio-Tek µQuant MQx200 spectrophotometer after 30min at 450nm with a reference 
wavelength of 570nm.  
 
Protein Isolation 
Protein was isolated from cells using Cytobuster™ supplemented with protease and phosphatase 
inhibitors. Following treatment, cells were rinsed twice with 0.1M PBS. Cytobuster™ reagent was 
added to cell culture flasks (250µL), and cells were mechanically lysed by scraping. The cell lysate was 
transferred to microcentrifuge tubes and incubated on ice for 10min, then centrifuged (10,000g, 4°C, 
10min). Crude protein (supernatant) was quantified using the Bicinchoninic acid (BCA) assay. Proteins 
were standardised to 1mg/ml and boiled in Laemmli buffer (0.5M Tris-HCl, 1% bromophenol blue, 
glycerol, 10% sodium dodecyl sulphate (SDS), β-mercaptoethanol and dH2O).  
 
Sodium dodecyl sulphate (SDS) - polyacrylamide gel electrophoresis (SDS-PAGE) and western 
blotting 
Prepared protein samples were separated on an SDS polyacrylamide gel (stacking: 4%; resolving: 7.5%) 
at 150V, then transferred onto nitrocellulose membrane using the Trans-Blot® Turbo™ system (Bio-
Rad). Membranes were blocked in 5% BSA in Tween20 Tris-buffered saline (TTBS: 25mM Tris, 
150mM NaCl, 0.05% Tween 20) for 2hr, at RT on a shaker, prior to immune-probing with primary 
antibodies: anti-phosphorylated NFκB p65 Ser536 (3033), anti-total NFκB p65 (8242), anti-
phosphorylated IκB kinase (IKK) Ser176/180 (2697), anti-total IKK (2370), anti-IκBα (4814), anti-
phosphorylated p53 Ser392 (9281), anti-total p53 (6243). Membranes were incubated with primary 
antibodies (1:5000 dilution in 5% BSA) at 4°C overnight. Thereafter membranes were washed with 
TTBS four times each (10min) and probed with HRP-conjugated secondary antibodies in 5% BSA for 
1hr at RT on a shaker. Unbound antibody was removed by washing in TTBS (4 x 10min). Clarity 
western ECL chemiluminescent substrate (400µL) was added to each membrane and images were 
captured using the ChemiDoc™ XRS+ Imaging system (Bio-Rad). Membranes were then quenched 
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using hydrogen peroxide (37C; 30min), blocked for 1hr (5% BSA in TTBS), washed twice using TTBS 
and probed with HRP-conjugated anti-β actin (Sigma-Aldrich). Densitometry analysis was performed 
using Image Lab software (version 5.1), relative band density (RBD) of each target antigen was 
measured and normalised against β-actin measurements for each respective sample. 
 
Statistical Analysis 
All assays were performed as 3 independent experiments with 3 technical replicates each. Statistical 
analysis was performed using GraphPad Prism version 5.0 (GraphPad software, San Diego, CA) and 
employing a one-way analysis of variance (ANOVA) test. Data is expressed as mean ± standard 
deviation with data considered statistically significant at p < 0.05.  
 
Results 
The effect of OTA on inflammatory and cell death pathways in HEK293 cells was evaluated at sub-
IC50 (O1): 0.5µM ; IC50 (O2): 1.2µM and supra-IC50 (O3): 2µM concentrations;  derived from the MTT 
assay reported previously (Raghubeer et al., 2015a).  
 
OTA activates the canonical NFκB pathway 
The protein expression of phosphorylated (p-)NFκB, total NFκB, p-IKK, total IKK, IκBα, p-p53 and 
total p53 was determined using SDS-PAGE and western blotting. A significant increase in p-NFκB was 
observed in treatment O1 (3.1x106 ± 436357 RBD) as compared to the control (1.8x106 ± 216168 RBD) 
(Fig 4.1; p = 0.0006). Both p-IKK (305736 ± 49040 vs 355933 ± 53887 RBD) and total IKK (5.3x106 
± 1.2x106 vs 5.9x106 ± 391511 RBD) were significantly decreased in O3 (Fig 4.2; p = 0.0143, p < 0.05 
respectively) while IκBα (1.4x107 ± 1.3x106 vs 9.7x106 ± 2.9x106 RBD) was significantly increased 
(Fig 4.2; p < 0.05). A significant increase in IκBα (1.6x107 ± 1.1x106 vs 9.7x106 ± 2.9x106 RBD) was 
observed in O2 (Fig 4.2; p = 0.0006), while total IKK (5.6x106 ± 432107 vs 5.9x106 ± 391511) was 
significantly decreased (Fig 4.2; p = 0.0046). Analysis indicates activation of the inflammatory pathway 
in O1, with decreased inflammatory signalling in O2 and O3 compared to O1. 
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Figure 4.1: Densitometric analysis and western blot images showing relative fold change in 
inflammatory protein expression at 24hr exposure to OTA with a significant increase in p-NFκB in O1 
treated HEK293 cells. ***p < 0.001 relative to untreated control.  
 
 
Figure 4.2: Densitometric analysis and western blot images showing relative fold change in 
inflammatory protein expression over 24hr exposure to OTA. Significant increases were observed in 
IκBα in O2 and O3 treated HEK293 cells. Significant decreases were observed in p-IKK and total IKK 
in O3. *p < 0.05; **p < 0.005; ***p < 0.001 relative to untreated control.  
 
OTA significantly increases the phosphorylation of p53 (Ser392) in O1 and O2. 
Figure 4.3 indicates increased expression of p-p53 in O1 (6.4x106 ± 412979 vs 3.8x106 ± 547685) and 
O2 (6.4x106 ± 433139 vs 3.8x106 ± 547685), with a simultaneous increase in total p53 in O1 (7.8x106 
± 324906 vs 5.9x106 ± 597597) and O2 (8x106 ± 508071 vs 5.9x106 ± 597597). 
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Figure 4.3: Densitometric analysis and western blot images showing relative fold change in protein 
expression of tumour suppressor p53. Significant increases were observed in p-p53 (Ser392) in O1 and 
O2, as well as total p53 in O1 and O2. *p < 0.05; **p < 0.005 relative to untreated control.  
 
Decreased IL-1β and Caspase 1 indicate decreased inflammatory signalling in O2. 
Caspase 1 activates IL-1β, which in turn activates NFκB. Significantly decreased IL-1β levels were 
observed in O2 (p = 0.0186) coupled with decreased caspase 1 levels when compared to O1 (p = 
0.0068). The decrease observed in O2 indicates that pro-inflammatory signalling has been dampened.  
 
 
Figure 4.4: Luminometric quantification of caspase 1 and ELISA results for IL-1β measurement 
(pg/ml). IL-1β and caspase 1 was significantly decreased in O2. #p < 0.005 relative to treatment O1; **p 
< 0.05 relative to untreated control cells.  
 
Increased apoptotic activity in O3. 
Caspases 3/7, 8, and 9 were all significantly increased in O3 (p = 0.0002, p = 0.0011 and p = 0.0002 
and respectively) with no changes in O1 and O2 (p > 0.05) (Fig. 4.5). This data indicates increased 
caspase activity in both the extrinsic and intrinsic pathways. 
71 
 
 
Figure 4.5: Luminometric assessment of caspase 3/7, 8 and 9 activity in HEK293 cells. Significantly 
increased caspase 3/7, 8, and 9 activity was observed in O3. **p < 0.05, ***p < 0.001 relative to 
untreated control. 
 
Increased ATP levels in lower OTA concentrations. 
Intracellular ATP levels were significantly increased in O1 and O2 (p < 0.05 and p = 0.0001 
respectively; Fig 4.6). The highest OTA concentration (O3) also elevated ATP levels relative to the 
control but this result was lower than that observed in O1 and O2.   
 
Figure 4.6: Intracellular ATP levels of HEK293 cells following acute exposure to OTA. Intracellular 
levels were significantly increased in O1 and O2 (p < 0.05 and p = 0.0001 respectively). *p < 0.05 and 
***p < 0.001 relative to untreated control.   
 
Discussion 
OTA, a mycotoxin contaminant of grains, animal feed and fruit, is classified as a group 2B carcinogen 
by the International Agency for Research on Cancer (IARC), indicating that the toxin is a possible 
human carcinogen (Koszegi and Poor, 2016). OTA has been implicated in BEN, a chronic kidney 
disease (CKD) resulting in tubulointerstitial nephritis and possible tumour formation (Pfohl-
Leszkowicz and Manderville, 2007). Tubulointerstitial nephritis and CKD results in renal dysfunction 
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with the formation of tumours in some cases (Gagliano et al., 2005). OTA participates in several adverse 
reactions once ingested by animals and humans. The toxin is known to promote pro-oxidant conditions 
- thus inducing oxidative stress, protein synthesis disruptions and DNA damage (Schaaf et al., 2002); 
all of which provide molecular mechanisms to clinical manifestations of OTA toxicity. 
 
Chronic inflammation aggravates kidney disease; however, OTA induced inflammation has not been 
assessed in renal toxicity. The transcription factor, NFκB, controls the transcription of genes associated 
with inflammation and apoptosis, determining the fate of the cell. This study reports, for the first time, 
the influence of OTA on NFκB in kidney cells. Under normal circumstances NFκB is rendered inactive 
in the cytosol by IκBα, however upon stimulation of appropriate extracellular signals IKK is activated 
and subsequently phosphorylates IκBα for ubiquitination (Lawrence, 2009). Once phosphorylated, 
IκBα dissociates from NFκB and is degraded by proteases while NFκB is free to translocate to the 
nucleus (Chaves et al., 2009). Nuclear translocation allows binding to a response element, allowing 
transcription of genes relating to inflammatory responses and even apoptosis. Activators of NFκB 
include ROS and IL-1β (Oeckinghaus and Ghosh, 2009).  
 
The sub-IC50 concentration is highly relevant in determining the toxicity of OTA, as it approximates 
plasma levels (0.5µM) in endemic populations. Our data indicates that the lowest concentration of OTA 
(O1) induced a strong pro-inflammatory response by increasing p-NFκB and IKK, with a concomitant 
decline in IκBα (Fig 4.2). Down-regulation of IκBα promotes NFκB translocation to the nucleus. 
Activation of NFκB induces an inflammatory response with the possible induction or inhibition of 
apoptosis, dependent on the extracellular signals received (Barkett and Gilmore, 1999). An 
inflammatory environment exacerbates the progression of kidney disease as it promotes the 
accumulation of pro-inflammatory cytokines and adhesion molecules, prompting fibrosis of kidney 
epithelia and progressive dysfunction (Silverstein, 2009). No significant apoptosis induction is seen in 
treatments O1 and O2 based on the caspase activity assays (Fig 4.5).  
 
As the concentration of OTA increases (O2), however, a decrease in inflammation is noted possibly 
due to decreased IL-1β and caspase 1 levels (Fig 4.4). Caspase 1 and IL-1β play a significant role in 
inflammation induction. Caspase 1, also known as interleukin-1 converting enzyme (ICE), has been 
found to process pro-IL-1β to the active IL-1β form, which influences NFκB-mediated inflammation 
(Denes et al., 2012). Decreased caspase 1 and IL-1β indicate decreased NFκB activation in O2. We also 
observe increased IκBα and decreased IKK levels (Fig 4.2), suggesting that NFκB is sequestered in the 
cytosol and IκBα is not targeted for degradation. The data indicates a shift from an anti-apoptotic, pro-
inflammatory environment to a pro-apoptotic environment as OTA concentration increases. This is 
evident by the increased activity of caspases 8, 9, 3 and 7 at the highest OTA concentration O3, 
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suggesting that both the extrinsic and intrinsic pathways of apoptosis are being stimulated. Furthermore, 
a significant decrease in IKK levels coupled with increased IκBα was observed (Fig 4.2).  
 
Apoptosis induction by OTA in varying concentrations has been reported in several studies (Essid et 
al., 2012; Petrik, 2005; Ringot et al., 2006; Sorrenti et al., 2013), with accompanying DNA damage in 
some cases (Hibi et al., 2013a; Kuroda et al., 2015). Petrik et al. (2005) proved (using MDCK, LLC-
PK1 and RK 13 cells) that as the concentration of OTA increases, so too does the induction of apoptosis 
(Petrik, 2005). This change in inflammatory environment as a result of increased OTA concentration 
could be attributed to the increased toxic insult to the cells. The adaptive cellular stress response 
preferentially selects apoptosis, over persistent inflammatory activation in response to high 
concentrations of OTA. Apoptosis is a viable means of restoring homeostasis by removing irreversibly 
compromised cells in a highly toxic environment.  
 
NFκB influences apoptosis by promoting the transcription of both pro and anti-apoptotic proteins 
(Kaltschmidt et al., 2000). The tumour suppressor, p53, is a pivotal regulator of cell cycle and apoptosis; 
it reacts to DNA damage or oncogene expression to bring about repair and initiate cell cycle checkpoints 
(Fridman and Lowe, 2003). Protein expression of both phosphorylated and total p53 were significantly 
increased in HEK293 cells in treatments O1 and O2 (Fig 4.3). Phosphorylation of p53 is an important 
posttranslational modification to regulate the tumour suppressor function (Matsumoto et al., 2004). 
Phosphorylation of p53 at serine residue 392 is reportedly increased in tumours; which correlates with 
the theory of eventual tumorigenesis as a result of persistent inflammation  (Ullrich et al., 1993). Kuroda 
et al. (2015) reported that p53 was activated in response to DNA damage by OTA (Kuroda et al., 2015). 
This information suggests that OTA causes DNA damage and induces an appropriate repair response. 
Our previous study also showed increased DNA damage, evidenced by increased comet tail lengths in 
HEK293 cells induced by OTA, as well as increased transcription of OGG1 (a DNA repair enzyme) 
(Raghubeer et al., 2015a). The present results indicate that OTA-induced DNA damage could eventually 
result in mutations, providing a purpose for phosphorylation of p53 at Ser392.    
 
Apoptosis is an energy consuming biological process. The ATP levels correlate with caspase activity, 
as its levels increased in O1 and O2, but not in O3, indicating that the process of apoptosis depletes 
ATP (Fig 4.6). Schwerdt et al. (2003) reported a similar increase in ATP levels upon acute exposure to 
OTA in kidney cells (Schwerdt et al., 2003). This research provides an alternative mechanism of OTA 
toxicity centred on the mycotoxin’s ability to induce inflammation via the canonical NFκB pathway. 
Endemic populations display up to a thousand times higher OTA plasma levels than healthy 
populations. Koszegi et al. (2016) reported that OTA plasma levels could reach hundreds of nmol/L in 
endemic populations , thus O1 provides a plausible model for kidney toxicity as the kidney accumulates 
OTA during nephron reabsorption (Koszegi and Poor, 2016).  
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We propose that OTA’s effect on the inflammatory pathway could be an influencing factor in the 
progression of kidney disease. Persistent inflammation could play a role in epithelial-mesenchymal 
transition and eventual tumorigenesis as a result of uncontrolled cell proliferation (Kalluri and Neilson, 
2003). Further research with chronic exposure is warranted, as well as to ascertain the extent of OTA’s 
influence on the inflammatory and proliferative pathways. This research could serve as a foundation for 
investigation into the inflammatory effects of OTA using an in vivo model, such as rats or mice. This 
could provide important answers to OTA’s mechanism of toxicity and involvement in the propagation 
of renal tumours.  
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Abstract 
Protein misfolding and aggregation caused by cellular stress activates the endoplasmic reticulum (ER)-
mediated unfolded protein response (UPR). The mycotoxin Ochratoxin A (OTA), a food contaminant, 
has been reported to disrupt redox status and protein homeostasis. We evaluated the effect of various 
OTA concentrations (0.5µM – 0.125µM) on ER stress and UPR markers in HEK293 and HepG2 cells 
over 24hr and 48hr. We employed western blotting, luminometry, qPCR and protein carbonyl 
quantification. OTA increased protein carbonyl concentrations in kidney (HEK293) cells, and 
simultaneously increased protein expression of LonP1, HSP70, PERK and p-eIF2α (p < 0.05) in both 
kidney and liver (HepG2) cells over both 24hr and 48hr time periods. Further, OTA increased gene 
expression of ATF4 (p < 0.05), with decreased CHOP expression and caspase 3/7 activity in both cell 
lines. Thus, OTA toxicity induces ER stress response in cell survival, and could provide new insights 
into the mechanisms of OTA toxicity in human kidney and liver cells.  
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Introduction 
Mycotoxins are secondary metabolites of fungal origin and are commonly found in human food 
products and animal feed - ensuring its presence in the food chain. Ochratoxin A (OTA) is a mycotoxin 
produced by species of Aspergillus and Penicillium fungi (Cabañes et al., 2010), and is a frequent 
contaminant of coffee, alcoholic beverages, animal products (pork), spices and fruit (Ostry et al., 2013). 
OTA-associated renal toxicity is well established, with secondary effects observed in the liver and 
immune system (Malir et al., 2016). Oxidative stress, DNA adducts, and protein damage all present 
molecular effects of OTA which manifest as clinical outcomes, such as tumour induction, renal failure, 
and immune dysfunction (Boesch-Saadatmandi et al., 2008; Mally, 2012). OTA has been suspected as 
an aetiological agent in nephropathies around the world, diseases associated with progressive kidney 
dysfunction, destruction of the renal tubular epithelium and possible tumour formation (Castegnaro et 
al., 2006; Wafa et al., 1998). Selective reabsorption of OTA exacerbates kidney toxicity, increasing the 
presence and effects of an already persistent toxin – the half-life in humans has been recorded at 35 
days (Reddy and Bhoola, 2010). 
 
Ochratoxin A has been reported to increase oxidative stress and induce DNA damage in both the kidney 
and liver (Gayathri et al., 2015; Pfohl-Leszkowicz and Manderville, 2007). Considering that oxidative 
stress leads to oxidative protein modifications, and OTA binds to plasma proteins; the protein 
maintenance network mediated by the ER may provide novel insight into OTA toxicity as knowledge 
of its effects on endoplasmic reticulum (ER) stress is limited. The ER is responsible for the cellular 
response to protein misfolding – a result of disruptions in protein homeostasis (Chaudhari et al., 2014). 
Under normal conditions protein aggregates are proteolytically cleared, however, an accumulation of 
misfolded proteins activates the unfolded protein response (UPR) via the ER stress pathway. The UPR 
aims to restore protein homeostasis by degrading damaged proteins, inhibiting further translation, and 
upregulating chaperone proteins to assist with protein folding efforts. Should this response fail, the UPR 
directs the cell towards apoptosis (Araki and Nagata, 2011).  
 
The protein kinase RNA-like endoplasmic reticulum kinase (PERK), eukaryotic initiation factor 2 alpha 
(eiF2α) and activating transcription factor 4 (ATF4) axis of the UPR was investigated in both HEK293 
and HepG2 cells. During ER stress the PERK-eIF2α pathway is activated immediately (Fribley et al., 
2009); activated PERK phosphorylates the alpha subunit of eIF2α at serine residue 51, thus inhibiting 
eIF2α and reducing global protein synthesis, to assist in reducing overall protein load (Fribley et al., 
2009). Selected proteins such as the transcription factor ATF4 are translated during this time; ATF4 
regulates expression of genes pertaining to amino acid metabolism, redox homeostasis and the ER stress 
response (Ye et al., 2010). Research shows that ATF4 is overexpressed in some human tumours, and 
could possibly allow tumour cell survival and cancer progression (Ye et al., 2010). ATF4 is a member 
of the cAMP response element binding (cREB) family and is central in regulating genes involved with 
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cell survival; it can upregulate the expression of CHOP, a pro-apoptotic factor in times of persistent ER 
stress. Overexpression of CHOP promotes apoptosis (Rozpędek et al., 2016).  
 
Recent research confirmed that OTA induced ER stress in mouse and rat mesangial cells (Sheu et al., 
2016). A previous study by our own research group  showed the induction of oxidative stress and 
activation of Lon protease (LonP1) by OTA at IC50 concentrations in human kidney cells (Raghubeer 
et al., 2015). These findings prompted an investigation into the effects of OTA on protein and ER stress 
responses in both human kidney and liver cells. Our study used a range of OTA concentrations based 
on upper levels (serum/urine) recorded in high OTA exposure regions (Jonsyn-Ellis, 2001; Wafa et al., 
1998). We also investigated protein oxidation, LonP1 expression, and executioner caspase activity. It 
is hoped that the data can be used to better understand the stress responses induced by OTA in humans 
and possibly lead to future therapeutic interventions.    
 
Materials 
Vendor authenticated human embryonic kidney (HEK293) and liver hepatocellular carcinoma (HepG2) 
cells were purchased from Highveld Biologicals (Johannesburg, South Africa). Dulbeccos’ minimum 
essential media (DMEM), Eagle’s minimum essential media (EMEM)), HEPES buffer and trypsin was 
purchased from Lonza (Basel, Switzerland). OTA (O1877) was sourced from Sigma-Aldrich (Missouri, 
USA). Luminometry activity kits were purchased from Promega (Madison, USA). All solvents and salts 
were purchased from Merck (Darmstadt, Germany) unless otherwise stated. 
  
Methods 
Cell Culture 
Human embryonic kidney (HEK293) cells and liver hepatocellular carcinoma (HepG2) cells were 
cultured in 25cm3 flasks, in monolayer (106 cells per flask), using DMEM and EMEM respectively 
(both supplemented with 10% foetal calf serum (FCS), 1% Penstrepfungizone, HEPES buffer and 1% 
L-glutamine). The cells were cultured in a 37°C humidified incubator (5% CO2). At 80% confluence, 
cells were treated with varying concentrations of OTA (0.125µM – 0.5µM) for 24hr and 48hr. 
Following treatment, cells were detached by incubation with trypsin (5min; 37C), counted (Invitrogen 
Countess™ automated cell counter), and adjusted for each subsequent assay. 
 
Ochratoxin A Treatments 
A 5mM stock solution of OTA was prepared in 60% dimethyl sulphoxide (DMSO). Concentrations 
used for treatment were based on high levels recorded in serum and urine (Jonsyn-Ellis, 2001; Wafa et 
al., 1998). The OTA range was delivered in increasing concentrations – OTA0.125: 0.125M, OTA0.25: 
0.25µM and OTA0.5: 0.5M. 
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Methylthiazol Tetrazolium (MTT) Assay 
Cells were seeded into a microtitre plate (15 000 cells/well) and attached overnight. Thereafter, cells 
were exposed to OTA (0.25µM – 50µM) over 24hr and 48hr. Culture media was removed and replaced 
with 20 µL MTT solution (5mg/ml in PBS) and CCM (100µL). After a 4hr incubation, the solution was 
removed and DMSO was added (100µL, 1hr incubation). A Bio-Tek MQx200 spectrophotometer was 
used to read absorbance at 595nm (reference wavelength 655nm). The 50% inhibitory concentration 
(IC50) was calculated.   
 
Luminometric assessment of Caspase activity 
The Caspase-Glo® 3/7 (G8098) and 6 (G0970) assay systems were used to assess caspase activity in 
HEK293 and HepG2 cells as per the manufacturer’s protocol. Briefly, 20, 000 cells (in 0.1M PBS) were 
seeded per well (triplicate) in an opaque microtitre plate. The respective detection reagents were added 
to each well (20µL) and plates were incubated at room temperature (RT) in the dark for 1hr and read 
on a Modulus™ microplate luminometer (Turner Biosystems, Sunnyvale, CA). Results were reported 
as relative light units (RLU), directly proportional to caspase activity. 
 
ER stress protein expression  
Protein isolation 
Protein was isolated from HEK293 and HepG2 cells using Cytobuster™ (Novagen (San Diego, USA)), 
with supplementary phosphatase (004906837001) and protease (05892791001) inhibitors as previously 
described (Sheik Abdul et al., 2016). Crude protein was quantified using the Bicinchoninic acid (BCA) 
assay, thereafter proteins were standardised to 1mg/ml and boiled (5min) in Laemmli buffer (0.5M Tris-
HCl, 1% bromophenol blue, glycerol, 10% sodium dodecyl sulphate (SDS), β-mercaptoethanol and 
dH2O).  
 
Sodium dodecyl sulphate (SDS) – polyacrylamide gel electrophoresis (SDS-PAGE) and western 
blotting 
Protein samples were separated on SDS polyacrylamide gel (stacking: 4%; resolving: 7.5%) at 150V 
(1hr) and subsequently electro-transferred to nitrocellulose membranes using a pre-programmed mixed 
MW protocol on the Trans-Blot® Turbo™ system (Bio-Rad). All membranes were blocked in 5% BSA 
in Tween20 Tris-buffered saline (TTBS: 25mM Tris, 150mM NaCl, 0.05% Tween 20) for 2hr, at RT 
on a shaker, prior to immune-probing with primary antibodies (1:1000) at 4°C overnight – anti-PERK 
(C33E10), anti-p-eIF2α (119A11) from Cell Signaling Technology (Massachusetts, USA), anti-LonP1 
(HPA002192) from Sigma-Aldrich (Missouri, USA) with anti-HSP70 (610607) and anti-HSP90 
(610418) antibodies from BD Biosciences (San Jose, CA, USA). Membranes were washed (TTBS, 4 x 
10min) and probed with horse-radish peroxidase (HRP)-conjugated anti-mouse (7076S) or HRP-
conjugated anti-rabbit (7074P2) secondary antibodies in 5% BSA (1hr, RT). Membranes were washed 
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(4 x 10min). Clarity™ Western ECL chemiluminescent substrate (Bio-Rad) was added to each 
membrane and images were captured using the ChemiDoc™ XRS+ Imaging system (Bio-Rad). 
Membranes were quenched using hydrogen peroxide (37C; 30min), blocked for 1hr (5% BSA in 
TTBS), washed twice, and probed with HRP-conjugated anti-β actin (Sigma-Aldrich). Densitometry 
analysis was performed using Image Lab software (version 5.1) and was quantified as relative band 
intensity (RBI) converted to fold change. All results were normalized against β-actin prior to statistical 
analysis. 
 
Messenger RNA (mRNA) quantification of ER stress regulators 
RNA Isolation and cDNA Synthesis 
RNA was isolated using an in-house protocol (Pillay et al., 2015) with QIAzol extraction reagent from 
Qiagen (Hilden, Germany). Once isolated, RNA was quantified using the NanoDrop2000 
spectrophotometer (Thermo Fisher Scientific, Massachusetts, USA) and standardised to 1000ng/µL. 
Standardised RNA was used to synthesise cDNA using iScript cDNA synthesis kit (Bio-Rad, Hercules, 
California, USA) as per the manufacturer’s protocol. Thermocycler conditions were 25°C(5min), 42°C 
(30min), 85°C (5min) and a final hold of 4°C.  
 
Quantitative Polymerase Chain Reaction (qPCR) 
Transcript levels of ATF4 (sense: 5’-GTTCTCCAGCGACAAGGCTA-3’, antisense: 5’-
ATCCTCCTTGCTGTTGTTGG-3’) and CHOP (sense: 5’-GGAAACAGAGTGGTCATTCCC-3’, 
antisense: 5’-CTGCTTGAGCCGTTCATTCTC-3’) was evaluated by qPCR. Primer sequences were 
obtained from Inqaba Biotechnical Industries (Pretoria, South Africa). A reaction mix of 5.5µL 
SsoAdvanced™ Universal SYBR® Green Supermix (Bio-Rad), 1µL cDNA, 1µL sense and antisense 
primers, and nuclease free H2O was made up to 10µL. The assays were carried out using 6 replicates 
per treatment with glyceraldehyde 3-phosphate dehydrogenase; GAPDH (sense: 5’-
TCCACCACCCTGTTGCTGTA-3’, antisense: 5’-ACCACAGTCCATGCCATCAC-3’) and β-actin 
(sense: 5’-TGACGGGTCACCCACACTGTGCCCAT-3’, antisense: 5’-
CTAGAAGCATTTGCGGTGGACGATGGAGGG-3’) as housekeeping genes. Reactions were 
carried out on the CFX Touch™ Real Time PCR detection system (Bio-Rad) as follows: Initial 
denaturation at 95°C (4min), followed by 37 cycles of denaturation (95°C, 15s), annealing (40sec; 
CHOP - 55°C, ATF4 - 65°C) and extension (72°C, 30sec). Analysis was performed as per the method 
described by Livak and Schmittgen, where 2-∆∆Ct represents the fold change relative to the 
housekeeping gene (Livak and Schmittgen, 2001).  
 
Protein Carbonyl Assay 
Protein was isolated from treated cells and standardised to 5mg/ml for protein carbonyl quantification. 
Dinitrophenylhydrazine (DNPH – 10mM in 2.5M hydrochloric acid) was added to each sample and 
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incubated (1hr, RT). Samples were then incubated on ice with 20% trichloroacetic acid (TCA) solution, 
protein precipitates were collected and washed with 10% TCA solution. Pellets were washed with 
ethanol-ethyl acetate (2 washes) and dissolved in guanidine hydrochloride (6M) during incubation 
(37°C, dark, 10min). The supernatant was collected, aliquoted into a 96-well microtiter plate (triplicate) 
and absorbance was measured using a Bio-Tek MQx200 spectrophotometer at 370nm. Optical density 
measurements were used to calculate protein carbonyl concentrations in each sample. 
 
Statistical Analysis 
Analysis was performed using GraphPad Prism version 5.0 (GraphPad software, San Diego, CA) and 
employing one-way analysis of variance (ANOVA) tests. Data is expressed as mean ± standard 
deviation with statistical significance considered at p < 0.05.  
 
Results 
Previously we showed that OTA induced oxidative stress and increased LonP1 expression at an IC50 
value in HEK293 cells (Raghubeer et al., 2015). In the present study we used a range of OTA 
concentrations (0.125M – 0.5M) to determine the effects on protein stress, ER stress and cell death 
in HEK293 and HepG2 cells. An increase in oxidative protein damage was observed, with the canonical 
PERK-eIF2α-ATF4 pathway being activated.   
 
HepG2 cytotoxicity test using MTT assay 
Acute exposure of HepG2 cells to OTA showed resistance to cell death induction by the toxin, 
producing an IC50 value of 47µM. However, at 48hr the cells responded similarly to previous 
cytotoxicity tests using HEK293 cells (Raghubeer et al., 2015), indicating an IC50 of 9µM.  
 
Figure 5.1: Cellular viability (%) post-exposure to a range of OTA concentrations over 24hr and 48hr. 
An IC50 of 47µM (24hr) and 9µM (48hr) was calculated from the dose-response curves. 
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LonP1 and HSP70 protein expressions were increased post-exposure to a range of OTA 
concentrations over 24hr and 48hr in HEK293 and HepG2 cells.  
The lowest concentration of OTA (OTA0.125 – 0.125µM) induced the highest LonP1 expression 
(0.34±0.082RBI vs control 0.013±0.005RBI; p = 0.0002), and increased HSP70 protein expression 
(2.028±0.4RBI vs control 0.82±0.07RBI, p = 0.0002) in HEK293 cells at 24hr (Fig 5.2). Although not 
as significant as OTA0.125, the higher doses of OTA also significantly increased LonP1 expression (9.5- 
and 8.3-fold respectively, 24hr). These observations differ with the 48hr results: OTA0.5 (0.5µM) 
significantly increased expression of LonP1 (0.42±0.02RBI vs control 0.26±0.02RBI; p < 0.005), while 
increases in HSP70 are observed in OTA0.25 (1.057±0.04RBI; p = 0.001) and OTA0.125 (1±0.18RBI; p 
< 0.05) compared to controls (0.67±0.005RBI) (Fig 5.2). In HepG2 cells exposed to OTA for 24hr we 
observed increased LonP1 protein levels at all concentrations with the most significant increase in 
OTA0.5 (0.64±0.1RBI vs control 0.12±0.04RBI; p = 0.0002) (Fig 5.3). At 48hr the lowest OTA 
concentration exhibited increased LonP1 (0.57±0.12RBI vs control 0.19±0.08RBI; p = 0.0003) in 
HepG2 cells (Fig 5.3).  
 
Figure 5.2: Densitometric analysis and western blot images showing relative fold change in LonP1 and 
HSP70 in HEK293 cells over 24hr and 48hr exposure to OTA – OTA0.125 (0.125µM), OTA0.25 (0.25µM) 
and OTA0.5 (0.5µM). *p < 0.05, **p < 0.005 and ***p < 0.0005 relative to untreated control.  
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Figure 5.3: Densitometric analysis and western blot images showing relative fold change in LonP1 and 
HSP70 in HepG2 cells over 24hr and 48hr exposure to OTA – OTA0.125 (0.125µM), OTA0.25 (0.25µM) 
and OTA0.5 (0.5µM). *p < 0.05 and ***p < 0.0005 relative to controls. 
 
Lower concentrations of OTA induce protein oxidation in HEK293. 
OTA significantly increased protein oxidation in OTA0.25 compared to OTA0.5 (1.5-fold, p < 0.0005) in 
HEK293 cells; whereas protein oxidation in OTA0.125 was significantly greater than both the control 
and OTA0.5 (1.2-fold, p < 0.05, Fig 5.4).  
 
48hr exposure to OTA induces a robust effect on protein oxidation in HepG2 cells. 
The opposite was true for HepG2 cells exposed to OTA0.125 over 24hr. OTA0.125 exhibits significantly 
lower protein carbonyl production than both OTA0.5 and OTA0.25, while OTA0.25 is significantly higher 
than both treatments and controls (p < 0.05, Fig 5.4). At 48hr, the lowest OTA concentration induces a 
greater increase in protein carbonyl formation. Both OTA0.25 and OTA0.125 show significantly greater 
protein oxidation than OTA0.5 (p < 0.05, Fig 5.4). Further to LonP1 expression and protein damage, we 
then evaluated the effects of OTA on ER stress.  
 
 
Figure 5.4: Analysis of protein carbonyl concentrations during exposure to a range of OTA in HEK293 
and HepG2 cells over 24hr and 48hr. *p < 0.05 and ***p < 0.0005 relative to respective controls. 
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OTA activates the ER stress pathway over 24hr and 48hr in HEK293 cells. 
OTA0.5 significantly increased the expression of PERK over 24hr (0.4±0.08RBI vs control 
0.25±0.03RBI, p = 0.013), with no change in eIF2α phosphorylation, however OTA0.125 significantly 
increased p-eIF2α (0.78±0.09RBI vs control 0.57±0.13RBI, p = 0.0002) (Fig 5.5). At 48hr OTA0.5 
increased both PERK (0.89±0.04RBI vs control 0.41±0.03RBI, p = 0.0005) and p-eIF2α (1.58±0.06RBI 
vs control 1.17±0.05RBI, p = 0.0001) significantly. OTA0.25 increased expression of p-eIF2α 
(1.49±0.07RBI), while OTA0.125 increased PERK expression (0.75±0.15RBI) at 48hr (Fig 5.5). Overall, 
this data indicates activation of the ER stress response across a range of OTA concentrations.  
 
Figure 5.5: Densitometric analysis and western blot images showing relative fold change in PERK and 
p-eIF2α following 24hr and 48hr exposure of HEK293 cells to a range of OTA concentrations. *p < 
0.05, **p < 0.005 and ***p < 0.0005 relative to respective controls.  
 
PERK expression increases during acute, but not prolonged exposure to OTA; p-eIF2α expression 
increases during prolonged, but not acute exposure to OTA concentrations in HepG2 cells.  
PERK and p-eIF2α display an inverse relationship in expression profiles over 24hr and 48hr exposure 
to OTA in HepG2 cells. At 24hr PERK protein expression is markedly increased at OTA0.5 
(0.1±0.01RBI, p = 0.0005), OTA0.25 (0.08±0.03RBI) and OTA0.125 (0.13±0.09RBI) compared to 
controls (0.04±0.0007RBI), with increased p-eIF2α only evident at OTA0.5 (1.35±0.3RBI vs control 
0.93±0.33RBI, p = 0.04) (Fig 5.6). At 48hr OTA0.25 (0.44±0.12RBI) and OTA0.125 (0.4±0.09RBI) 
significantly decreased PERK expression when compared to OTA0.5 (0.66±0.14RBI), while significant 
increases in p-eIF2α was observed during OTA0.5 (1.06±0.17RBI, p = 0.0002), OTA0.25 (0.81±0.23RBI) 
and OTA0.125 (0.64±0.21RBI) exposure, compared to controls (0.41±0.02RBI).  
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Figure 5.6: Densitometric analysis and western blot images showing relative fold change in PERK and 
p-eIF2α following HepG2 cell exposure to a range of OTA concentrations over 24hr and 48hr. *p < 
0.05, **p < 0.005 and ***p < 0.0005 relative to controls.  
 
The ATF4 axis is stimulated at prolonged and not acute exposure to OTA in HEK293 cells. 
Increases in p-eIF2α correlate with ATF4 increases observed during 48hr exposure to OTA. OTA0.25 
significantly decreased mRNA levels of ATF4 and CHOP at 24hr (p < 0.0005), whilst OTA0.125 
significantly decreased ATF4 expression only (p < 0.0005) in HEK293 cells (Fig 5.7). ATF4 expression 
was significantly increased by OTA0.5 (3-fold, p < 0.0005), non-significantly by OTA0.25 (1.4-fold) and 
OTA0.125 (2.6-fold, Fig 5.7). A decrease in CHOP expression suggests the promotion of cell survival. 
 
Figure 5.7: mRNA analysis of ATF4 and CHOP in HEK293 cells after treatment with a range of OTA 
concentrations over 24hr and 48hr. **p < 0.005 and ***p < 0.0005 relative to control. 
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OTA decreased the activity of Caspases 3/7 and 6 during both 24hr and 48hr exposure in HEK293 
cells. 
OTA0.125 significantly decreased caspase 3/7 activity in HEK293 cells over 24hr (p < 0.005; Table 1), 
however after 48hr OTA0.5 also significantly decreased caspase 3/7 and 6 activities (p < 0.05 and p < 
0.005 respectively; Table 1). In addition, OTA0.125 significantly decreased caspase 3/7 activity at 48hr 
(p < 0.05).  
 
Table 1: Caspase 3/7 and 6 activities assessed by luminometry in HEK293 cells over 24hr and 48hr 
post OTA exposure. 
24hr HEK293 Caspase 3/7 Caspase 6 
Control 100089±22656 230788±20509 
O0,125 72944±5495** 195533±9598 
O0,25 104016±1447 240231±25981 
O0,5 96429±3588 218417±15058 
48hr HEK293 
  
Control 274809±52901 333573±12434 
O0,125 192683±38448* 293875±37132 
O0,25 211130±8147 331035±15422 
O0,5 201828±16593 * 247386±16070** 
 
 
ATF4 gene expression was increased by the highest OTA concentration at both 24hr and 48hr in 
HepG2 cells. 
OTA0.5 induced a significant increase in ATF4 gene expression at both 24hr (3.9-fold, p < 0.05, Fig 5.8) 
and 48hr (2.6-fold, p < 0.0005), whilst OTA0.125 significantly decreased ATF4 expression at 24hr (p < 
0.05) and significantly increased its expression at 48hr (p < 0.05). CHOP expression was significantly 
decreased by OTA0.25 (p < 0.005) and OTA0.125 (p < 0.0005) exposure over 24hr (Fig 5.8). These results 
indicate ATF4-induced cell survival. 
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Figure 5.8: Analysis of ATF4 and CHOP mRNA levels in HepG2 cells following treatment with a 
range of OTA concentration over 24hr and 48hr. *p < 0.05 and **p < 0.005 and ***p < 0.0005 relative 
to untreated controls.  
 
Executioner caspases were not significantly affected across OTA treatments during 48hr exposure 
of HepG2 cells.  
Caspase 6 activity was significantly increased by OTA0.5 exposure at 24hr. All other treatments did not 
significantly increase activity of executioner caspases.  
 
Table 2: Quantification of caspase 3/7 and 6 activity in OTA treated HepG2 cells at 24hr and 48hr. 
24hr HepG2 Caspase 3/7 Caspase 6 
Control 72992±1975 83294±3504 
O0,125 61874±8953 72454±3272 
O0,25 70711±8294 103603±5990 
O0,5 123340±6642 123255±12401* 
48hr HepG2 
  
Control 90066±21323 129587±16861 
O0,125 86861±7270 141528±6195 
O0,25 112046±14333 151011±33071 
O0,5 70031±3009 123372±11254 
      *p < 0.05 comparable to controls 
 
Discussion 
Ochratoxin A is a frequent contaminant of foods consumed by humans. OTA is one of the most 
persistent mycotoxins in humans, with a half-life of 35 days and plasma detectability up to 280 days 
91 
 
(Petzinger and Ziegler, 2000), up to 99% of the ingested toxin binds to plasma proteins (Hagelberg et 
al., 1989). While OTA is best known as a renal toxicant; however, it can also participate in enterohepatic 
circulation, increasing interaction with hepatocytes and contributing to hepatotoxicity (Roth et al., 
1988). Current literature shows induction of ER stress in rat and mouse mesangial cells (Sheu et al., 
2016) and in the kidney and spleen of pigs (Gan et al., 2017). This mode of toxicity has yet to be 
investigated in human stress responses. Using both renal (HEK293) and hepatic (HepG2) in vitro 
models, we investigated the effects of OTA toxicity related to protein damage and ER stress. 
 
Exogenous stress inducers, such as toxins or drugs, often alter protein homeostasis and disrupt the 
proper folding and transportation of proteins, resulting in protein aggregation and occlusions 
(Oyadomari and Mori, 2003). LonP1 is a protease that regulates mitochondrial quality control by 
degrading damaged proteins and maintaining mitochondrial DNA turnover (Quiros et al., 2014). LonP1 
is a pro-survival response initiated by ER stress and hypoxia, however, it has also been linked to tumour 
promotion when overexpressed (Quiros et al., 2014). Heat shock protein (HSP) 70 interacts with LonP1 
as a chaperone protein (Kao et al., 2015) and assists in the folding of misfolded proteins, thereby 
promoting cell survival (Bukau and Horwich, 1998). Together with HSP60, LonP1 and HSP70 provide 
a mitochondrial response to ER stress.  
 
LonP1 expression was increased at 24hr in human kidney cells (Fig 2), with the most significant 
increase occurring at the lowest OTA concentration (OTA0.125). However, expression of LonP1 was 
markedly reduced after 48hr, suggesting that OTA induced acute stress to mitochondria (Fig 2). In 
cancerous liver cells, all OTA concentrations increased expression of LonP1 over 24hr, with an increase 
observed at 48hr by the lowest concentration (OTA0.125; Fig 3). The transient increase in LonP1 
expression at 24hr in kidney and liver cells suggests the induction of cellular repair responses. 
Differences in expression over 48hr could be attributed to the HepG2 cancer cell as opposed to the 
normal HEK293 cells. Normal kidney cells might respond to the repair processes more effectively than 
cancerous liver cells. The HepG2 MTT assay also demonstrated that the liver cells were more resistant 
to OTA-induced cell death; kidney cells proved far more sensitive to OTA toxic effects. For the first 
time, we report on OTA-induced protein carbonylation in HEK293 cells, with increased concentrations 
of protein carbonyls at the lower concentrations of OTA over 24hr and 48hr (Fig 4). HEK293 cells 
appeared more sensitive to protein oxidation than HepG2 cells. The data shows that low OTA 
concentrations generate higher protein carbonyl concentrations. 
 
During toxic insult or intracellular disruptions, proteins destabilise and revert to non-native forms, these 
proteins become misfolded and aggregate in the ER, which then activates the ER stress response and 
the UPR (Bravo et al., 2013). The UPR attempts to restore homeostasis by preventing further 
accumulation of dysfunctional proteins in the ER lumen. It does this by altering protein synthesis, 
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increasing protein folding capacity and degrading misfolded proteins that cannot be repaired (Fribley 
et al., 2009). PERK protein expression levels were increased only during OTA0.5 exposure at 24hr, and 
during OTA0.5 and OTA0.125 exposure at 48hr in HEK293 cells (Fig 5). In addition, increased 
phosphorylation of eIF2α was observed, this strongly suggests attenuation of protein synthesis due to 
misfolded protein accumulation. In liver cells, a similar pattern of protein synthesis inhibition was 
observed (Fig 6). PERK protein expression increased at 24hr, but decreased at 48hr, however, eIF2α 
activation increased significantly suggesting that greater levels of PERK had been activated to 
phosphorylate eIF2α.  
 
Phosphorylation of eIF2α would inhibit global protein synthesis and favour ATF4 upregulation. 
Prolonged exposure of kidney cells to OTA increased transcription of ATF4 (Fig 7), which correlated 
with increased p-eIF2α over 48hr in kidney cells. All 3 concentrations of OTA decreased CHOP gene 
expression in HEK293 cells during acute and prolonged exposure, implying promotion of cell survival. 
Contrary to results observed in kidney cells, we see increased ATF4 expression in liver cells exposed 
to OTA0.5 (24hr and 48hr, Fig 8). Increased ATF4 expression correlates with observed increases in 
PERK and p-eIF2α. Furthermore, expression of CHOP is decreased in HepG2 cells (24hr), while we 
observe a slight increase at OTA0.25 (48hr, Fig 8). All OTA concentrations decreased caspase 3/7 activity 
in kidney cells, indicating the stimulation of cell survival efforts (Table 1). In liver cells we observed 
no change in caspase 3/7 expression (Table 2).  
 
Overall, this data indicates that OTA can induce toxicity by inducing ER stress, modulating UPR 
pathways, and preventing apoptosis. Feng (2014) shows that the PERK-eIF2α-ATF4 pathway is 
activated during epithelial-mesenchymal transition (EMT) and this pathway promotes cancer 
progression (Feng et al., 2014). The research indicates that the PERK pathway could promote malignant 
behaviour and allow for cell survival (Feng et al., 2014). It is known that OTA induces inflammation 
(González-Arias et al., 2015; Raghubeer et al., 2017); this suggests that OTA could increase 
inflammation and ER stress, while promoting EMT and tumourigenesis. Our research corresponds with 
this theory as ER stress and protein damage was observed, without apoptosis induction. 
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Abstract 
Cellular adaptation to hypoxia is controlled by hypoxia-inducible factor 1α (HIF1α); a transcription 
factor activated in response to oxygen tension, reactive oxygen species (ROS) and inflammation. 
Overexpression of HIF1α and HSP90 has been associated with cancer induction. Ochratoxin A (OTA), 
a mycotoxin often contaminating food and beverages, has been linked to renal tumours and progressive 
nephropathies, and displays inflammatory and pro-oxidant effects. The aim of our study was to 
determine the effects of OTA on hypoxic stress response proteins and the resulting metabolic 
alterations. We evaluated the protein expression of phosphorylated (p)NFκB, pNrf2, HIF1α, HSP90 
and PDK1 (western blotting), gene expression of HIF1α, VEGF and TGFβ (qPCR), and ATP production 
(luminometry) in HEK293 and HepG2 cells exposed to a range of OTA concentrations (0.125µM-
0.5µM) at 24hr and 48hr. Acute (24hr) OTA exposure decreased pNrf2 expression in both HEK293 and 
HepG2 cells, with increased inflammatory proteins in HEK293 cells (48hr) and HepG2 cells (24hr) (p 
< 0.05). OTA-induced hypoxia (HIF1α protein) was recorded at 24hr in kidney and liver cells (p < 
0.005). VEGF and TGFβ was significantly increased in kidney cells at 48hr, while only TGFβ was 
increased in HepG2 cells at 48hr. We also observed alterations in PDK1 expression, which correlates 
with ATP presence. We conclude that OTA induces acute hypoxia and modulates growth signalling 
(VEGF, TGFβ), which may lead to tumourigenesis.  
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Introduction 
Ochratoxin A (OTA) is a mycotoxin produced by various species of Penicillium and Aspergillus fungi 
(Pfohl-Leszkowicz and Manderville, 2007). It contaminates foods frequently ingested by humans 
(grains, fruit, wine, coffee), as well as animal feed – thereby contaminating animal products (Malir et 
al., 2016). A known renal toxicant, OTA has been linked to nephropathies around the world (Castegnaro 
et al., 2006; Abid et al., 2003). These diseases present as renal dysfunction often progressing into renal 
failure, and may lead to tumour initiation (Castegnaro et al., 2006). Toxic effects of OTA on the liver 
and immune system have previously been reported to a lesser extent as that observed in the kidney 
(Darif et al., 2016; Gayathri et al., 2015). Research has shown the oxidative stress induction following 
OTA exposure (Arbillaga et al., 2007; El Golli Bennour et al., 2009), as well as inflammation 
(Bernardini et al., 2014). The effects of OTA on hypoxic response, however, have not been elucidated 
in human cells. Considering the redox imbalance and inflammatory environment induced by OTA, 
understanding the biochemical response to hypoxia would provide important information on OTA 
toxicity and its possible role in tumourigenesis.  
 
The tumour microenvironment contains areas of hypoxia, low pH levels, and nutrient deprivation 
(Vaupel, 2004). Hypoxia is characteristic of cancer cells, O2 deficiency provides a highly mutagenic 
environment and allows for genetic instability (Yuan and Glazer, 1998). Cellular hypoxic response is 
regulated by hypoxia inducing factor 1 (HIF1α) – a heterodimer consisting of two subunits, HIF1α and 
HIF1β (Wang et al., 1995a). The cytoplasmic HIF1α is dependent on cellular oxygen (O2) tension, while 
nuclear HIF1β is O2 independent (Semenza, 2001a). In well-oxygenated cells O2-dependent enzymes 
hydroxylate prolyl residues on HIF1α, allowing the binding of von Hippel-Lindau protein (pVHL), 
inducing proteasomal degradation of HIF1α (Vaupel, 2004). In hypoxic cells HIF1α accumulates and 
translocates to the nucleus, where it binds with HIF1β to transcribe genes relating to the hypoxic 
response, such as erythropoietin (EPO), vascular endothelial growth factor (VEGF) and glycolytic 
enzymes (Vaupel, 2004). HIF1α stabilisation not only depends on O2 tension, it can also be influenced 
by ROS (Chun et al., 2002) – a product of OTA toxicity. Research has shown that HIF1 activity is not 
only induced in hypoxic cancers; HIF1 protein levels are often increased in some cancers without 
measurable hypoxia (Kuschel et al., 2012).  
 
Heat shock protein (HSP) 90, a chaperone protein, has been found to modulate the expression of HIF1α, 
as well as stabilise or degrade damaged proteins (Buchner, 1999). HSP90 can stabilise mutant proteins, 
alter growth signals and induce VEGF expression (Fontana et al., 2002), enabling a pro-survival 
phenotype. HIF1α modulates the expression of pyruvate dehydrogenase kinase 1 (PDK1), which 
inactivates pyruvate dehydrogenase (PDH) – an enzyme that converts pyruvate into acetyl-CoA (used 
in the Krebs cycle for ATP production) (Liu and Yin, 2017). This process, called the “Pasteur Effect”, 
promotes cytosolic lactate formation and reduces pyruvate oxidation (Prigione et al., 2014). Together, 
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HIF1α and PDK1 induce a glycolytic shift. In this way OTA would influence metabolic efficiency (ATP 
production) and ROS generation. 
 
Nuclear factor kappa light-chain-enhancer of activated B-cells (NFκB) phosphorylation leads to its 
translocation to the nucleus and transcription of genes relating to the inflammatory response and cell 
cycle, such as growth factors, apoptosis regulators and stress response genes (Pahl, 1999). Recent 
research has shown OTA induction of inflammation via NFκB activation (Raghubeer et al., 2017). An 
inflammatory environment can heighten the effects of transforming growth factor beta (TGFβ) – a 
cytokine with angiogenic, apoptotic and proliferative abilities – leading to fibrotic or malignant 
conditions (Massagué et al., 2000). TGFβ can be activated by oxidative stress and inflammation, and 
its overexpression has been reported in several human cancers (dos Reis et al., 2011; Higashi et al., 
2001). There are six hallmarks of cancer, they are defined as the ability to continuously proliferate, 
bypass apoptosis, evade the immune system, ignore growth suppressive signals, induce angiogenesis 
and foster metastatic characteristics (Hanahan and Weinberg, 2011). TGFβ and VEGF represent 
hallmarks of the cancer phenotype. Therefore, OTA-induced reactive oxygen species (ROS) and 
inflammation could promote transformation and carcinogenesis. NFκB has also been reported to 
activate HIF1α in conjunction with ROS (Bonello et al., 2007). Nuclear factor-erythroid 2-related factor 
2 (Nrf2) is a transcription factor responsible for the response to redox imbalance. Phosphorylation of 
Nrf2 allows it to translocate to the nucleus, bind to the antioxidant response element (ARE) in the 
promoter regions of antioxidant enzyme genes, and transcribe genes functional in neutralising ROS and 
restoring homeostasis (Bryan et al., 2013). OTA has been widely reported to decrease Nrf2 activity, 
thus dampening cellular response to ROS, rendering the cell vulnerable to oxidative damage (Boesch-
Saadatmandi et al., 2008; Raghubeer et al., 2015b).  
 
Previous studies showed that OTA induced oxidative stress at IC50 concentrations (24hr: 1.5µM, 48hr: 
9.4µM) (Raghubeer et al., 2015b) and inflammation at a sub-IC50 concentration (0.5µM) in kidney cells 
(Raghubeer et al., 2017). The lack of information on OTA-hypoxia research relating to inflammation 
and oxidative stress in human cells prompted our investigation of these pathways. This study employed 
a range concentrations based on plasma levels reported in regions with high OTA exposure (Koszegi 
and Poor, 2016). We exposed human embryonic kidney (HEK293) and hepatocellular carcinoma 
(HepG2) cells to three different OTA concentrations (0.125µM, 0.25µM and 0.5µM) over 24 hours (hr) 
and 48hr, thereafter, we examined the effects on biomarkers of inflammation, oxidative stress, and 
hypoxia response.  
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Materials 
Vendor authenticated human embryonic kidney (HEK293) and liver hepatocellular carcinoma (HepG2) 
cells were purchased from Highveld Biologicals (Johannesburg, South Africa). Dulbeccos’ minimum 
essential media (DMEM), Eagle’s minimum essential media (EMEM), HEPES buffer and trypsin was 
purchased from Lonza (Basel, Switzerland). Ochratoxin A (O1877) was sourced from Sigma-Aldrich 
(Missouri, USA). Solvents and salts were purchased from Merck (Darmstadt, Germany). All 
quantitative PCR (qPCR) consumables and reagents were obtained from Bio-Rad (Hercules, USA) with 
primer sequences synthesized by Inqaba Biotechnical Industries (Pretoria, South Africa). 
 
Methods 
Cell Culture 
HEK293 cells and HepG2 cells were cultured in 25cm3 flasks, in monolayer (106 cells per flask), using 
DMEM and EMEM respectively (both supplemented with 10% foetal calf serum (FCS), 1% 
Penstrepfungizone, HEPES buffer and 1% L-glutamine). The cells were cultured in a humidified 
incubator (37°C, 5% CO2). At 80% confluence, cells were exposed to OTA (0.125µM; 0.25 µM; 
0.5µM) for 24hr and 48hr. Following treatment, cells were detached by incubation with trypsin (5min; 
37C), counted (Invitrogen Countess™ automated cell counter), and adjusted for subsequent assays. 
Experiments were performed under non-hypoxic conditions. 
 
Ochratoxin A Treatments 
A 5mM stock solution of OTA was prepared in 60% dimethyl sulphoxide (DMSO). Concentrations 
used for treatment were based on high levels recorded in serum and urine (Jonsyn-Ellis, 2001; Wafa et 
al., 1998). The OTA range was delivered in concentrations – O0.5: 0.5M, O0.25: 0.25µM and O0.125: 
0.125M. 
 
Luminometric assessment of Adenosine Triphosphate (ATP) 
The CellTiter-Glo® Luminescent Cell Viability assay (G7570, Promega, Madison, USA) was used, as 
per the manufacturer’s protocol, to measure ATP in cells exposed to OTA. Briefly, 20, 000 cells (in 
0.1M PBS) were seeded in an opaque microtitre plate (in triplicate). The detection reagent was added 
to each well (20µL), plates were incubated (room temperature (RT), dark, 1hr), and read on a 
Modulus™ microplate luminometer (Turner Biosystems, Sunnyvale, CA). Results were reported as 
relative light units (RLU), directly proportional to ATP content. 
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Quantification of Protein Expression  
Protein isolation 
Cytobuster™ (Novagen, San Diego, USA), with supplementary phosphatase (004906837001) and 
protease (05892791001) inhibitors (Roche, Basel, Switzerland), was used to isolate protein from 
HEK293 and HepG2 cells as previously described (Ghazi et al., 2017). The Bicinchoninic acid (BCA) 
assay was used to quantify crude protein, thereafter samples were standardised to 1mg/ml and boiled 
(5min) in Laemmli buffer (0.5M Tris-HCl, 1% bromophenol blue, glycerol, 10% sodium dodecyl 
sulphate (SDS), β-mercaptoethanol and dH2O). 
 
Sodium dodecyl sulphate (SDS) – polyacrylamide gel electrophoresis (SDS-PAGE) and western 
blotting 
Protein samples were separated on SDS polyacrylamide gel (stacking: 4%; resolving: 7.5%) at 150V 
(1hr) and electro-transferred to nitrocellulose membranes using the pre-programmed Trans-Blot® 
Turbo™ system (Bio-Rad). Membranes were blocked in 5% BSA in Tween20 Tris-buffered saline 
(TTBS: 25mM Tris, 150mM NaCl, 0.05% Tween20) on a shaker (1hr, RT) prior to immune-probing 
with primary antibodies (1:1000) at 4°C overnight – anti-PDK1 (ab207450) and anti-phosphorylated 
(p)Nrf2 (ser40, ab76026) from Abcam (Cambridge, UK), anti-pNFκB (ser536, 3033T), anti-NFκB 
(8242T), and anti-Nrf2 (12721S) from Cell Signaling Technology (Massachusetts, USA), anti-HIF1α 
(PLA0081) from Sigma-Aldrich (Missouri, USA), and anti-HSP90 (610418) from BD Biosciences (San 
Jose, CA, USA). Membranes were washed post-primary antibody incubation (TTBS, 4 x 10min), 
probed with horse-radish peroxidase (HRP)-conjugated anti-mouse (7076S) or HRP-conjugated anti-
rabbit (7074P2) secondary antibodies (5% BSA, 1hr, RT) and washed post-secondary antibody 
incubation (4 x 10min).  Clarity™ Western ECL chemiluminescent substrate (Bio-Rad) was added to 
each membrane and images were captured using the ChemiDoc™ XRS+ Imaging system (Bio-Rad). 
Membranes were quenched using hydrogen peroxide (37C; 30min), blocked, (5% BSA in TTBS, 1hr, 
RT), washed twice, and probed with HRP-conjugated anti-β actin (Sigma-Aldrich). Image Lab software 
(version 5.1) was used for densitometry analysis, and quantified as relative band intensity (RBI) 
converted to fold change. All results were normalized against β-actin prior to statistical analysis. 
 
Messenger RNA (mRNA) quantification of hypoxic response 
RNA Isolation and cDNA Synthesis 
An in-house protocol using QIAzol extraction reagent (Qiagen, Hilden, Germany) was employed to 
isolate RNA (Pillay et al., 2015). Isolated RNA was quantified using the NanoDrop2000 
spectrophotometer (Thermo Fisher Scientific, Massachusetts, USA) and standardised to 1000ng/µL. 
cDNA was synthesised using iScript cDNA synthesis kit (Bio-Rad) as per manufacturer’s protocol. 
Thermocycler conditions were 25°C (5min), 42°C (30min), 85°C (5min) and a final hold of 4°C.  
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Quantitative Polymerase Chain Reaction (qPCR) 
Transcript levels of HIF1α (sense: 5′-GAACGTCGAAAAGAAAAGTCTCG-3′, antisense: 5′-
CCTTATCAAGATGCGAACTCACA-3′), VEGF (sense: 5′-AGGGCAGAATCATCACGAAGT-3′, 
antisense: 5′-AGGGTCTCGATTGGATGGCA-3′), and TGFβ1 (sense: 5′-
CTAATGGTGGAAACCCACAACG-3′, antisense: 5′-TATCGCCAGGAATTGTTGCTG-3′), were 
evaluated by qPCR. A reaction mix of 5.5µL SsoAdvanced™ Universal SYBR® Green Supermix 
(Bio-Rad), 1µL cDNA, 1µL sense and antisense primers, and nuclease-free H2O was made up to 
10µL. Three independent experiments were carried out using six replicates per treatment with 
glyceraldehyde 3-phosphate dehydrogenase GAPDH (sense: 5’-TCCACCACCCTGTTGCTGTA-3’, 
antisense: 5’-ACCACAGTCCATGCCATCAC-3’) and β-actin (sense: 5’-
TGACGGGTCACCCACACTGTGCCCAT-3’, antisense: 5’-
CTAGAAGCATTTGCGGTGGACGATGGAGGG-3’) as housekeeping genes. Reactions were 
performed on the CFX Touch™ Real Time PCR detection system (Bio-Rad) as follows: Initial 
denaturation (95°C, 4min), denaturation (37 cycles, 95°C, 15s), annealing (HIF1α, VEGF and TGFβ – 
55°C, 40sec) and extension (72°C, 30sec). Analysis was performed using the method described by 
Livak and Schmittgen, where 2-∆∆Ct represents fold change relative to housekeeping gene (Livak and 
Schmittgen, 2001).  
 
Statistical Analysis 
GraphPad Prism version 5.0 (GraphPad software, San Diego, CA) was used for all analysis, employing 
one-way analysis of variance (ANOVA) tests. Data is expressed as mean ± standard deviation with 
statistical significance considered at p < 0.05.  
 
Results 
Previous work showed that OTA induced oxidative stress and inflammation in human kidney cells 
(Raghubeer et al., 2017; Raghubeer et al., 2015b). The current study investigated the effect of OTA on 
cellular hypoxia and related signalling in HEK293 and HepG2 cells exposed to OTA. 
 
Protein expression of pNFκB and pNrf2 is decreased at 24hr, but increased at 48hr in HEK293 cells, 
suggesting acute oxidative stress with OTA-induced inflammation at prolonged exposure periods.  
Phosphorylation of both NFκB and Nrf2 was downregulated at 24hr by OTA in HEK293 cells (Fig 6.1), 
with significant decreases in pNFκB and pNrf2 observed in O0.25 compared to controls (0.36 ± 0.11 vs 
0.18 ± 0.03RBI, p = 0.0018 and 17.12 ± 2.06 vs 5.23 ± 0.66RBI, p < 0.05 respectively). pNrf2 was also 
significantly decreased at O0.125 (24hr; 2.99 ± 0.37RBI, p < 0.0001). This trend was reversed during 
48hr exposure with significant upregulation of pNFκB at O0.25 (0.34 ± 0.03RBI, p < 0.005) and O0.125 
(0.36 ± 0.13RBI, p = 0.0003) compared to controls (0.24 ± 0.03RBI; Fig 6.1). pNrf2 is significantly 
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increased at the same OTA concentrations – O0.25 (9.14 ± 1.69RBI, p < 0.05) and O0.125 (12.71 ± 
1.55RBI, p = 0.0001). 
 
 
Figure 6.1: Densitometric analysis and western blot images showing relative fold change in pNFκB 
and pNrf2 in HEK293 cells over 24hr and 48hr exposure to OTA – O0.5 (0.5µM), O0.25 (0.25µM) and 
O0.125 (0.125µM). *p < 0.05, **p < 0.005 and ***p < 0.0005 relative to untreated control. 
 
OTA induces inflammation at 24hr by increasing phosphorylation of NFκB in liver cells, while 
decreasing activation of Nrf2. Expression of pNFκB is decreased at O0.5 exposure and pNrf2 
expression is decreased at O0.125 exposure in HepG2 cells over 48hr.  
Significant increases in pNFκB were recorded at O0.5 (0.45 ± 0.09RBI, p < 0.05) and O0.125 (0.39 ± 
0.10RBI, p = 0.0023) at 24hr compared to controls in HepG2 cells (0.27 ± 0.04RBI) (Fig 6.2). 
Phosphorylation of NFκB was decreased at 48hr during O0.5 exposure (1.27 ± 0.08 vs 0.86 ± 0.14RBI, 
p < 0.05). Contrary to NFκB phosphorylation, we observed decreased expression of pNrf2 across 
treatments in HepG2 cells (Fig 6.2). Significant pNrf2 decreases were observed at O0.25 (8.99 ± 3.09RBI, 
p < 0.05) and O0.125 (7.6 ± 2.63RBI, p = 0.0013) compared to controls (18.72 ± 3.9RBI) at 24hr, and at 
O0.125 (13.98 ± 0.94 vs 7.19 ± 1.13RBI, p < 0.05) at 48hr in HepG2 cells. Activation of transcription 
factors relating to oxidative stress and inflammation led to interest in the expression of proteins involved 
in hypoxia responses. 
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Figure 6.2: Densitometric analysis and western blot images showing relative fold change in pNFκB 
and pNrf2 in HepG2 cells over 24hr and 48hr exposure to OTA. *p < 0.05 and **p < 0.005 relative to 
untreated control. 
 
OTA upregulates hypoxic responses in kidney cells at 24hr, but decreases these responses at 48hr 
exposure.  
The protein expression of HIF1α was upregulated 3.25-fold at the lowest OTA concentration (O0.125) at 
24hr exposure (0.11 ± 0.01 vs 0.35 ± 0.04RBI, p < 0.0001), however, this expression is dampened at 
48hr (Fig 6.3). HIF1α expression was decreased significantly at O0.25 (0.26 ± 0.07RBI, p < 0.005) and 
O0.125 (0.27 ± 0.12RBI, p = 0.0002) compared to controls (1.01 ± 0.04RBI) at 48hr in HEK293 cells. 
Expression of the chaperone protein, HSP90, was significantly increased across all OTA treatments at 
24hr (p = 0.0044) compared to controls (0.83 ± 0.14RBI) – O0.5 (1.02 ± 0.15RBI), O0.25 (1.07 ± 0.13RBI) 
and O0.125 (1.05 ± 0.2RBI). HSP90 was also significantly increased at O0.125 during 48hr in HEK293 
cells (1.05 ± 0.11 vs 1.5 ± 0.2RBI, p = 0.0037). HIF1α and PDK1 function in tandem to modulate 
energy usage and ATP production during hypoxic stress. Expression of PDK1 was significantly 
increased at O0.5 (0.75 ± 0.08RBI) and O0.25 (0.76 ± 0.09RBI) compared to controls (0.44 ± 0.09RBI) 
during 24hr (p = 0.0018), however, PDK1 expression was decreased at 48hr OTA treatments with a 
significant decline observed at O0.25 compared to controls (0.78 ± 0.13 vs 0.6 ± 0.08RBI, p = 0.022).  
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Figure 6.3: Densitometric analysis and western blot images showing relative fold change in proteins 
related to hypoxic response. Expression of HIF1α, HSP90 and PDK1 in HEK293 cells over 24hr and 
48hr exposure to OTA. *p < 0.05, **p < 0.005 and ***p < 0.0005 relative to untreated control. 
 
Liver cells exhibit increased protein expression of HIF1α and HSP90 at 24hr during O0.125 exposure, 
with decreased overall hypoxic responses at 48hr. 
Hypoxic stabilisation and accumulation of HIF1α was observed during O0.125 exposure to HepG2 cells 
at 24hr (0.40 ± 0.05 vs 0.72 ± 0.11RBI, p = 0.0012), this was accompanied with a non-significant 
increase in HSP90 expression (Fig 6.4). Reduced protein expression of PDK1 was noted at O0.25 (24hr; 
0.11 ± 0.02 vs 0.07 ± 0.01RBI, p = 0.0017) and at O0.125 (48hr; 0.16 ± 0.01 vs 0.09 ± 0.02RBI, p < 0.05) 
exposure. We then investigated the gene expression of HIF1α as well as the downstream targets.  
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Figure 6.4: Densitometric analysis and western blot images showing proteins related to hypoxic 
response. Relative fold change of HIF1α, HSP90 and PDK1 in HepG2 cells over 24hr and 48hr exposure 
to OTA. *p < 0.05 and **p < 0.005 relative to controls. 
 
Gene expression of HIF1α is decreased at 24hr and 48hr in HEK293 cells. VEGF and TGFβ is 
decreased in HEK293 cells at 24hr, while increased at 48hr. 
The mRNA levels of HIF1α do not correlate with the protein expression at O0.125 at 24hr in HEK293 
cells, as a decreased gene expression of HIF1α (p < 0.05) was noted. Decreased HIF1α mRNA at O0.25 
(Fig 6.5) in kidney cells (48hr) correlates with decreased HIF1α protein expression (Fig 6.3). Gene 
expression of VEGF was significantly decreased at O0.5 (p < 0.05) and O0.25 (p = 0.0005) during 24hr 
exposure, however, the opposite was observed at 48hr with a 2.7-fold increase in VEGF mRNA content 
at both O0.5 (p = 0.0002) and O0.125 (p < 0.005) in kidney cells (Fig 6.5). A similar pattern was observed 
with TGFβ mRNA levels – significant decreases were recorded at O0.5 (p < 0.05) and O0.25 (p = 0.0003), 
while 48hr exposure to O0.125 yielded a 2-fold increase in TGFβ expression (p < 0.0001) in HEK293 
cells (Fig 6.5).  
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Figure 6.5: mRNA analysis of HIF1α, VEGF and TGFβ in HEK293 cells after treatment with a range 
of OTA concentrations over 24hr and 48hr. *p < 0.05, **p < 0.005 and ***p < 0.0005 relative to control. 
 
HIF1α gene expression was downregulated at 24hr and 48hr in liver cells. VEGF was upregulated 
at 24hr only, with TGFβ decreased at 24hr and increased at 48hr post OTA-exposure in HepG2 cells. 
Gene expression of HIF1α was significantly decreased at O0.25 (p < 0.05) and O0.125 (p < 0.0001) in 
HepG2 cells (24hr); expression was also decreased at 48hr by O0.5 (p < 0.05) and O0.25 (p = 0.0005) (Fig 
6.6). As previously observed in HEK293 cells, the mRNA and protein expressions of HIF1α at O0.125 
does not correlate. mRNA transcripts of VEGF significantly increased at 24hr during O0.5 and O0.25 
exposure (p = 0.0004 and p < 0.05 respectively). Gene expression of TGFβ was significantly decreased 
at O0.25 (p < 0.05) during 24hr exposure, however, the opposite was observed during 48hr exposure of 
HepG2 cells to O0.25 – TGFβ expression increased 4.7-fold (p = 0.0002) (Fig 6.6). 
 
Figure 6.6: Analysis of HIF1α, VEGF and TGFβ mRNA levels in HepG2 cells following treatment 
with a range of OTA concentrations over 24hr and 48hr. *p < 0.05 and **p < 0.005 and ***p < 0.0005 
relative to untreated controls.  
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ATP production was increased at 24hr and 48hr in both HEK293 and HepG2 cells exposed to a range 
of OTA concentrations.  
Cellular ATP content was measured to determine the energy status of hypoxic cells, and the influence 
of PDK1 on its production. ATP was significantly increased by O0.125 during 24hr (p < 0.0001) and O0.25 
during 48hr exposure (p = 0.0002) in HEK293 cells. The presence of ATP was significantly increased 
during 24hr exposure to O0.5 (p < 0.0001) and O0.25 (p < 0.05), as well as 48hr exposure to O0.125 (p = 
0.0023) in HepG2 cells. Decreases recorded in PDK1 expression correlate with increased ATP levels.  
 
 
Figure 6.7: Luminometric quantification of ATP in HEK293 and HepG2 cells over 24hr and 48hr post-
exposure to a range of OTA concentrations. *p < 0.05 and **p < 0.005 compared to control 
measurements. 
 
Discussion 
In general, a hypoxic environment is often characteristic of a cancer phenotype (Eales et al., 2016). 
These conditions can promote mutagenesis and cell survival; it is therefore fundamental to determine 
hypoxic effects of mycotoxins in relation to carcinogenesis. OTA targets the kidney and liver, and has 
been linked to immune dysfunction and cancer initiation (Castegnaro et al., 2006). It is well documented 
that OTA induces oxidative stress and modulates cellular antioxidant responses, however, there is a 
dearth of research regarding its hypoxia-inducing abilities in human kidney and liver cells. Stachurska 
et al. (2011) demonstrated differential regulation of hypoxia inducing factors (HIFs) and VEGF in 
porcine kidney cells (Stachurska et al., 2011), this research prompted an investigation into the effects 
of plausible plasma range concentrations of OTA on human kidney and liver cells. Using renal 
(HEK293) and hepatic (HepG2) in vitro models, we investigated the biochemical responses to OTA 
toxicity related to inflammation and hypoxia.  
 
OTA disrupts the antioxidant response by downregulating Nrf2 activity, thus dampening the 
transcription of antioxidant enzymes (Boesch-Saadatmandi et al., 2008; Ramyaa and Padma, 2013). At 
24hr exposure to a range of OTA concentrations, we observed significantly decreased pNrf2 in HEK293 
cells at O0.25 and O0.125, indicating a decreased antioxidant response. At 48hr, significantly higher levels 
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of pNrf2 was recorded in O0.25 and O0.125, coupled with increased phosphorylation of NFκB, a 
transcription factor responsible for inflammatory induction (Fig 6.1). This suggests OTA induces acute 
oxidative stress without inflammation, but over prolonged exposure the toxin induces an inflammatory 
environment while cellular antioxidant responses increase.  
 
In the liver, a different trend is observed. OTA induces inflammation during acute exposure to O0.5 and 
O0.125, with similar dampening of Nrf2 activity at O0.25 and O0.125 (Fig 6.2). The inflammatory 
environment is not sustained at 48hr, and pNrf2 does not increase in HEK293 cells, but significantly 
decreased during O0.125 exposure in liver cells. This indicates a compromised antioxidant response. In 
both cell lines we observe inflammatory activation with increased oxidative stress, these conditions 
allow for genomic instability and cell cycle disruptions.  
 
HIF1α stabilisation occurs during periods of low oxygen, allowing transcription of genes that would 
increase oxygen delivery (EPO) and angiogenesis (VEGF) (Vaupel, 2004). HIF1α functions closely 
with HSP90, which aids in stabilising protein conformation, apoptosis signalling, and plays a role in 
VEGF induction (Calderwood et al., 2006). Significantly increased expression of HIF1α was recorded 
at the lowest OTA concentration (O0.125), with increased HSP90 at all three OTA concentrations (O0.5, 
O0.25, O0.125) at 24hr in kidney cells (Fig 6.3). Chandel et al (1998) demonstrated that increased ROS 
further stabilises and activates HIF1α (Chandel et al., 1998). This can be seen in the downregulation of 
pNrf2 at O0.125 in HEK293 cells at 24hr (Fig 6.1), with increased HIF1α expression (Fig 6.3), as well as 
decreased pNrf2 in HepG2 cells (Fig 6.2) accompanied with increased HIF1α (Fig 6.4). At 48hr, HIF1α 
protein expression was significantly decreased, with increased HSP90 at O0.125. HSP90 also participates 
in oncogenic processes as it can alter growth receptor activity and angiogenesis; these capabilities allow 
it to promote proliferation of mutated cells and induce angiogenesis, as such HSP90 is often 
overexpressed in tumours (Whitesell and Lindquist, 2005). Overexpression of HSP90 and HIF1α has 
been linked to carcinogenic tendencies by promoting cancer cell survival, proliferation and adaptation 
to hostile environments (Graeber et al., 1996). Yasuda et al. (2004) showed that HIF1α can upregulate 
VEGF and hexokinase expression in hepatocellular carcinoma (HCC), thereby activating a metabolic 
switch in cancer cells (Yasuda et al., 2004). Increased levels of HIF1α and VEGF have been reported 
in metastatic breast cancer (Kallergi et al., 2009).  
 
PDK1 alters the mechanism of energy production; it prevents the conversion of pyruvate into acetyl-
CoA and instead promotes lactate formation in the cytosol (Liu and Yin, 2017). In HEK293 cells, we 
observed significantly increased PDK1 expression at O0.5 and O0.25 (24hr; Fig 6.3), but significantly 
decreased PDK1 at O0.25 (48hr). The expression of PDK1 correlates with ATP production in HEK293 
cells; we see lower ATP levels at 24hr and greater levels at 48hr (Fig 6.7), indicating that increased 
PDK1 resulted in lower ATP production. 
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The mRNA levels of HIF1α did not correlate with protein expression at O0.125 (24hr) in HEK293 cells; 
we observed significantly decreased gene expression (Fig 6.5), but significantly increased protein 
expression (Fig 6.3). It is relevant to note that HSP90 was also upregulated during 24hr at O0.125. This 
discrepancy in protein expression could be due to post-translational modifications or HSP90 stabilising 
HIF1α protein. HIF1α expression can be affected by several post-translational mechanisms – 
acetylation, hydroxylation and phosphorylation (Kuschel et al., 2012). At 48hr HIF1α gene expression 
was significantly decreased at O0.25 (Fig 6.5) which corresponds with the observed protein expression.  
 
A main target of HIF1α is VEGF, a potent inducer of angiogenesis. The gene expression of VEGF was 
decreased across all three OTA treatments at 24hr in kidney cells, with significance reported in O0.5 and 
O0.25 (Fig 6.5). This was coupled with significant decreases in TGFβ expression at O0.5 and O0.25. The 
opposite trend was observed at 48hr in kidney cells – a 2.7-fold increase in VEGF was recorded at O0.5 
and O0.125, with a 2-fold increase in TGFβ during O0.125 exposure. VEGF and TGFβ levels indicate a 
robust increase in gene expression during prolonged exposure to OTA as opposed to acute exposure 
periods. This scenario is very likely to occur as reabsorption coupled with the extended half-life of OTA 
results in toxin persistence in the kidney (Ringot et al., 2006).  
 
Protein expression of HIF1α, PDK1 and HSP90 did not vary as significantly in liver cells as compared 
to kidney cells. The HepG2 cell line represents an in vitro liver model, however it is a cancerous cell 
line, and thus behaves differently to normal cells (HEK293). The kidney is more sensitive to effects of 
OTA, and the toxin would therefore induce a more robust effect in HEK293 than HepG2 cells. The 
kidney and liver exhibit vastly different metabolic activities, which could be another reason for 
differences between cell lines. PDK1 expression was significantly decreased during O0.25 exposure and 
HIF1α was significantly increased (1.8-fold) during O0.125 exposure at 24hr in HepG2 cells (Fig 6.4). At 
48hr the only significant observed change was a decrease in PDK1 expression at O0.125 in HepG2 cells 
(Fig 6.4). The mRNA transcript of HIF1α in HepG2 cells exhibited a similar trend to that seen in 
HEK293 cells. HIF1α was significantly decreased at O0.25 and O0.125 at 24hr, and at O0.5 and O0.25 at 48hr 
exposure in HepG2 cells (Fig 6.6). The mRNA expression conflicts with protein expression of HIF1α 
observed at O0.125 (24hr). HSP90 protein was increased, and could possibly affect HIF1α stability, or 
post-translational modifications could have altered the protein expression.  
 
Interestingly, the gene expression of VEGF was significantly increased at O0.5 and O0.25 at 24hr, with a 
non-significant increase (1.8-fold) at O0.5 during 48hr in HepG2 cells (Fig 6.6). Suggesting acute 
induction of VEGF, but a less potent response during prolonged exposure to OTA. The expression of 
TGFβ was increased across all three OTA concentrations – O0.5 (3-fold), O0.125 (2.8-fold), with a 
significant increase at O0.25 (4.7-fold) (Fig 6.6). This data indicates that prolonged exposure of OTA to 
liver cells could disrupt normal growth signals, possibly contributing to malignant transformation. 
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Increased ATP production was recorded during exposure to O0.5 and O0.25 over 24hr, and O0.125 over 48hr 
in liver cells (Fig 6.7). This parallels the decline in PDK1 expression during exposure to O0.25 at 24hr, 
and O0.125 at 48hr (Fig 6.4). 
 
Our data shows novel interactions between OTA and the hypoxic response in human kidney and liver 
cells. We observed acute inflammatory induction, coupled with increased hypoxia (HIF1α protein 
expression) and VEGF expression in HepG2 cells, while HEK293 cells exhibited decreased 
inflammation, increased oxidative and metabolic stress with hypoxia at 24hr. At prolonged exposure to 
OTA, kidney cells upregulated VEGF and TGFβ gene expression, while HepG2 cells demonstrated 
increased TGFβ expression. We report, for the first time, the effects of OTA on HIF1α, HSP90, VEGF 
and TGFβ in HEK293 and HepG2 cells. This data is crucial in providing a molecular basis for the 
mechanism of OTA toxicity and carcinogenesis, especially regarding the tumour promoting 
characteristics of HIF1α and HSP90. 
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CHAPTER 7 
CONCLUSION 
 
OTA is a known renal toxicant, with proven carcinogenicity in rodents (Cavin et al., 2009; Gautier et 
al., 2001). It is classified as a group 2B carcinogen – possibly carcinogenic to humans – and has been 
linked to the onset and progression of several nephropathies and tumour formation (Castegnaro et al., 
2006; Zaied et al., 2011). The mechanism of renal fibrosis and tumour development has not been 
conclusively elucidated, instead the toxin is reported to act on several biochemical pathways that 
promote cancer induction. OTA is also hepatotoxic and immunotoxic (Gayathri et al., 2015; Thuvander 
et al., 1995). OTA was shown to induce renal carcinomas in male and hepatic carcinomas in female 
B6C3F1 mice (Bendele et al., 1985). DNA fragmentation was observed in Sprague-Dawley rat kidney 
cells and cultured primary human kidney cells (Robbiano et al., 2004), indicating OTA-induced DNA 
damage.  
 
The oxidative capacity of OTA has been extensively reported (Arbillaga et al., 2007; Ferrante et al., 
2006; Kamp et al., 2005b), with research suggesting that disruption of the antioxidant defence response 
filters through multiple downstream pathways, pre-disposing malignant transformation. The Nrf2 
pathway is the first line of defence in cellular antioxidant response; OTA involvement in Nrf2 
downregulation has been reported in several in vitro (Boesch-Saadatmandi et al., 2009; Stachurska et 
al., 2013) and in vivo (Cavin et al., 2007; Loboda et al., 2017) models. Resveratrol possesses antioxidant 
and anti-cancer properties (Fremont, 2000; Leonard et al., 2003). Studies have shown that resveratrol 
is able to upregulate Nrf2 expression, augmenting the antioxidant response (Bishayee et al., 2010; Chen 
et al., 2005). Thus, natural compounds could be promising in minimising OTA-induced oxidative stress.  
 
Sheu et al. (2016) demonstrated OTA-induced oxidative and ER stress, with resultant apoptosis (Sheu 
et al., 2016); indicating toxicity induction by multiple interconnected pathways. An imbalance between 
cell proliferation and apoptosis is critical in cancer initiation and progression. Bouaziz et al. showed 
OTA-induced modulation of proteins involved in apoptosis control – Bcl-2 family proteins (Bouaziz et 
al., 2011), suggesting that OTA can affect cell cycle check points and induce cell death. Prolonged 
inflammation and hypoxia can contribute to cell death and cancer formation. OTA upregulates 
inflammatory genes via NFκB activity (Hennemeier et al., 2012; Ramyaa and Padma, 2013), and the 
activity of HIFs; ultimately promoting genetic instability and compromising cell function (Stachurska 
et al., 2011). OTA has been proven to disrupt several pathways involved in cancer initiation, however 
few studies chronicle these events in human cells, with little information available on how the toxin 
integrates manipulation of different pathways.  
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This study showed that OTA affects biochemical pathways in human kidney (HEK293) and liver 
(HepG2) cells. The data shows that OTA at 48hr (IC50 = 9.4µM) induced oxidative stress and depleted 
GSH; mRNA expression of Nrf2 was significantly downregulated while protein expression increased. 
OTA at 24hr (IC50 = 1.5µM) and 48hr exposure induced DNA fragmentation evidenced by increased 
comet tail length. The addition of resveratrol (25µM) produced significant reductions in OTA toxicity: 
decreased intracellular ROS, increased GSH (24hr), decreased DNA fragmentation, and increased DNA 
repair via base excision repair enzyme OGG1 (48hr) relative to the OTA only treatment. Resveratrol 
increased the protein expression of pSIRT1 (Ser47), and LonP1, a mitochondrial repair protein, at acute 
and prolonged time periods. SIRT1 is involved in the regulation of cellular stress responses, DNA repair 
and metabolism (Nasrin et al., 2009). This data suggests that OTA is involved in the downregulation of 
antioxidant repair responses, while resveratrol is able to rescue the cell from oxidative damage and 
promote repair processes. Cellular redox imbalance promotes an inflammatory environment, governed 
by NFκB. This transcription factor is responsible for pro- and anti-inflammatory proteins, as well as 
apoptosis induction.  
 
The canonical NFκB pathway was activated at a sub-IC50 (0.5µM) concentration of OTA. Protein 
expression of pNFκB (Ser536) and pIKK (Ser176/180) was increased, indicating NFκB translocation 
into the nucleus, initiating transcriptional activity. Furthermore, ATP content and phospho-p53 (Ser392) 
was increased (0.5µM and 1.2µM). Interestingly, 1.2µM OTA decreased inflammation markers – 
caspase 1 and IL-1β was reduced, while IκBα (inhibitor of NFκB translocation) protein expression was 
significantly increased, suggesting sequestration of NFκB in the cytoplasm. Initiator caspases 8 and 9, 
and executioner caspases 3/7 were significantly increased at the highest OTA concentration (2µM), 
coupled with decreased ATP (compared to other OTA concentrations). This indicates apoptosis 
induction and immunosuppression at high concentrations of OTA. Low concentrations of OTA, 
however, promote inflammation and cell survival, possibly leading to an environment which favours 
transformation (epithelial-mesenchymal transition), which would encourage renal cell fibrosis. 
Oxidative stress and inflammation increase the incidence of protein damage and misfolding; as such, 
the ER response is important in regaining homeostasis.  
 
Plasma range concentrations of OTA showed increased protein damage and ER-stress induced cellular 
survival in human kidney and liver cells. LonP1 was significantly increased in HEK293 and HepG2 
cells over 24hr and 48hr. Protein carbonyl concentrations were quantified in HEK293 cells exposed to 
OTA, with results showing increased sensitivity to protein oxidation by OTA compared to HepG2 cells. 
OTA increased expression of PERK, with subsequent increased peIF2α (Ser51) in both kidney and liver 
cells. Increased ATF4 mRNA expression was observed, however, CHOP (apoptosis mediator) 
expression was significantly decreased; indicating the promotion of cell survival by ER-stress 
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pathways. This finding was further substantiated by decreased expression of executioner caspases 6 and 
3/7.  
 
Disturbances in antioxidant responses was observed in both kidney and liver cells over 24hr and 48hr, 
by determining levels of pNrf2 (Ser40). Liver and kidney cells exhibited inflammation (increased 
pNFκB) at 24hr and 48hr respectively. The lowest OTA concentration (0.125µM) increased protein 
expression of HIF1α in both cell lines at 24hr, indicating alterations in oxygen tension and metabolism. 
HSP90 expression was increased in HEK293 cells, with PDK1 increased at 24hr, but decreased at 48hr. 
HepG2 exhibited decreased PDK1 expression. PDK1 expression correlates with ATP presence in both 
cell lines. Interestingly, HEK293 cells exhibited decreased mRNA expression of VEGF and TGFβ at 
24hr, with increased levels at 48hr. Similarly, HepG2 cells exhibited increased mRNA expression of 
TGFβ at 48hr, but increased VEGF at 24hr. 
 
This data suggests that OTA affects antioxidant responses, inflammatory pathways and hypoxia 
responses simultaneously. OTA can exert toxicity at low concentration and is able to promote 
conditions favouring cancer formation (inflammation, hypoxia) while upregulating transformative 
biomarkers, such as VEGF, TGFβ and HSP90. High concentrations of OTA induce cell death; 
conversely, low concentrations promote cell survival accompanied with increased cellular stress. 
Endemic populations often ingest low concentrations of OTA over prolonged time periods – this data 
provides novel insight to nephropathies involving tumour formation. The cellular conditions induced 
by OTA would promote genetic instability and mutations, leading to organ dysfunction and possible 
renal or hepatic tumours.  
 
This study provides valuable insight to molecular mechanisms of toxicity in human kidney and liver 
cells exposed to varying concentrations of OTA; however, there are shortcomings to in vitro studies. 
The kidney and liver are detoxification organs, as such organ function is determined by the efficiency 
of the entire system. In vitro models cannot account for explanations of toxicity in a multi-organ system, 
therefore the next step would be to carry out the study in an in vivo (animal) model, and eventually 
collect blood and tissue samples from individuals exposed to high concentrations of OTA. These results 
can be used to further investigate the carcinogenic effects of OTA. 
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APPENDIX A 
 
Preliminary intracellular ROS data  
Data measured using DCFDA assay, intracellular ROS was measured in cells exposed to OTA (IC50 
concentration – 1.5µM) and resveratrol. Multiple controls (untreated and DMSO vehicle controls) were 
observed to determine if DMSO significantly affected the assay results. Results from DMSO treated 
cells (vehicle controls ranging from 0.01% - 0.98% DMSO) did not significantly vary from untreated 
controls, as such untreated control cells were used for the length of the study.  
 
Table 1: Measurements of intracellular ROS in cells exposed to OTA and resveratrol over 24hr.  
  DCF positive 
A01 SR DCF C1 0,4249 0,3967 0,4249 0,3967 0,4249 0,3967 0,4249 
A02 SR DCF C1 0,5087 0,4792 0,5087 0,4792 0,5087 0,4792 0,5087 
A03 SR DCF C1 0,5379 0,5032 0,5379 0,5032 0,5379 0,5032 0,5379 
A04 SR DCF C2 0,6238 0,5932 0,6239 0,5932 0,6239 0,5932 0,6239 
A05 SR DCF C2 0,6133 0,5818 0,6133 0,5818 0,6133 0,5818 0,6133 
A06 SR DCF C2 0,6368 0,6023 0,6368 0,6023 0,6368 0,6023 0,6368 
A07 SR DCF V1 0,4448 0,419 0,4448 0,419 0,4448 0,419 0,4448 
A08 SR DCF V1 0,5055 0,4737 0,5055 0,4737 0,5055 0,4737 0,5055 
A09 SR DCF V1 0,5078 0,4764 0,5078 0,4764 0,5078 0,4764 0,5078 
A10 SR DCF V2 0,3117 0,2912 0,3117 0,2912 0,3117 0,2912 0,3117 
A11 SR DCF V2 0,3158 0,2954 0,3158 0,2954 0,3158 0,2954 0,3158 
A12 SR DCF V2 0,322 0,3013 0,322 0,3013 0,322 0,3013 0,322 
B01 SR DCF O1 0,239 0,2235 0,239 0,2235 0,239 0,2235 0,239 
B02 SR DCF O1 0,2291 0,2137 0,2291 0,2137 0,2291 0,2137 0,2291 
B03 SR DCF O1 0,2272 0,2109 0,2272 0,2109 0,2272 0,2109 0,2272 
B04 SR DCF O2 0,1761 0,1613 0,1761 0,1613 0,1761 0,1613 0,1761 
B05 SR DCF O2 0,2788 0,2559 0,2788 0,2559 0,2788 0,2559 0,2788 
B06 SR DCF O2 0,27 0,2462 0,27 0,2462 0,27 0,2462 0,27 
B07 SR DCF R1 0,2107 0,1949 0,2107 0,1949 0,2107 0,1949 0,2107 
B08 SR DCF R1 0,2089 0,1925 0,2089 0,1925 0,2089 0,1925 0,2089 
B09 SR DCF R1 0,2084 0,1925 0,2084 0,1925 0,2084 0,1925 0,2084 
B10 SR DCF R2 0,4185 0,3935 0,4185 0,3935 0,4185 0,3935 0,4185 
B11 SR DCF R2 0,4255 0,4002 0,4255 0,4002 0,4255 0,4002 0,4255 
B12 SR DCF R2 0,4201 0,3969 0,4201 0,3969 0,4201 0,3969 0,4201 
C01 SR DCF OR1 0,3341 0,3156 0,3341 0,3156 0,3341 0,3156 0,3341 
C02 SR DCF OR1 0,3273 0,3073 0,3273 0,3073 0,3273 0,3073 0,3273 
C03 SR DCF OR1 0,3021 0,2851 0,3021 0,2851 0,3021 0,2851 0,3021 
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C04 SR DCF OR2 0,2981 0,28 0,2981 0,28 0,2981 0,28 0,2981 
C05 SR DCF OR2 0,3015 0,2828 0,3015 0,2828 0,3015 0,2828 0,3015 
C06 SR DCF OR2 0,2915 0,2732 0,2915 0,2732 0,2915 0,2732 0,2915 
C07 SR DCF Pre-treatment 1 0,1979 0,1847 0,1979 0,1847 0,1979 0,1847 0,1979 
C08 SR DCF Pre-treatment 1 0,1955 0,1837 0,1955 0,1837 0,1955 0,1837 0,1955 
C09 SR DCF Pre-treatment 1 0,1936 0,181 0,1936 0,181 0,1936 0,181 0,1936 
C10 SR DCF Pre-treatment 2 0,4509 0,4239 0,4509 0,4239 0,4509 0,4239 0,4509 
C11 SR DCF Pre-treatment 2 0,4345 0,4066 0,4345 0,4066 0,4345 0,4066 0,4345 
C12 SR DCF Pre-treatment 2 0,4621 0,4328 0,4621 0,4328 0,4621 0,4328 0,4621 
D01 SR Post treatment 1 0,305 0,2868 0,305 0,2868 0,305 0,2868 0,305 
D02 SR Post treatment 1 0,311 0,2909 0,311 0,2909 0,311 0,2909 0,311 
D03 SR Post treatment 1 0,2977 0,2795 0,2977 0,2795 0,2977 0,2795 0,2977 
D04 SR Post treatment 2 0,6737 0,6355 0,6737 0,6355 0,6737 0,6355 0,6737 
D05 SR Post treatment 2 0,6963 0,6562 0,6963 0,6562 0,6963 0,6562 0,6963 
D06 SR Post treatment 2 0,7141 0,6743 0,7142 0,6743 0,7142 0,6743 0,7142 
 
 
Fluorescence Peaks 
Preliminary data for intracellular ROS assessment, using untreated control cells and OTA (24hr, 
1.5µM). 
 
 
 
 
 
 
 
 
 
Figure 1: Fluorescence peaks for DCFDA intracellular ROS assay – determined using BD Accuri flow 
cytometer.  
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APPENDIX B 
 
qPCR analysis of oxidative stress parameters 
Gene expression of Nrf2, GPx, catalase, SOD1 and OGG1 was determined using qPCR. All 
treatments were compared to untreated controls and expressed as fold change 
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Figure 1: mRNA expression of genes associated with cellular protection and the antioxidant response 
determined post-exposure to OTA and resveratrol at 24hr in HEK293 cells. *p < 0.05, **p < 0.005  
 
 
Mitochondrial DNA damage 
Damage to mitochondrial DNA was measured using qPCR and isolated DNA. 
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Figure 2: mtDNA damage induced in kidney cells exposed to OTA and resveratrol at 24hr. *p < 0.05 
and **p < 0.005. 
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APPENDIX C 
 
Lactate dehydrogenase measurement 
Lactate dehydrogenase (LDH) catalyses the conversion of lactate to pyruvic acid, it also reverses the 
reaction. LDH often leaks out of cells with compromised membrane integrity, it can be used as a 
marker of necrosis. Measurements were obtained using the LDH cytotoxicity detection kit (Roche, 
Mannheim, Germany) by incubating 100µL of treatment supernatant (collected media post-treatment 
incubation) with 100µL substrate solution (diaphorase/NAD+; INT/sodium lactate) in a 96-well 
microtitre plate (30min, RT, dark). Thereafter, the optical density was read at 500nm using a 
spectrophotometric plate reader.  
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Figure 1: Extracellular LDH levels used as a biomarker for necrosis and membrane damage to HEK293 
cells over 24hr and 48hr post-exposure to varying concentrations of OTA (*p < 0.05).  
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Figure 2: Extracellular LDH levels used as a biomarker for necrosis and membrane damage to HepG2 
cells over 24hr and 48hr in response to OTA exposure. 
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APPENDIX D 
 
Caspase activity in HEK293 cells 
The activity of caspase 8 and 9 in HEK293 cells was measured using Caspase-Glo® 8 and 9 assay kits 
from Promega, as per the manufacturer’s protocol. Caspase 8 represents the initiator of the extrinsic 
apoptotic pathway, whereas caspase 9 initiates the intrinsic pathway. OTA promoted activity of caspase 
8 over 24hr and 48hr. Caspase 9 activity was increased at 24hr, but decreased at 48hr. 
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Figure 1: Quantification of caspase 8 activity in OTA treated HEK293 cells at 24hr and 48hr. *p < 
0.05, **p < 0.005 and ***p < 0.0005 relative to untreated controls.  
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Figure 2: Quantification of caspase 9 activity in OTA treated HEK293 cells at 24hr and 48hr. *p < 
0.05, **p < 0.005 and ***p < 0.0005 relative to untreated controls.  
 
Caspase activity in HepG2 cells 
The activity of caspase 8 and 9 in HepG2 cells was measured using Caspase-Glo® 8 and 9 assay kits 
from Promega, as per the manufacturer’s protocol. OTA increased acute activity of caspase 8 in all 3 
concentrations (0.5µM, 0.25µM, 0.125µM), but increased activity in only 0.125µM at 48hr. The same 
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pattern was observed with caspase 9 activity – increased at 24hr in all concentrations, but only increased 
at 0.125µM at 48hr. 
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Figure 3: Quantification of caspase 8 activity in HepG2 cells exposed to varying concentrations of 
OTA over 24hr and 48hr. **p < 0.005 and ***p < 0.0005 relative to untreated controls.  
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Figure 4: Quantification of caspase 9 activity in HepG2 cells exposed to varying concentrations of 
OTA over 24hr and 48hr. *p < 0.05, **p < 0.005 and ***p < 0.0005 relative to untreated controls.  
 
